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General introduction
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Chronic obstructive pulmonary disease (COPD)
COPD is defined as ‘a common, preventable and treatable disease that is characterized 
by persistent respiratory symptoms and airflow limitation that is due to airway and/or 
alveolar abnormalities usually caused by significant exposure to noxious particles or 
gases and influenced by host factors including abnormal lung development. Significant 
comorbidities may have an impact on morbidity and mortality’.1 Worldwide, the 
prevalence of COPD was estimated by the Global Burden of Disease Study at 3.9% 
in 2017.2 COPD is a major cause of burden and mortality. Annually, COPD accounts 
for 5.7% of all-cause deaths and 3.3% of all-cause disability-adjusted life years.2 In 
the Netherlands, the prevalence was estimated at 3.4% in 2019, and about 7000 
people died because of COPD.3 Due to longevity and persistent exposure to COPD 
risk factors, prevalence and burden of COPD will continue to increase.1 According 
to the World Health Organization (WHO), COPD will be the fourth leading cause 
of mortality and the seventh leading cause of disability-adjusted life years in 
2030.4 COPD is also associated with an increased economic and societal burden. 
COPD results in increased disability, leading to increased healthcare costs. Within 
the European Union, 6% of healthcare spending is accounted to direct costs of 
COPD.5 Especially exacerbations and hospital admissions attribute to an increase 
in healthcare costs.6-9
Most common symptoms in advanced COPD are breathlessness, fatigue, muscle 
weakness, cough and sputum production.1,10 Presence of these symptoms has a 
major impact on quality of life and functional status.11-13 A prospective survey among 
100 patients with advanced COPD showed that impairment in quality of life was 
strongly associated with high symptom burden, disease-related dysfunction and 
impaired psychological wellbeing.14 Furthermore, COPD is associated with a higher 
number of comorbidities than other diseases,15 including cardiovascular, cachectic, 
metabolic and psychological comorbidities.10,16 As was shown by a cross-sectional 
analysis of Scottish national data, half of patients with COPD aged over 65 has at 
least three other morbidities.17
Management of COPD includes reduction of exposure to risk factors like smoking 
cessation, pharmacological treatment like inhaled bronchodilators or corticosteroids 
and nonpharmacological treatment like pulmonary rehabilitation. In patients who 
still experience symptoms despite optimal pharmacological and nonpharmacological 
management, palliative care is indicated.1
Palliative care
Palliative care is defined by the WHO as ‘an approach that improves the quality of 
life of patients and their families facing the problem associated with life-threatening 
illness, through the prevention and relief of suffering by means of early identification and 
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impeccable assessment and treatment of pain and other problems, physical, psychosocial 
and spiritual. Palliative care provides relief from pain and other distressing symptoms; 
affirms life and regards dying as a normal process; intends neither to hasten or postpone 
death; integrates the psychological and spiritual aspects of patient care; offers a support 
system to help patients live as actively as possible until death; offers a support system 
to help the family cope during the patients illness and in their own bereavement; uses a 
team approach to address the needs of patients and their families, including bereavement 
counselling, if indicated; will enhance quality of life and may also positively influence the 
course of illness; is applicable early in the course of illness, in conjunction with other 
therapies that are intended to prolong life, such as chemotherapy or radiation therapy; 
and includes those investigations needed to better understand and manage distressing 
clinical complications.’18 Palliative care is directed to relief of distressing symptoms, 
enhancement of quality of life and supporting loved ones during the palliative phase 
of the disease and after the patient is deceased. Palliative care can be provided 
simultaneously to disease-modifying treatment and is a multidisciplinary approach 
in which generalist and specialist caregivers collaborate with the patient and his or 
her loved ones, taking into account the values, wishes and needs of the patient.19 
Palliative care improves the patient’s quality of life, symptom burden, healthcare 
utilization and patient and caregiver satisfaction after one to three months of follow-
up, without affecting survival.20
Palliative care in patients with COPD
A large proportion of patients with COPD experience symptom burden despite 
optimal treatment of their disease and comorbidities.10 There is a need for additional 
treatment, next to the disease-modifying treatment, to reduce symptoms and 
improve functioning and quality of life. Patients with advanced COPD more 
often experience worse quality of life and symptoms of anxiety, depression or 
breathlessness compared to patients with lung cancer.21,22 However, patients with 
COPD are less likely to receive symptom relief in the last six months of life compared 
to patients with lung cancer.23
The course of COPD is unpredictable, with patients often living with the disease for 
years. They experience acute deteriorations, mainly due to exacerbations, and often 
there is no distinct terminal phase.24,25 Therefore, early recognition of palliative care 
needs in COPD is important. This is also endorsed by pulmonologists.26 During stable 
phases of the disease, patients in the Netherlands are treated by several different 
(para)medical specialists, like the general practitioner, pulmonologist, pulmonary 
nurse specialist or physiotherapist. During hospital admissions, treatment is mainly 
performed by pulmonologists (in training) and pulmonary nurse specialists.26 
Furthermore, due to comorbidities, other specialties are often involved as well. 
Therefore, a multidisciplinary and integrated management is necessary to provide 
the most optimal palliative care.27





Breathlessness is one of the most common symptoms in advanced COPD and 
is reported by 94% of patients.10 It is a multidimensional experience, and the 
underlying mechanisms are complex. Breathlessness is defined as ‘a subjective 
experience of breathing discomfort that consists of qualitatively distinct sensations that 
vary in intensity ’.28 This breathing discomfort originates from an imbalance between 
the afferent information to the central nervous system and the mechanical response 
of the respiratory system, also called an efferent-afferent dissociation or demand-
capacity imbalance.29,30 Afferent sensory information from mechanoreceptors, 
chemoreceptors and respiratory muscle receptors throughout the respiratory 
system is processed in the central nervous system, specifically in respiratory control 
centers in the brainstem. Efferent output from the respiratory control centers to 
respiratory muscles controls respiration. Information on this output is relayed to 
the somatosensory cortex via corollary discharge.29-31 In the somatosensory cortex, 
afferent input and efferent output is compared. A mismatch between input and 
output beyond a certain threshold is perceived as breathlessness, specifically the 
sensory component of breathlessness (i.e. intensity).28-30 Afferent information is 
relayed to the limbic system as well. As this system is involved in the affective 
state, the efferent-afferent dissociation provokes a strong emotional response to 
breathlessness (i.e. anxiety, panic, distress), inducing the affective component of 
breathlessness (i.e. unpleasantness).29,31,32 Perception of breathlessness is influenced 
by expectations and beliefs based on previous experiences (priors). This process 
of anticipatory learning evokes conditional behavioral (avoidance) responses.30-32
The language of breathlessness
The different mechanisms and afferent pathways involved in breathing are 
associated with distinct different sensory qualities.28 These qualities can vary in 
intensity and unpleasantness,28 can vary over the day or week33 and are described 
by a variety of descriptors.28 Patients with different medical conditions use different 
descriptors.28,34,35 Also, different sensations can be induced in healthy volunteers 
using different physiological mechanisms.28,36,37 These descriptors have been 
combined in factor analytic studies to clusters.34,35 The cluster of breathing work/
effort (‘I feel out of breath’ or ‘my breathing requires work/effort’ ) is hypothesized to 
originate from a mismatch between afferent input from respiratory muscle receptors 
and increased voluntary respiratory motor output. On the contrary, the cluster of 
air hunger/unsatisfied inspiration (‘I cannot get enough air’ ) has been related to an 
increased spontaneous ventilatory drive, which cannot be fulfilled with sufficient 
ventilation. A third common cluster of sensory descriptors is chest tightness (‘my 
chest feels tight/constricted’). This cluster is commonly related to bronchoconstriction 
and arises from stimulation of airway receptors. Where patients with COPD during 
stable phases of their disease usually describe their breathlessness as breathing 
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work/effort and air hunger, patients usually experience all clusters during an 
exacerbation.34,35,38-40
Assessing breathlessness
Measurement of breathlessness serves different purposes. First, measures can be 
used to discriminate between patients with mild or severe breathlessness. Second, 
change of breathlessness over time can be measured, for instance to evaluate the 
effectiveness of an intervention.41
Since breathlessness is a subjective sensation, it is assessed using patient-reported 
measures. Intensity of breathlessness is generally assessed with unidimensional 
measures like a visual analogue scale (VAS),42 numeric rating scale (NRS)43 or 
modified Borg scale.44 Using these measures, breathlessness during a certain 
period (i.e. today, during the previous week) or during a certain activity (i.e. 
walking, climbing the stairs) can be assessed. These measures are especially suited 
to evaluate changes of breathlessness over time and less useful to discriminate 
between patients.45 The minimal clinical important difference of the 0-100 VAS and 
0-10 NRS has been determined at 10 points or 1 point, respectively.46
Burden or impact of breathlessness on daily activities is most frequently assessed 
using the modified Medical Research Council (mMRC) breathlessness scale.47,48 
The mMRC breathlessness scale is a short and simple assessment, including five 
descriptions of impact of breathlessness on functional ability: grade 0 (‘I only 
get breathless with strenuous exercise’ ) to grade 4 (‘I am too breathless to leave the 
house or I am breathless when dressing’ ). The mMRC is able to discriminate between 
patients with low breathlessness burden (mMRC grade 0 to 1) and patients with high 
breathlessness burden (mMRC grade ≥2).1 Also, the mMRC has shown to predict 
survival in patients with COPD.49,50 Due to the broad grades the mMRC has limited 
ability to assess changes over time.51
Finally, the multidimensional properties of breathlessness can be assessed using 
measures like the Multidimensional Dyspnea Profile.52,53 The Multidimensional 
Dyspnea Profile assesses both the sensory and affective dimensions of 
breathlessness. Breathing unpleasantness, five sensory clusters (breathing work/
effort, air hunger, chest tightness, mental effort and hyperpnoea) and five affective 
emotional responses (depression, anxiety, frustration, anger and fear) are rated on a 
0 to 10 NRS. This measure has shown to be responsive to clinical changes over time.53
Breathlessness burden
Breathlessness can be an invisible symptom for the patient’s environment 
and healthcare professionals,54 but has major psychosocial consequences like 
care dependency, social limitations and anxiety.13 When COPD progresses and 
breathlessness worsens, patients experience more trouble during daily life activities, 
more anxiety restricting them to their house and growing dependence. This shifts 
over time with ups and downs due to the erratic course of COPD.54




Worsening of breathlessness over time increases healthcare utilization.8,9 Patients 
with high breathlessness burden (mMRC grade ≥2) have more inpatients and 
outpatient healthcare utilization compared to patients with low breathlessness 
burden during a period of six months. These patients also receive more 
prescriptions for COPD-related medication.9 Main cost drivers are exacerbations 
and hospital admissions.8,9 Furthermore, healthcare utilization increases with the 
presence of comorbidities.6 The worsening of breathlessness over time impacts 
workplace productivity and activities of daily living, leading to an increasing need 
for help from informal caregivers.8,55,56 Societal costs increase significant when 
an informal caregiver is involved.8 Costs for lost productivity are mainly driven 
by early retirement of patients.55 This emphasizes the societal burden of COPD. 
As the current knowledge on the economic burden of breathlessness arises from 
studies using retrospective claims data, the long-term impact of breathlessness on 
healthcare and societal costs as reported by patients is not known.
Treatment of breathlessness
Breathlessness can be insensitive to treatment of the underlying disease and 
result in disability, thus becoming a treatment goal in itself.57 Current clinical 
guidelines emphasize the importance of palliation of chronic breathlessness using 
(a combination of) pharmacological and nonpharmacological interventions.58,59
Pulmonary rehabilitation has shown to be an effective intervention to improve 
breathlessness, exercise capacity and quality of life.60 A pulmonary rehabilitation 
program should ideally last six to eight weeks and should be personalized.1
Components of pulmonary rehabilitation include education, self-management, 
endurance and strength training (including neuromuscular electrical stimulation 
and inspiratory muscle training), breathing strategies and the opportunity for 
nutritional support, smoking cessation and psychosocial support.61 Use of a hand-
held fan directed to the face has shown to decrease breathlessness when used for 
at least five minutes.62,63 The main perceived benefit was a shorter recovery time 
after activity.64 Other nonpharmacological treatment interventions include the use 
of walking aids (i.e. walker),65 breathing techniques,66,67 inspiratory and expiratory 
muscle training,68,69 long-term oxygen therapy for patient with severe hypoxemia70
and noninvasive ventilation for patients with hypercapnia.71,72
Pharmacological interventions include opioids, benzodiazepines and 
antidepressants. Opioids will be discussed in the next section. Benzodiazepines 
relieve anxiety and are used to treat breathlessness. However, a Cochrane review 
showed that benzodiazepines have no beneficial effect on breathlessness, both 
for the total included population of 214 patients with chronic breathlessness as 
for the subpopulation of 61 patients with COPD. There was no difference in type of 
benzodiazepine, dose, route or dosing schedule. Patients in the treatment group 
had an increased risk of adverse effects.73 Recently, two randomized controlled 
trials have assessed the effect of antidepressants on breathlessness. Sertraline 
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did not show a beneficial effect after four weeks in 223 patients with chronic 
breathlessness.74 The same results were found for mirtazapine treatment after 
four weeks in 64 patients with chronic breathlessness.75
Opioids
It has been hypothesized that opioids relieve breathlessness by centrally 
modulating the perception of breathlessness.76 Opioids modulate the awareness 
of breathlessness by acting upon respiratory control centers and centers in the 
somatosensory cortex involved in respiration.77-79
Also, in processing afferent sensory information in the central nervous system, 
limbic areas (including the anterior cingulate cortex, amygdala and thalamus) are 
activated.29,32 As these areas are abundantly innervated with opioid receptors, 
they are involved in modulation of breathlessness by opioids as well.80,81 The most 
extensively studied opioid to treat chronic breathlessness is morphine.
Effectiveness
Several systematic reviews have determined the effect of opioids for chronic 
breathlessness.82-85 The first Cochrane systematic review, conducted in patients 
with different life-limiting illnesses,82 showed moderate-level evidence that oral and 
parenteral opioids significantly reduced breathlessness, while nebulized opioids did 
not. A subgroup analysis in patients with COPD showed similar results as in the total 
included population. An update of this systematic review in 2016 showed smaller 
effects.83 However, the meta-analysis, which did not account for cross-over designs 
and a repeat analysis,85 showed a mean difference of 1 point on a 0 to 10 NRS, which 
corresponds to a clinically important difference.86 A third systematic review was 
performed in patients with COPD and showed moderate-level evidence that opioids 
improved breathlessness. The evidence was most consistent for systemic opioids 
and when given in steady state.84
As the goal of palliative care is to improve quality of life, among other things, by 
alleviating symptoms,18 it is important to assess the effect of palliative treatment on 
quality of life. Only five studies so far have included an outcome of quality of life, of 
which three showed no effect.87-89 Shohrati et al.90 showed an improvement of global 
quality of life after five days of nebulized morphine. Poole et al.91 reported a slight 
worsening of the mastery domain of the Chronic Respiratory Disease Questionnaire 
after six weeks of sustained-release morphine.
The effect of opioids on functional performance has been studied more extensively. 
Three meta-analyses showed no effect of opioids on exercise performance.82-84 The 
results were consistent for systemic and nebulized opioids and for measurements 
at steady state. A recent small clinical trial on the acute effect of a single dose 
of immediate-release morphine during constant-load cardiopulmonary cycle 




exercise testing showed that exertional breathlessness and exercise endurance 
improved significantly and clinically relevant. This improvement was associated 
with a reduction in ventilation and respiratory rate.78 Since the vast majority of 
studies examined the effect on functional performance after a single dose or a 
short treatment duration, the long-term effect of opioids on functional performance 
remains unknown.
Safety and adverse effects
As opioids have been an important analgesic treatment for centuries, the safety and 
occurrence of adverse effects has been studied extensively. In fear of the occurrence 
of respiratory depression or other adverse effects, physicians indicate to be hesitant 
to prescribe opioids to patients with advanced COPD.92-94 Systematic reviews on 
the effects of opioids on chronic breathlessness showed no evidence for an effect 
of opioids on respiratory outcomes.82-84 On the contrary, three case reports have 
described cases of serious respiratory depression after high doses of nebulized 
morphine,95 immediate-release oral morphine96 or transmucosal fentanyl.97 Known 
other adverse effects of morphine are nausea, constipation and drowsiness. 
Clinical studies into the treatment of chronic breathlessness have shown that these 
adverse effects are mainly mild or moderate. Symptoms reduce after treatment 
with laxatives or anti-emetics or resolve after discontinuation of the treatment. No 
serious adverse effects have been registered.82-84,98
Safety profiles on the longer term have been assessed in large observational studies. 
A prospective cohort of 2249 patients with COPD starting long-term oxygen therapy 
that was followed-up for four years showed no increase in hospital admissions or 
increased mortality after treatment with ≤30 mg morphine equivalent per day.99
A retrospective cohort of 130,979 patients with COPD showed that the incidence 
of opioid prescription was 68.2% and was associated with a small increase in 
respiratory-related hospital admissions, respiratory-related mortality and all-cause 
mortality within 30 days after commencement of the treatment.100 However, the 
opioid dose or indication of prescription was unknown.
Beneficial response to morphine
A dose increment and pharmacovigilance study in patients with different life-limiting 
illnesses has been performed.101,102 Patient started at 10 mg sustained-release 
morphine per day for one week. When no clinical relevant improvement was shown 
after this week, the dose was increased to 20 mg per day for a week and necessarily 
to 30 mg per day a week later. Results showed that 62% of patients accomplished 
a clinically relevant improvement in breathlessness. For 70% of these patients, 10 
mg per day was effective.101 In patients that needed upward titration to 20 or 30 mg 
daily, an improvement was shown within the first 24 hours. The effect continued to 
improve over the successive six days.102 Patients that showed a clinically relevant 
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improvement were followed-up; about one-third of patients maintained benefit 
after three months of treatment.101
The above mentioned study also shows that 31% of patients showed no beneficial 
effect to morphine at the maximal dose or experienced unacceptable side effects 
and withdrew before achieving the maximal dose. Current literature is conflicting 
regarding whether breathlessness intensity, age and clusters of sensory description 
of breathlessness are predictors of response to morphine.101,103,104 Younger age has 
been associated with a beneficial response.103,104 Worse baseline breathlessness 
intensity was not associated with a beneficial response in two clinical trials,101,103 
but a pooled analysis did show a favorable effect.104 Results on the contribution 
of clusters of sensory breathlessness description suggest a favorable effect in 
laboratory models in healthy subject describing breathlessness as air hunger,105 but 
not as breathing work/effort.106 In a mixed patient population, a favorable effect for 
air hunger was shown as well.104 However, since patients with different conditions 
use different descriptors,34-36 it remains unknown what the attribution of sensory 
description of breathlessness on a beneficial response to morphine in COPD is.
Attitudes of physicians and patients
Although opioids have proven to be effective and safe and are recommended 
in several national and international guidelines, chronic breathlessness is often 
still undertreated.107,108 Although physicians recognize chronic breathlessness in a 
case scenario, they are less likely to recognize the need for further treatment and 
offer symptomatic treatment, and are less likely to prescribe opioids compared to 
patients with chronic pain.109 In daily practice, 47% of physicians,109 45% of general 
practitioners,110 18.5% of pulmonologists92 and 13.5% of junior doctors111 report 
not to prescribe opioids to outpatients with advanced COPD. Main reasons for 
not treating with opioids mentioned by physicians are insufficient knowledge or 
experience, risk of adverse effects, including respiratory depression, resistance of 
the patient and lack of guidelines.92-94,109-111
Small qualitative studies in patients revealed barriers like fear of dependence and 
fear of imminent death.93,112 Clinical studies on the effect of opioids had difficulties 
including patients.98,113 Patients that did start opioid treatment mentioned doing as 
much as possible as most important reason.93,112
Aims of this thesis
Chronic breathlessness is a common and significant symptom in patients with 
advanced COPD. Opioids are suggested as palliative treatment, with the best 
evidence for low-dose, oral sustained-relief morphine. Palliative care is directed 
at relief of distressing symptoms and enhancing quality of life, without hastening 
death. Not all of these aspects are clear for low-dose morphine. The effect on quality 




of life, functional performance, respiratory outcomes and breathlessness remains 
conflicting. Also, the long-term economic burden of chronic breathlessness using 
prospective, patient-reported data is unclear and no data on cost-effectiveness of 
oral morphine treatment is available. Therefore, the central aim of this thesis was 
to assess these palliative aspects of low-dose morphine.
The specific aims of this thesis were:
• To systematically review the occurrence of respiratory adverse effects in patients 
with life-limiting illnesses and chronic breathlessness who are treated with 
opioids;
• To examine whether and to what extent regular, low-dose, oral sustained-release 
morphine leads to respiratory adverse effects in patients with advanced COPD 
and chronic breathlessness;
• To study whether and to what extent regular, low-dose, oral sustained-release 
morphine improves disease-specific health status, functional performance and 
breathlessness in patients with advanced COPD and chronic breathlessness;
• To explore the relationship between response to morphine, intensity and 
sensory description of breathlessness and baseline characteristics in patients 
with advanced COPD and chronic breathlessness;
• To analyze the impact of breathlessness burden in COPD on healthcare and 
societal costs;
• To analyze the cost-effectiveness of regular, low-dose, oral sustained-release 
morphine in patients with advanced COPD and chronic breathlessness from a 
healthcare and societal perspective;
• To assess the willingness of patients with chronic lung disease or chronic heart 
failure to use opioids for chronic breathlessness and possible barriers or reasons 
to use opioids.
Outline
Chapter 2 describes the results of a systematic review and meta-analysis, which 
examines the effect of opioid treatment for chronic breathlessness on respiratory 
outcomes in patients with life-limiting illnesses. Chapter 3 presents the economic 
burden of chronic breathlessness. This chapter describes the healthcare and societal 
costs during a two-year follow-up in patients with COPD who recently completed 
a comprehensive pulmonary rehabilitation program. Chapter 4 describes the 
methodology of a randomized, double-blind, placebo-controlled, parallel-arm 
intervention study we performed for this thesis in detail. Chapter 5 presents the 
clinical results of this randomized clinical trial. More specifically, it shows the effect 
of regular, low-dose, oral sustained-release morphine on health-related quality of 
life, respiratory outcomes, breathlessness and functional performance. Chapter 
151445_Cindy_van_den_Berg_BNW-def.indd   17 13-9-2021   12:34:15
18
Chapter 1
6 shows the relationship between a beneficial response to regular, low-dose, oral 
morphine treatment, intensity and description of breathlessness and baseline 
patient characteristics. Chapter 7 describes the cost-effectiveness of regular, low-
dose, oral sustained-release morphine treatment from a healthcare and societal 
perspective. Chapter 8 explores the willingness of patients with chronic lung or 
heart disease to use opioids for breathlessness and perceived barriers or reasons 
to use opioids. Chapter 9 is the general discussion, in which the clinical implications 
of this thesis and directions for future research are discussed.
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Previous studies have shown that opioids can reduce chronic breathlessness in 
advanced disease. However, physicians remain reluctant to prescribe opioids for 
these patients, commonly due to fear of respiratory adverse effects. The aim of this 
study was to systematically review reported respiratory adverse effects of opioids 
in patients with advanced disease and chronic breathlessness.
PubMed, Embase, the Cochrane Central Register of Controlled Trials, CINAHL, 
ClinicalTrials.gov and the reference lists of relevant systematic reviews were 
searched. Two independent researchers screened against predefined inclusion 
criteria and extracted data. Meta-analysis was conducted where possible.
We included 63 out of 1990 articles, describing 67 studies. Meta-analysis showed 
an increase in carbon dioxide tension (0.27 kPa, 95% CI 0.08 to 0.45 kPa) and 
no significant change in oxygen tension and oxygen saturation (both p>0.05). 
Nonserious respiratory depression (definition variable/not stated) was described 
in four out of 1064 patients. One cancer patient pretreated with morphine for 
pain needed temporary respiratory support following nebulised morphine for 
breathlessness (single case study).
We found no evidence of significant or clinically relevant respiratory adverse effects 
of opioids for chronic breathlessness. Heterogeneity of design and study population, 
and low study quality are limitations. Larger studies designed to detect respiratory 
adverse effects are needed.
Take home message
There is no evidence for clinically relevant respiratory adverse effects of opioids 
for chronic breathlessness.
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Introduction
Breathlessness is defined as ‘a subjective experience of breathing discomfort that 
consists of qualitatively distinct sensations that vary in intensity’.1 Breathlessness is 
one of the most uncomfortable symptoms in patients with advanced disease.1 In 
cancer, 50 to 70% of patients suffer from breathlessness, while in chronic obstructive 
pulmonary disease (COPD) this prevalence is as much as 56 to 98%.2,3
Opioids can reduce chronic breathlessness (breathlessness that persists despite 
optimal treatment of the underlying pathophysiology and results in disability4) in 
patients with advanced diseases.5-8 However, while physicians are mostly willing to 
prescribe opioids for breathlessness in the last days or weeks of life, they are often 
reluctant to prescribe opioids to those earlier in their disease trajectory.9 Their 
main concerns are fears of respiratory adverse effects and lack of evidence-based 
guidelines.10-12 Data about respiratory adverse effects of opioids are limited and 
conflicting. Systematic reviews on the effects of opioids on chronic breathlessness 
in adults with advanced life-limiting disease showed no evidence for the following 
outcomes: respiratory depression, increase in arterial carbon dioxide tension 
(PaCO2), increase in end-tidal carbon dioxide tension (PETCO2), decrease in arterial 
oxygen tension (PaO2) or decrease in arterial oxygen saturation (SaO2).
5-8 However, 
meta-analyses on these outcomes have not been conducted before.
Conversely, observational studies have reported one or more cases of severe 
respiratory depression in patients using opioids for breathlessness.13-16
Most guidelines in palliative care recommend the use of opioids for chronic 
breathlessness.17-19 However, guidelines in respiratory medicine, for example the 
recent Global Initiative for Chronic Obstructive Lung Disease guidelines,20 are more 
circumspect because of possible serious adverse events and limited effectiveness. 
To date there is little evidence whether and to what extent opioids lead to respiratory 
adverse effects in patients with chronic breathlessness.
The aim of this systematic review and meta-analysis was to study the occurrence 
of respiratory adverse effects (in particular increase of PaCO2 and PETCO2, decrease 
of PaO2 and SaO2, decrease in respiratory rate and occurrence of respiratory 
depression) in patients with advanced disease and chronic breathlessness who 
are treated with opioids. Respiratory adverse effects are examined in experimental 
studies and observational studies, as well as case reports. However, none of the 
previous reported reviews included all these study types. Therefore, to generate 
a full overview of the current knowledge, we included experimental studies, 
observational studies and case reports.




A systematic review and meta-analysis was performed according to the Cochrane 
methodology.21 Results are reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.22 The protocol 
is registered in the International Prospective Register of Systematic Reviews 
(PROSPERO, CRD42016033691).
Search strategy
The following databases were searched: PubMed, Embase on Ovid, Cochrane 
Central Register of Controlled Trials and CINAHL on EBSCO (inception date to 
March 31, 2016). Search terms comprised (dyspnoea OR synonyms) AND (opioid 
OR synonyms) and included both terms of controlled vocabulary and free search in 
title and abstract (Supplemental Methods A-D). Furthermore, ClinicalTrials.gov was 
searched for ongoing or completed studies using the same search terms (May 29, 
2017; Supplemental Methods E). Following de-duplication, we included all original 
research articles such as randomised controlled trials (RCTs), nonrandomised trials 
(NRTs), case-control studies, cohort studies, chart reviews, case reports and case 
studies. Reference lists of three relevant systematic reviews6-8 were searched by 
hand and experts in the field were contacted. We included articles in the English, 
Dutch, German, French and Spanish languages. When a full-text article was not 
accessible, this was requested from the authors.
Study selection
For study screening, we used Endnote X7 (Thomson Reuters, Philadelphia, PA, USA). 
The titles and abstracts were screened independently by two researchers (CV and 
either DJ, MvdB or SD) and selected based on the description of treatment for 
chronic breathlessness using opioids. The remaining full-text articles were screened 
by two researchers (CV and either SD [English], DJ [German or Dutch] or LV [French or 
Spanish]) against all eligibility criteria: 1) participants included patients, regardless of 
their primary condition; 2) any opioid as intervention prescribed for breathlessness, 
regardless of dose or route of prescription; and 3) primary or secondary outcomes 
included PaCO2, PaO2, SaO2 or respiratory rate. During the screening process, 
we decided in addition to include PETCO2, occurrence of respiratory depression 
and breathlessness as outcomes. Any type of control group was considered. We 
excluded studies including only healthy subjects or studies that used an opioid 
in combination with other treatments and the effect of the opioid could not be 
distinguished. Consensus was reached by discussion. The study designs of included 
articles were categorised as follows: RCTs, NRTs, prospective observational studies 
(POSs), retrospective observational studies (ROSs) and case reports.
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Risk of bias
Two researchers independently assessed the risk of bias on the study level (CV and 
either SD [English], DJ [German] or LV [French]). For the RCTs, we assessed this risk 
of bias regarding random sequence generation, allocation concealment, blinding, 
incomplete outcome data and selective reporting using the Cochrane risk of bias 
tool.21 In addition, the Cochrane risk of bias tool was used to assess the risk of bias 
in NRTs. Since no control condition was included in these studies, a high risk of 
selection bias, performance bias and detection bias were estimated in all NRTs. For 
POSs, we assessed the risk of bias regarding selection, comparability and exposure/
outcome using the Newcastle-Ottawa quality assessment scale.23 Consensus was 
reached by discussion. The risk of bias in ROSs and case reports was not assessed.
Data collection
Data were extracted by two researchers (CV and either SD [English], DJ [German] or 
LV [French]) using a predefined extraction form in Excel (Microsoft, Redmond, WA, 
USA), including data on study characteristics (design, duration, setting and inclusion 
and exclusion criteria), type of intervention (intervention, comparison, dose, mode 
and timing of administration), study population (sample size, age, sex, diagnosis, 
disease severity and use of oxygen) and outcomes (breathlessness, respiratory 
outcomes: PaCO2, PETCO2, PaO2, SaO2, respiratory rate and occurrence of respiratory 
depression, mode of assessment and missing data). When two articles appeared to 
describe overlapping research questions and study populations, we contacted the 
authors to request more information. We recorded the baseline values and change 
from baseline or post-treatment scores of the respiratory outcomes. When only 
a description of the change from baseline was given, this was taken into account. 
The form was piloted on two articles of each study type and adapted as needed.
Data synthesis
Change from baseline measurement scores or post-treatment measurement scores 
were collected for the PaCO2, PETCO2, PaO2, SaO2 and respiratory rate. For the RCTs, 
these results were compared between the intervention and control groups. For 
the NRTs, POSs, ROSs and case reports, the change from baseline was examined. 
Meta-analyses were performed using the results of RCTs; however, RCTs without a 
placebo comparator group were not included. When both a change from baseline 
and a post-treatment score were reported, the post-treatment score was used 
in the meta-analysis. Furthermore, the highest dose or latest measurement was 
included in the meta-analyses if multiple doses of the same opioid or repeated 
measurements were reported. When an RCT compared more than one opioid with 
placebo, the morphine group was included in the meta-analysis. For measurements 
on exertion, the submaximal measures at a fixed time point were included. To verify 
whether the included RCTs showed a pooled effect of improving breathlessness, 
meta-analysis on the effect of opioids on breathlessness was performed. These 
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results were presented as standardised mean difference (95% CI), since different 
scales to measure breathlessness were used. Results of the meta-analyses on 
PaCO2, PETCO2, PaO2, SaO2 and respiratory rate were presented as mean difference 
(MD) (95% CI), as the same scales to measure comparable outcomes were used. In 
all meta-analyses a random effects model was used, since the study designs were 
heterogeneous.21 Results of PaO2 and PaCO2 that were reported in mmHg were 
converted to kPa (1 mmHg = 0.133 kPa).
Some RCTs contributed more than one contrast between the opioid and control 
group for the same outcome (i.e. subjects were measured multiple times under 
comparable conditions). To account for this clustering of multiple contrasts within 
one study sample, we used a multilevel meta-analysis approach to determine if any 
within-study clustering was present. If there was evidence of within-study clustering, 
quantified by the intraclass correlation coefficient, the results of the multilevel 
approach were preferred over the standard approach.24 To examine the impact of 
the context of assessment (at rest or on exertion), the number of doses (single dose 
or multiple doses) or the route of administration (nebulised or systemic), a mixed-
effects meta-regression was performed. Subgroup analyses were performed for 
variables which appeared to be of impact. When no impact appeared, all outcomes 
were analysed together.
When a study assessed the occurrence of respiratory depression, the frequency 
of occurrence and the definition used was reported. Analysis of this outcome was 
descriptive.
Analyses were performed using Review Manager (version 5.3; The Northern 
Cochrane Centre, 2014, Copenhagen, Denmark) and R (version 3.2.3; R Foundation 
for Statistical Computing, Vienna, Austria). GRADEPro Guideline Development Tool 
software (www.gradepro.org) was used to construct the Summary of Findings Table. 




The search identified 1990 articles, of which 63 met the inclusion criteria (Figure 1). 
The 63 articles included reported on 67 studies: 35 RCTs (Table 1), 17 NRTs (Table 
1), four POSs (Supplemental Table S1), five ROSs (Supplemental Table S1) and six 
case reports (Supplemental Table S2). Six ongoing studies, four RCTs and two NRTs 
were identified (Supplemental Table S3). PaCO2, PaO2 and PETCO2 were examined in 
one study; SaO2 was examined in four studies and respiratory rate was examined in 
three studies. In one study, it is not clear which blood gases were examined. In one 
study the respiratory adverse effects were a primary outcome, and in five studies 
the respiratory adverse effects were secondary outcomes.
151445_Cindy_van_den_Berg_BNW-def.indd   34 13-9-2021   12:34:19
35
Respiratory adverse effect of opioids for breathlessness
2
Figure 1. Study selection.
Abbreviations: PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; PETCO2, end-tidal carbon 
dioxide tension; RCTs, randomised controlled trials; RD, respiratory depressions; RR, respiratory rate; SaO2, arterial 
oxygen saturation.
19 RCTs were included in the meta-analysis on the effect of opioid treatment 
on breathlessness.25-42 Eight RCTs used a visual analogue scale to examine 
breathlessness,25,26,29,35,36,38,40 six RCTs used the Borg scale,27,30-34 three RCTs used 
a numeric rating scale,28,39,41 one RCT used the dyspnoea domain of the Chronic 
Respiratory Questionnaire42 and one RCT used an oxygen cost diagram.37 The 
RCTs that reported post-treatment scores showed effectivity of opioids in relieving 
breathlessness (standardised mean difference −0.42, 95% CI −0.62 to −0.21; I2 27%; 
Supplemental Figure S1). The RCTs that reported changes from baseline were not 
able to show effectivity of opioids in relieving breathlessness (standardised mean 
difference −0.09, 95% CI −0.78 to 0.60; I2 62%; Supplemental Figure S1).
Risk of bias
As shown in Supplemental Table S4, the risk of bias of the RCTs was estimated to be 
low or unclear in most studies. Other sources of bias were assessed as high risk in 
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43% of the studies, mainly because of the absence of a washout period in crossover 
trials. Supplemental Table S5 shows the risk of bias of the NRTs. High risk of selection 
bias, performance bias and detection bias were estimated, as no control condition 
was included in these studies. In the other categories, the risk of bias was assessed 
as low in most studies. The POSs were graded with three to six out of eight stars 
due to comparability and representativeness of cohorts (Supplemental Table S6).
Effect on outcomes of respiratory adverse effects
The effects of opioid treatment on outcomes of respiratory adverse effects are 
shown in Supplemental Tables S1, S2, S7 and S8. A summary of the effects of the RCTs 
included in the meta-analyses is presented in Table 2. Since none of the intraclass 
correlation coefficients of comparisons within RCTs were significantly different 
from zero, and therefore the effect of clustering on the outcomes was negligible 
for RCTs that contributed more than one contrast for a single outcome measure, 
the results are analyzed using regular meta-analyses instead of three-level meta-
analyses. Most of the included RCTs were crossover trials, and we included both 
parallel and crossover trials in the meta-analyses together. Results of 12 RCTs could 
not be included in the meta-analyses because they compared opioid treatment to 
something other than placebo (treatment with another substance,43-45 another dose 
or route of administration46-49 or usual care50 [Supplemental Table S7]). Results of 
seven RCTs could not be included in the meta-analyses because they reported their 
outcomes as median scores,51 did not report the outcomes per treatment arm52,53 
or reported the outcome in qualitative wording only30,54-56 (Supplemental Table S7).
Effect on PaCO2
The effect of opioid treatment on PaCO2 was assessed in nine RCTs,
29,33,37,43,45,50,51,55 
five of which could be included in the meta-analysis.29,33,37,51 The meta-analysis 
showed that treatment with opioids increased PaCO2 (MD 0.27, 95% CI 0.08 to 0.45; 
I2 0%; Figure 2a). The meta-regression revealed no influence from the context of 
assessment (p=0.437; however, there was only one RCT during exercise) or the 
number of doses (p=0.507) on the PaCO2. Route of administration was not taken into 
account, since all RCTs administered the opioid systemically. One RCT examined the 
effect of opioids on PaCO2 during exercise.
33 The difference between the intervention 
and control groups after administration of morphine was statistically significant at 
maximal exercise (5.8 and 5.1 kPa, respectively; p<0.001).
The effect on PaCO2 was assessed in seven NRTs.
43,57-62 One NRT found a significant 
increase in PaCO2.
57 Finally, the effect on PaCO2 was assessed in one ROS
63 and one 
case report describing two cases.64 In both studies the opioids were nebulised. The 
opioids were prescribed as a single dose or for up to 15 days. In all studies, PaCO2 
was measured at rest. None of these studies showed a significant effect of opioid 
treatment on PaCO2.
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Effect on PETCO2
The effect of opioid treatment on PETCO2 was assessed in seven RCTs,
27,29,30,32,34,54,66
five of which could be included in the meta-analysis.27,29,32,34,66 The meta-analysis 
showed a nonsignificant increase of the PETCO2 (MD 0.13, 95% CI −0.02 to 0.27; I
2
0%; Figure 2b). The RCT by Light et al.34 had a low variance compared to the other 
studies and consequently a high weight in the analysis. Therefore, as a sensitivity 
analysis, the meta-analysis was repeated, but with weighing based on the sample 
size. The effect on PETCO2 was still not significant (MD 0.13, 95% CI −0.11 to 0.37; I
2
0%). The meta-regression revealed no influence from the context of assessment 
(p=0.375), the number of doses (p=0.679) or the route of administration (p=0.473) 
on the PETCO2.
The effect on PETCO2 was assessed in two NRTs.
67,69 These studies reported no 
significant change in PETCO2.
67,69
Figure 2. Effect of opioid treatment in patients with advanced disease on a) arterial carbon 
dioxide tension (PaCO2); b) end-tidal carbon dioxide tension (PETCO2).
Notes: Data are presented as mean±SD or mean difference (95% CI), unless otherwise stated. Abbreviations: E, 
measured on exertion; R, measured at rest.
Effect on PaO2
The effect of opioid treatment on PaO2 was assessed in nine RCTs,
29,33,37,43,45,50,51,55 four 
of which could be included in the meta-analysis.29,33,37 The meta-analysis showed a 
nonsignificant decrease of the PaO2 (MD −0.26, 95% CI −0.68 to 0.15; I
2 0%; Figure 
3). The meta-regression revealed no influence from the context of assessment 
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(p=0.420; however, only one RCT was conducted during exercise) or the number of 
doses (p=0.815) on the PaO2. Route of administration was not taken into account, 
since all RCTs administered the opioid systemically. One RCT examined the effect 
of opioids on PaO2 during exercise.
33 The difference between the intervention and 
control groups after administration of morphine was statistically significant at 
maximal exercise (8.8 and 9.6 kPa, respectively; p<0.05).
The effect on PaO2 was assessed in two NRTs.
43,57 One NRT found a significant 
decrease in PaO2.
57 Finally, the effect on PaO2 was assessed in one case report 
describing two cases.64 In this study the opioids were nebulised for up to 15 days. 
PaO2 was measured at rest. This study showed no significant effect of opioid 
treatment on PaO2.
Figure 3. Effect of opioid treatment in patients with advanced disease on arterial oxygen 
tension (PaO2).
Abbreviations: E, measured on exertion; R, measured at rest.
Effect on SaO2
The effect of opioid treatment on SaO2 was assessed in 24 RCTs,
25-33,35,38-44,47-49,52-54,56
14 of which could be included in the meta-analysis.26-33,35,38-42 The meta-analysis 
showed that SaO2 decreased after opioid use (MD −0.41, 95% CI −0.73 to −0.08; 
I2 0%; Figure 4). The study by Chua et al.27 was the only RCT showing a significant 
difference in SaO2 between the intervention and control groups at rest (99.3% and 
100%, respectively; p=0.03). This RCT reported a variance of zero in the control 
group in rest and consequently had a high weight in the analysis. Therefore, as a 
sensitivity analysis the meta-analysis was repeated, but with weighing based on 
the sample size. The effect on SaO2 was no longer significant (MD −0.31, 95% CI 
−1.06 to 0.45; I2 0%). The meta-regression revealed no influence from the context of 
assessment (p=0.730), the number of doses (p=0.165) or the route of administration 
(p=0.538) on the SaO2.
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Figure 4. Effect of opioid treatment in patients with advanced disease on arterial oxygen 
saturation (SaO2).
Abbreviations: E, measured on exertion; R, measured at rest.
Furthermore, the effect of opioids on SaO2 was assessed in 12 NRTs.
43,58-62,67,69-71,73,74
One NRT showed a significant decrease in SaO2 from 93% to 92% after a single 
dose of 120 mg codeine.43 However, this decrease was temporary and not clinically 
relevant. Finally, the effect of opioids on SaO2 was assessed in two POSs,
75,76 two 
ROSs63,77 and three case reports describing seven cases.64,78,79 In these studies, the 
opioids were administered systemically (n=3), nebulised (n=2) or via an unknown 
route (n=1). The opioids were prescribed as single dose or as repeated doses up to 
3 months. In all studies, SaO2 was measured at rest. None of these studies showed 
a significant effect of opioid treatment on SaO2. In two RCTs
25,54 and one NRT67 SaO2
was measured, but no outcome data were reported.
Effect on respiratory rate
The effect of opioid treatment on respiratory rate was assessed in 23 RCTs,25-
28,30,32,33,35,36,38-41,43,46,47,49,51-53,56,65,66 13 of which could be included in the meta-analy
sis.25,26,30,32,33,35,36,38-41,65,66 The meta-analysis showed that treatment with opioids 
significantly decreased the respiratory rate (MD −1.10, 95% CI −1.49 to −0.71; I2 0%; 
Figure 5). The study by Shohrati et al.36 was the only RCT showing a significant 
difference in change in respiratory rate between the intervention and control groups 
(−1.5 and −0.1, respectively; p<0.001). This RCT had a low variance compared to 
the other studies and consequently a high weight in the analysis. Therefore, as 
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a sensitivity analysis, the meta-analysis was repeated, but with weighing based 
on the sample size. The effect on respiratory rate was no longer significant (MD 
−0.58, 95% CI −1.72 to 0.56; I2 0%). The heterogeneity among the RCTs describing 
post-treatment scores was 0%. The meta-regression revealed no influence from 
the context of assessment (p=0.496), the number of doses (p=0.904) or the route 
of administration (p=0.139) on the respiratory rate.
Figure 5. Effect of opioid treatment in patients with advanced disease on respiratory rate.
Abbreviations: E, measured on exertion; R, measured at rest; N: nebulised administration; S: systemic 
administration.
The effect on respiratory rate was also assessed in 15 NRTs.43,49,57-62,67-71,73,74 These 
studies also showed that opioids caused no significant change in respiratory rate. 
Finally, the effect on respiratory rate was assessed in three POSs,75,76,80 two ROSs63,77
and four case reports describing ten cases.64,78,79,81 In these studies, the opioids were 
administered systemically (n=4), nebulised (n=4) or via an unknown route (n=1). The 
opioids were prescribed as single dose or as repeated doses up to 3 months. In all 
studies, RR was measured at rest. These studies also showed that opioids caused 
no significant change in respiratory rate. In two RCTs28,43 and one NRT,43 respiratory 
rate was measured, but no outcome data were reported.
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Occurrence of respiratory depression
The occurrence of respiratory depressions was reported in five RCTs,25,32,40,47,50
11 NRTs,26,43,58-62,67,70,72,74 two POSs,14,75 three ROSs15,82,83 and four case reports 
describing ten cases.13,64,79,84 Out of these 25 studies, 11 defined respiratory 
depression.13,14,40,58-62,74,75,84 Definitions were based on an increase in PaCO2 of >0.5 
kPa or to >6.0 kPa, a decrease in respiratory rate of >10% or to <10 breaths·min-1
and a decrease in SaO2 of >5% or to <90%. Hu et al.
14 observed a case of respiratory 
depression (defined as decrease in respiratory rate to <10 breaths·min-1) in one 
patient with terminal cancer both at the beginning of the POS and two days prior 
to death. Kawabata and Kaneishi15 reported three patients experiencing respiratory 
depressions (no definition given), which were not serious. It was not stated whether 
these patients were treated for pain or breathlessness. Lang and Jedeikin13
described a case of respiratory depression (defined as respiratory rate of 4 to 5 
breaths·min-1, very poor respiratory effort and minimal wheezing over both lung 
fields) after administration of 4 mg nebulised morphine and 4 mg dexamethasone 
for breakthrough breathlessness in a patient already using 10 mg oral slow-release 
morphine three times per day and 10 mg oral immediate-release morphine when 
required for cancer-related pain.
Quality of the evidence
The quality of the evidence was assessed as very low to moderate for the different 
outcomes (Table 2). Only RCTs were included in this assessment. For all outcomes, 
the majority of the RCTs were small with insufficient power to assess respiratory 
adverse events and the quality was therefore downgraded. Furthermore, limitations 
in the design and implementation were observed. In several RCTs, patients who 
were pretreated with opioids were included, which had a negative effect on the 
quality of the evidence. Finally, only a small number of RCTs included assessment 
of PaCO2 and PaO2.
Discussion
Main findings
This systematic review on the occurrence of respiratory adverse effects following 
opioid treatment for breathlessness shows a great heterogeneity of treatment 
regimens and patient populations. Given this heterogeneity, we found no evidence 
that clinically relevant respiratory adverse effects are to be expected in patients 
with breathlessness who are treated with opioids, while included studies confirmed 
previous reports of opioid-related benefit for breathlessness. This suggests that 
clinicians’ fears of respiratory obtundation with the use of low-dose opioids seem 
to be unfounded.
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The meta-analysis showed an increase in PaCO2 of 0.27 (0.09 to 0.46) kPa. Although 
this increase is statistically significant, it is not considered to be clinically relevant.85 
Indeed, the pooled mean±SD PaCO2 was 5.35±1.08 kPa, so the mean difference in 
PaCO2 was only 25% of the standard deviation. However, few RCTs reported on 
PaCO2, and the quality of this evidence is assessed as very low. One NRT reported 
a significant deterioration of blood gases, but the participants received 120 mg 
parenteral morphine per day.57 Given that 20 to 40% of oral morphine is bioavailable, 
this represents a much higher dose than the oral morphine doses required in the 
dose titration study (10 to 30 mg oral morphine per day)72 or the oral morphine 
repeat dose trials (20 mg oral morphine per day).25,41,65 The meta-analyses showed a 
significant decrease in SaO2 of 0.41% (0.73 to 0.08%) and respiratory rate of 1.10 (1.49 
to 0.71) breaths·min-1. However, in both analyses one study had a high weighting 
due to a small variance. The statistical significance disappeared when the analyses 
were repeated weighted on sample size. In four cases, a diagnosis of respiratory 
depression was made during the study, but the definition was poorly stated. In three 
occasions the indication and dose were not clear.15 In the fourth case, respiratory 
depression occurred in a patient with advanced metastatic cancer pretreated with 
opioids. The additive effect of both treatments, leading to a high dose of morphine, 
may have led to respiratory depression.13 It is notable that no cases of respiratory 
depression were noted in the context of RCTs, with their close monitoring. Neither 
the meta-analyses of PETCO2, PaO2, SaO2 and respiratory rate nor the studies that 
were not included in the meta-analyses showed a significant deterioration of these 
outcomes. The meta-regression did not provide a significant effect for the context 
of assessment (at rest or on exertion), the number of doses (single dose or multiple 
doses) or the route of administration (nebulised or systemic), which is surprising 
especially for the route of administration. Previous reviews have reported a different 
effect of opioids on breathlessness when administered systemically or nebulised.5,6 
The results of this meta-regression might be related to small effects within the 
included studies and the fact that only six studies included in the meta-analysis 
used nebulised opioid.
Six ongoing studies were identified. Three of those only examine a single or double 
dose of opioids and therefore will not illuminate the long-term effect. Of the three 
other studies, two have respiratory adverse effects as a secondary outcome, and the 
sample size calculation will therefore probably not be based on this outcome. Only 
the MORDYC (Morphine for Dyspnea in COPD) study focuses primarily on respiratory 
adverse effects, and the sample size calculation is based on the PaCO2.
85 This study 
will add valuable information about the occurrence of respiratory adverse effects.
Our findings are consistent with other reviews on opioids for chronic 
breathlessness5,6,86 and episodic breathlessness.87 These reviews included 
RCTs,5,6,86,87 NRTs6,86 and case reports.87 The authors of these reviews found no 
clinically relevant effect on blood gases, oxygen saturation or respiratory depression 
after treatment with different types of opioids in patients with advanced disease. 
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In hypoxic patients with cancer, an improvement of SaO2 was reported.
6 However, 
these reviews only included 39 studies, and meta-analyses could not be performed 
due to limited results on respiratory adverse effects. Furthermore, the focus of 
these reviews was on the effect of opioid treatment on breathlessness, and search 
terms for respiratory adverse effects were not included.
Limitations of the included studies
First, the risk of bias of the included studies was often difficult to estimate. The 
outcomes of interest in the current review were secondary outcomes in the majority 
of the included studies, and therefore the method of outcome assessment was 
often not described. The method of randomisation or allocation concealment was 
inadequately described in most studies. Since it was difficult to score the risk of bias 
and to set a cut-off point, we did not include a sensitivity analysis including only the 
studies with a low risk of bias. Second, there was great heterogeneity in the dosing 
regimens and comparators used. The prescribed doses ranged between the studies, 
with eight studies prescribing high doses of opioids. In 34 experimental studies, one 
observational study and seven cases, only a single dose of opioids was prescribed, so 
the long-term effect was not assessed. Seven RCTs did not include a placebo group, 
but used different doses, other medication or usual care as comparator. Third, the 
patient populations were heterogeneous. In some studies patients had to be opioid-
naïve, but not in others; patients could continue opioids for pain or the dose of the 
study medication was based on current analgesic treatment. Fourth, the included 
studies had a small sample size. The experimental studies included between one 
and 83 participants, with only six studies including a sample size of ≥30 participants 
per treatment group. These studies included outcomes of respiratory adverse 
effects, but were underpowered to properly assess a change in these outcomes. 
The observational studies used larger sample sizes, but only a proportion of these 
patients received opioids for breathlessness. In some studies, the results accounted 
for the entire group, making it impossible to draw conclusions for the subgroup 
of our interest. Fifth, the definition of respiratory depression differed between 
studies. The most reliable assessment of respiratory depression is based on the 
PaO2 and PaCO2. Measurement of SaO2 is less reliable.
88 Some authors included 
respiratory rate as a measure of respiratory depression, because this is easier to 
estimate. Only 11 studies defined respiratory depression, and eight used a decrease 
in SaO2 as part of the definition. Only four also included an increase of PaCO2. Finally, 
five studies mentioned the assessment of respiratory outcomes in their method 
section, but didn’t include the results (n=3) or only reported the baseline data (n=2). 
Furthermore, 25 studies reported on the occurrence of respiratory depression, but 
only nine of them mentioned the assessment of respiratory depression in their 
methods section. Therefore, it is not known if a respiratory depression occurred in 
any of the remaining 42 studies.
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Strengths and limitations of the current review
Our study has several strengths. We included several study types; although RCTs 
yield the most reliable evidence, observational studies and case reports are closer 
to daily clinical practice. Furthermore, we included studies that were published in 
five languages. Because of the large number of included studies, we were able to 
present the current knowledge of six different outcomes of respiratory adverse 
effects, and we were able to perform meta-analyses on five of these. This provides 
an overall estimate of the effect of opioid treatment on these outcomes.
Our review has several limitations. First, we only searched four databases. Due to 
publication bias, we might have failed to identify negative results. However, we also 
searched one trial register, sought expert opinions and hand-searched the reference 
lists of important reviews in the field of opioid treatment for chronic breathlessness. 
We identified a large number of studies, decreasing the chance that we missed 
important studies. Second, several RCTs could not be included in the meta-analyses 
because of reasons discussed earlier. Third, we combined results from studies with 
different contexts of assessment, different number of doses and different route of 
administration; however, this was done only after the meta-regression which did not 
yield evidence that these moderators had an effect on the outcome. The number 
of studies used for this analysis was in some cases very low, making the power to 
detect effects questionable. However, due to the robustness of the results (i.e. no 
single moderator was significant in any of the analyses), we combined all measures 
to be pooled. Fourth, the patient populations were too diverse to specify the results 
for different populations. We primarily expect that patients with COPD and chronic 
respiratory failure are more at risk of respiratory adverse effects than patients with 
cancer or heart failure, for example. Most of the studies included patients with a 
specified primary diagnosis (n=54), of which 16 studies only included patients with 
COPD. However, from these populations it is not known which patients experienced 
chronic respiratory failure. Fifth, we used the Cochrane risk of bias tool to assess 
the risk of bias in RCTs and NRTs. This tool is designed for use in RCTs, but there was 
no appropriate alternative to use in NRTs. After assessment of the risk of bias was 
completed, the Risk of Bias in Nonrandomized Studies - of Interventions (ROBINS-I) 
tool was published.89 This might have been a better tool to assess the risk of bias 
in NRTs and can be used in future studies. Finally, we included both crossover trials 
and parallel trials in the meta-analysis together, and we analysed the crossover trials 
as if they were parallel trials. This might result in a unit of analysis error, leading to 
an underweighting of the crossover trials. Since only two studies included in the 
meta-analyses of SaO2 and respiratory rate were parallel trials and the remaining 
studies were crossover trials, we assume this influence to be negligible.
Implications for clinical practice and future research
Patients are willing to consider opioid treatment for chronic breathlessness, 
despite the occurrence of adverse effects, and report improvement of quality 
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of life and relief of breathlessness as their main reasons.12 However, physicians 
remain reluctant to prescribe opioids for chronic breathlessness, because of fear 
of adverse clinical outcomes, among others.9-12 A recent large observational study 
of older adults with COPD by Vozoris et al.90 showed an association between new 
prescription of opioid and a small, but statistically significant increase in 30-day 
mortality and emergency visits. However, palliative care patients (and thus those 
who form the main group for whom opioids would be prescribed for breathlessness) 
were excluded and other differences between patients with and without opioid 
use might explain these findings. In contrast, a registry study of people with 
advanced COPD on long-term oxygen therapy, with four years of follow-up found 
no association with either hospital admission or survival in people taking ≤30 mg 
of oral morphine per day.91
This review has shown that the current evidence on respiratory adverse effects 
of opioid treatment in chronic breathlessness is inconsistent and heterogenic. 
Only one serious episode of respiratory depression is described and that in the 
context of high-dose opioids. Based on the evidence included in this review, low-
dose opioids can be considered as safe treatment for chronic breathlessness in the 
context of good clinical care and appropriate monitoring. However, the studies that 
have been conducted are mostly of low quality, short duration and not designed 
to assess the effect of low-dose opioids on respiratory adverse effects. A long-
term, well-powered randomised controlled trial, such as the MORDYC study, is 
needed. Moreover, including a common respiratory outcome set in all trials of 
opioids for breathlessness, so that a more robust synthesis could be conducted, 
is recommended.
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analgesics, opioid/adverse effects[Mesh Terms]




















8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 
OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28
30 animals[Mesh Terms] NOT humans[Mesh Terms]
31 (#7 AND #29) NOT #30
32 Limit #31 to article types case reports, clinical studies, clinical trials, comparative 
studies, multicentre studies, observational studies, randomized controlled trials.








exp dyspnea/dt [Drug Therapy]
dyspn*.mp [mp=title, abstract, heading word, drug trade name, original title, device 





1 OR 2 OR 3 OR 4 OR 5 OR 6
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exp opiate/ae, dt [Adverse Drug Reaction, Drug Therapy]
opioid*.mp
opiate*.mp
exp codeine/ae, dt [Adverse Drug Reaction, Drug Therapy]
codeine.mp
exp diamorphine/ae, dt [Adverse Drug Reaction, Drug Therapy]
diamorphine.mp
exp fentanyl/ae, dt [Adverse Drug Reaction, Drug Therapy]
fentanyl.mp
exp dihydrocodeine/ae, dt [Adverse Drug Reaction, Drug Therapy]
dihydrocodeine.mp
exp morphine/ae, dt [Adverse Drug Reaction, Drug Therapy]
morphine.mp
exp oxycodone/ae, dt [Adverse Drug Reaction, Drug Therapy]
oxycodone.mp
8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 
OR 22
24 7 AND 23
25 Limit 24 to human
26 Limit 25 publication type to Journal: Article








MeSH descriptor: [Dyspnea] explode all trees and with qualifier(s): [Drug therapy 
– DT]
dyspn*.ti,ab,kw (Word variations have been searched)
breathless*.ti,ab,kw (Word variations have been searched)
“breath* labour*”.ti,ab,kw (Word variations have been searched)
“short* of breath*”.ti,ab,kw (Word variations have been searched)
“breath* difficult*”.ti,ab,kw (Word variations have been searched)
















MeSH descriptor: [Analgesics, Opioid] explode all trees and with qualifier(s): 
[Adverse effects – AE, Therapeutic use – TU]
opioid*.ti,ab,kw (Word variations have been searched)
opiate*.ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Codeine] explode all trees and with qualifier(s): [Adverse 
effects – AE, Therapeutic use – TU]
codeine.ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Heroin] explode all trees and with qualifier(s): [Adverse effects 
– AE, Therapeutic use – TU]
diamorphine.ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Fentanyl] explode all trees and with qualifier(s): [Adverse 
effects – AE, Therapeutic use – TU]
fentanyl.ti,ab,kw (Word variations have been searched)
dihydrocodeine.ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Morphine] explode all trees and with qualifier(s): [Adverse 
effects – AE, Therapeutic use – TU]
morphine.ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Oxycodone] explode all trees and with qualifier(s): [Adverse 
effects – AE, Therapeutic use – TU]
oxycodone.ti,ab,kw (Word variations have been searched)
#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
OR #19 OR #20 OR #21
#23 #7 AND #22
#24 Limit #23 to trials
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TI dyspn* OR AB dyspn*
TI breathless* OR AB breathless*
TI “breath* labour*” OR AB “breath* labour*”
TI “short* of breath*” OR AB “short* of breath*”
TI “breath* difficult*” OR AB “breath* difficult*”

















TI opioid* OR AB opioid*
TI opiate* OR AB opiate*
(MH “Codeine+/AE/TU ”)
TI codeine OR AB codeine
(MH “Heroin+/AE/TU ”)
TI diamorphine OR AB diamorphine
(MH “Fentanyl+/AE/TU ”)
TI fentanyl OR AB fentanyl
TI dihydrocodeine OR AB dihydrocodeine
(MH “Morphine+/AE/TU ”)
TI morphine OR AB morphine
(MH “Oxycodone+/AE/TU ”)
TI oxycodone OR AB oxycodone
S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR 
S19 OR S20 OR S21
S23 S7 AND S21; Limiters - Human




















































S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR 
S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25
S27 S7 AND S26
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Table S4. Risk of bias of randomized controlled trials




















































































































































Abernethy, 200316 + + + + + – –
Allard, 199917 ? + + + + + +
Beauford, 199318 ? ? + ? + – –
Bruera, 1993 (part 1)19 ? ? ? ? + + –
Charles, 200820 + + + + + + –
Chua, 199721 ? ? + ? + + –
Cuervo Pinna, 201522 ? ? + ? + – +
Eiser, 1991 (part 1)23 ? ? ? ? + + –
Eiser, 1991 (part 2)23 ? ? ? ? + + –
Gamborg, 201324 ? ? + ? + – +
Grimbert, 200425 ? + + + + – +
Harris-Eze, 199526 ? + + + + + +
Hui, 201427 + + + + + + –
Jankelson, 199728 ? + + + + + –
Jensen, 201229 ? + + + – + +
Johnson, 200230 + + + + + + +
Krajnik, 200931 ? ? – – + – +
Light, 198932 ? ? – – + + –
Light, 199633 ? ? + ? + + ?
Masood, 199534 ? ? + ? + – +
Mazzocato, 199935 ? ? + ? + + +
Munck, 1990 (part 2)36 ? ? ? ? – + +
Natalini, 201137 + + + + + + +
Navigante, 201038 + + – – + – +
Noseda, 199739 ? ? + + + + +
Otulana, 2004 (phase 3)40 – – – – ? – –
Oxberry, 201141 + + + + + + +
Poole, 199842 + + ? + + + +
Rice, 198743 + ? ? ? + + +
Robin, 198644 + + – – – + +
Schonhofer, 199845 – – – – – + –
Shohrati, 201246 ? ? + ? + + –
Smith, 200947 ? ? + + – + ?
Williams, 200348 ? ? + + + + –
Woodcock, 198249 ? ? + + – ? –
Notes: + low risk of bias; – high risk of bias; ? unclear risk of bias.
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Table S5. Risk of bias of nonrandomized trials




















































































































































Allcroft, 201350 – – – – + – +
Boyd, 199751 – – – – + + +
Bruera, 199052 – – – – + + +
Bruera, 1993 (part 2)19 – – – – + + –
Clemens, 200753 – – – – + + +
Clemens, 2008.154 – – – – + + +
Clemens, 2008.255 – – – – + + +
Clemens, 2008.356 – – – – + + +
Clemens, 200957 – – – – + + +
Clemens, 201158 – – – – + + +
Cohen, 199159 – – – – + + +
Coyne, 200260 – – – – – + +
Currow, 201161 – – – – + + +
Gauna, 200862 – – – – + + –
Munck, 1990 (part 1)36 – – – – + – +
Otulana, 2004 (phase 4)40 – – – – ? – –
Tanaka, 199963 – – – – + + –
Notes: + low risk of bias; – high risk of bias; ? unclear risk of bias.
Table S6. Risk of bias of prospective observational studies




















































































































Allen, 20051       6
Hu, 20044    3
Oxberry, 20137     4
Pang, 20168      5
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Figure S1. Effect of opioid treatment in patients with advanced disease on breathlessness.
Abbreviations: E, measured on exertion; N, nebulized administration; R, measured at rest; S, systemic 
administration.
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Chapter 3
Healthcare and societal costs in 
patients with COPD and breathlessness 
after completion of a comprehensive 
rehabilitation program
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Breathlessness is one of the most frequent symptoms in chronic obstructive 
pulmonary disease (COPD). COPD may result in disability, decreased productivity 
and increased healthcare costs. The presence of comorbidities increases healthcare 
utilization. However, the impact of breathlessness burden on healthcare utilization 
and daily activities is unclear. This study’s goal was to analyze the impact of 
breathlessness burden on healthcare and societal costs. In this observational 
single-center study, patients with COPD were followed-up for 24 months after 
completion of a comprehensive pulmonary rehabilitation program. Every three 
months participants completed a cost questionnaire, covering healthcare utilization 
and impact on daily activities. The results were compared between participants 
with low (modified Medical Research Council [mMRC] grade <2; LBB) and high 
baseline breathlessness burden (mMRC grade ≥2; HBB). Healthcare costs in year 1 
were €7302 (95% confidence interval €6476-€8258) for participants with LBB and 
€10,738 (€9141-€12,708) for participants with HBB. In year 2, costs were €8830 
(€7372-€10,562) and €14,933 (€12,041-€18,520), respectively. Main cost drivers were 
hospitalizations, contact with other healthcare professionals and rehabilitation. 
Costs outside the healthcare sector in year 1 were €682 (€520-€900) for participants 
with LBB and €1520 (€1210-€1947) for participants with HBB. In year 2, costs were 
€829 (€662-€1046) and €1457 (€1126-€1821), respectively. HBB in patients with COPD 
is associated with higher healthcare and societal costs, which increases over time. 
This study highlights the relevance of reducing costs with adequate breathlessness 
relief. When conventional approaches fail to improve breathlessness, a personalized 
holistic approach is warranted.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic disease that is 
characterized by persistent reduction of airflow and respiratory symptoms.1 The 
worldwide prevalence of COPD was estimated at 3.9% in 2017,2 and annually about 
three million people die because of COPD.3 The prevalence of COPD is expected 
to increase globally in the coming years due to higher smoking prevalence in low-
income countries and ageing of the population.4
The most frequently reported symptoms of COPD are breathlessness, coughing 
and fatigue.5 Disease severity is determined using the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification.1 Within this classification, the 
modified Medical Research Council (mMRC) scale6 and COPD Assessment Test 
(CAT)7,8 are used to measure symptom burden. Low breathlessness burden is 
represented by a mMRC grade of 0 or 1 point and high breathlessness burden by 
a mMRC grade of ≥2 points; low health status is represented by a CAT score of <10 
points and high health status by a CAT score of ≥10 points.1
COPD may result in disability, decreased productivity and increased health-related 
costs.1 In COPD, exacerbations and hospital admissions account for the largest 
component of health-related costs.9-11 With increasing disease severity, healthcare 
utilization increases.9,11,12 Furthermore, healthcare costs increase with the presence 
of comorbidities.9 Next to the healthcare costs, COPD has a major impact on 
society.13 In 2017, COPD was the sixth leading cause of loss in disability-adjusted 
life years for women and ninth leading cause for men worldwide.14 With increasing 
disease severity, there is impact on workplace and home productivity and on the 
burden for relatives.9,10,13
Current knowledge on the impact of disease severity and breathlessness burden on 
healthcare utilization and costs is based on retrospective claims data9,12 or patient 
data recalling 12 months.10 The goal of this study was to prospectively analyze the 
impact of breathlessness burden in COPD, assessed by the mMRC scale, on societal 
costs over a follow-up period of 24 months after completion of a comprehensive 
pulmonary rehabilitation (PR) program.





This was a secondary analysis of the CIRO CO-morbidity (CIROCO) study, an 
observational single-center study to identify biomarkers, comorbidities, increased 
healthcare costs and poor prognosis in patients with COPD. The methodology of 
the CIROCO study has been described in detail elsewhere.15 For the current analysis, 
data of the PR program were left aside. The baseline assessment for this analysis 
was therefore the final assessment of the PR program. Participants were recruited 
between November 2007 and November 2010. All subjects provided written 
informed consent. The study was approved by the local medical ethics committee 
(MEC 10-3-067) and conducted in accordance with the Declaration of Helsinki.
For the current analysis, a societal perspective was adopted including healthcare 
costs and costs outside the healthcare sector.
Participants
Patients were eligible to participate in the CIROCO study if they were diagnosed with 
moderate to very severe COPD (GOLD grades II–IV), smoked at least 10 pack-years 
and were aged between 40 and 80 years. For the current analysis, participants had 
to have completed an 8-week inpatient (5 days/week) or 14-week outpatient (3 days/
week) comprehensive PR program at CIRO in Horn, The Netherlands and at least one 
visit during the follow-up. Exclusion criteria were described in detail elsewhere.15
Assessments and questionnaires
Baseline measurements
At baseline, participants underwent a two-day assessment at the end of the PR 
program, during which data were collected on demographics, smoking status, 
number of exacerbations and hospital admissions in the past 12 months, lung 
function, comorbidities using the Charlson Comorbidity Index (CCI)16 and mMRC 
grade.6
Follow-up
During a follow-up of 24 months, participants completed the mMRC breathlessness 
scale and a cost questionnaire (Supplemental Methods 1) every three months during 
a phone call. The mMRC breathlessness scale assesses the perceived disability of 
breathlessness in activities of daily living. The scale consists of five grades (grade 
0: ‘breathless only with strenuous exercise ’; grade 4: ‘too breathless to leave the house 
or breathless when dressing ’).6 The cost questionnaire covered healthcare utilization, 
employment status at baseline, inability to perform daily activities (employed and/
or household work of both participants and informal caregivers) and long-term 
sick leave. Healthcare utilization included contact with healthcare professionals, 
hospitalization, respiratory tests and use of long-term oxygen therapy (LTOT). For all 
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questions, the reason (breathing problems or other health problems) and number 
of times or number of days were collected. Furthermore, prescribed and over-the-
counter medication use was discussed. At the end of the follow-up, information 
on participation in a second PR program was collected from the patient file and 
prescribed medication use was checked using medication lists.
To be able to calculate healthcare costs, several assumptions about exacerbations 
and hospital admissions, medication use and use of LTOT were made. These are 
described in Supplemental Methods 2.
Healthcare costs
For valuation of healthcare resource use, reference prices were obtained from 
the cost manual of the Dutch National Healthcare Institute17 and indexed to July 
2019. For the reference prices not stated in the cost manual, the rate list first-line 
diagnostics of the Dutch Healthcare Authority18 was used. Prescribed medication 
was valued using medication prices of July 2019 from the medication database 
by the Dutch National Healthcare Institute.19 Prices of medication that were not 
on the market anymore were extracted from the Farmacotherapeutisch Kompas 
2008 and indexed to July 2019. Delivery costs by the pharmacist were accounted 
for medication within the drug reimbursement system. For the base-case analysis, 
the lowest medication price was used.17 A sensitivity analysis using the highest 
medication price was conducted.
Costs outside healthcare sector
Information on employment status was only collected at baseline of the CIROCO 
study. Data collection regarding impact on daily activities did not distinguish between 
household activities or paid work. Therefore, in the base-case analysis impact on 
daily activities for both participants and informal caregivers was conservatively 
valued as household work. In a sensitivity analysis, impact on daily activities for 
the subgroup of participants that were employed at baseline was valued using the 
friction cost method.17 Impact on daily activities for the other participants was still 
valued as household work. In another sensitivity analysis, impact on daily activities 
of informal caregivers was excluded from the analysis. Over-the-counter medication 
was valued using medication prices of July 2019 from the medication database 
by the Dutch National Healthcare Institute.19 Data on transportation to healthcare 
professionals or the hospital were not collected. Based on the mean distance to 
healthcare professionals or the hospital, transportation by car and reference prices 
from the cost manual,17 costs for transportation were calculated.
Statistical analysis
Analyses were performed using SPSS statistics version 25.0 (IBM Corp, Armonk, 
NY). Participant characteristics, healthcare utilization and impact on daily activities 
were described as mean (SD) for continuous variables and number (percentage) 
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for categorical variables. Cost data of the first and second year were presented as 
mean (95% bootstrapped bias-corrected and accelerated confidence interval; 95% 
BCa CI). Cost data for the second year were discounted with 4%, according to the 
Dutch cost manual.17 Comparison between the years was performed using Wilcoxon 
signed rank tests.
Baseline mMRC grades were used to compose two breathlessness burden profiles. 
Participants with low breathlessness burden reported a mMRC grade of <2 points 
at start of the follow-up, and participants with high breathlessness burden 
reported a mMRC grade of ≥2 points at start of the follow-up, according to the 
GOLD classification.1 Differences in baseline characteristics, healthcare utilization 
or impact on daily activities between the groups with low and high breathlessness 
burden were analyzed using independent samples T-tests or Mann-Whitney U tests, 
according to data distribution. Differences in healthcare utilization or impact on 
daily activities within breathlessness burden groups between breathing and other 
health problems were analyzed using dependent samples T-tests or Wilcoxon signed 
rank tests, according to data distribution. Categorical data were analyzed using 
χ2-tests. Correlation between continuous parameters was analyzed using Pearson 
or Spearman correlation coefficient, according to data distribution. Missing data 




Of the 213 participants included in the CIROCO study, data of 178 was included in the 
current analysis (Figure 1). A total of 350 patient years was collected, 2.0 (0.2) years 
per participant. The total population was aged 63.6 (7.0) years and 60.1% was male.
Participants not included in the analysis withdrew consent, deceased, dropped-out 
because of physical or mental inability to complete the study before the first follow-
up visit or missed an mMRC grade at baseline (Figure 1). Participants not included 
in the analysis were comparable to participants included in the analysis, except 
for smoking status: participants not included were more often smoker (44.1% vs. 
19.1%; p=0.002).
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Figure 1. Flow chart
Breathlessness burden
Before the PR program 59 participants (33.1%) experienced low breathlessness 
burden, and 119 participants (66.9%) experienced high breathlessness burden. 
During PR, in 10 participants breathlessness burden changed from low to high 
breathlessness burden and in 33 participants from high to low breathlessness 
burden. After the PR program, so at baseline of these analyses, 82 participants (46.1%) 
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experienced low breathlessness burden, and 96 participants (53.9%) experienced 
high breathlessness burden. Participants with low and high breathlessness burden 
were similar at baseline, except for number of exacerbations in the previous 12 
months, CCI and FEV1 (Table 1). Breathlessness burden during follow-up is shown 
in Supplemental Table S1.









Age (years) 63.6 ± 7.0 62.8 ± 7.6 64.2 ± 6.4 0.183
Male, n (%) 107 (60.1) 48 (58.5) 59 (61.5) 0.692
BMI (kg/m2) 26.7 ± 5.4 26.5 ± 4.4 27.0 ± 6.1 0.821
Smoking status, n (%)
   Ex-smoker








Exacerbations in <12 months (n) 1.4 ± 1.6 0.9 ± 1.2 1.8 ± 1.9 0.002
Hospital admissions in <12 
months (n)
0.5 ± 1.1 0.4 ± 0.9 0.6 ± 1.2 0.206
CCI (points) 1.6 ± 0.9 1.4 ± 0.7 1.8 ± 1.0 0.007
FEV1, (l) 1.42 ± 0.56 1.56 ± 0.54 1.30 ± 0.54 <0.001
Notes: Data are shown as mean ± SD. Significance testing was performed using Mann-Whitney U tests or χ2 tests, 
as appropriate. a significant p-values are shown in bold. Abbreviations: BMI, Body Mass Index; CCI, Charlson 
Comorbidity Index; FEV1, forced expiratory volume in 1 s.
Employment status
Ten participants (5.6%) were employed full-time at baseline (seven with low 
breathlessness burden and three with high breathlessness burden) and were 
working 39.9 (6.8) hours/week. Eight participants (4.5%) were employed part-time 
(seven with low breathlessness burden and one with high breathlessness burden) 
and were working 25.8 (5.4) hours/week. Another four participants (2.2%) were 
employed, but the amount of hours is unknown. 26 participants (14.6%) were on 
long-term sick leave for a period of 7.5 (7.8) months. Reasons for long-term sick 
leave were breathing problems (50.0%), other health problems (15.4%), breathing 
and other health problems (3.8%) or unknown (30.8%). 14 participants (7.9%) were 
incapacitated for work. The other participants were retired (87, 48.9%), house-
person (25, 14.0%) or unemployed (4, 2.2%).
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During the follow-up, all participants visited a healthcare professional for 
breathing problems as well as other health problems. The family doctor 
and medical specialist were visited more often by participants with high 
breathlessness burden compared to participants with low breathlessness 
burden (p=0.015 and p=0.042, respectively), while other healthcare 
professionals (including, but not limited to physiotherapists, occupational 
therapists and nurses) were visited equally often (p=0.152; Table 2). In the 
majority of cases, visits were more often for breathing problems than for other 
health problems (Table 2).
In the first year, costs for outpatient care for participants with low 
breathlessness burden were €3527 and for participants with high 
breathlessness burden €3792. In the second year, these costs were €3634 
and €4166, respectively. Costs did not differ between groups (Table 3 and 
Supplemental Table S2) or years (Table 3).
Inpatient care
Participants with high breathlessness burden more often needed inpatient 
care compared to participants with low breathlessness burden (71.9% vs. 
57.3%; p=0.042). Especially, participants with high breathlessness burden 
more often visited the emergency room or were more often hospitalized 
compared to participants with low breathlessness burden (p=0.016 and 
p=0.005, respectively; Table 2). In the majority of cases, contacts were more 
often for breathing problems than for other health problems (Table 2).
In the first year, costs for inpatient care were €1606 for participants with 
low breathlessness burden and €3934 for patients with high breathlessness 
burden. In the second year, these costs were €1876 and €3910, respectively. 
Costs for participants with high breathlessness burden were higher in both 
years (Table 3 and Supplemental Table S2). Costs did not differ between the 
years (Table 3).
Diagnostics
The number of participants that underwent a respiratory test (including 
spirometry test, advanced pulmonary test, plain chest X-ray and chest 
computer tomography) and the number of tests were similar for participants 
with low and high breathlessness burden (p=0.619 and p=0.199, respectively; 
Table 2). Costs for pulmonary tests were similar for participants with low and 
high breathlessness burden in the first year (€191 and €240 per participant, 
respectively) and second year (€274 and €311 per participant, respectively; 
Table 3 and Supplemental Table S2).
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Year 1 Year 2 p-valuea Year 1 Year 2 p-valuea
Healthcare costs
Outpatient 3527 3634 0.844 3792 4166 0.200
Inpatient 1606 1876 0.672 3934 3910 0.776
Diagnostics 191 274 0.113 240 311 0.128
Rehabilitationb 16,174c 17,625 0.173 12,338d 21,109 0.008
Prescribed medication 1616 1772 0.008 1867 2028 0.114
LTOTe 566 713 0.199 629 681 0.020
Subtotal healthcare costs 7302 8830 0.507 10,738 14,933 0.012
Costs outside healthcare sector
Impact daily activities 
participant
339 493 0.485 1153 963 0.553
Impact daily activities 
informal caregiver
49 27 0.280 23 204 0.001
Transportation 105 98 0.172 102 109 0.210
Over-the-counter 
medication
189 212 0.137 242 181 0.027
Subtotal costs outside 
healthcare sector
682 829 0.335 1520 1457 0.556
Total societal costs 7985 9660 0.441 12,258 16,390 0.059
Notes: Data are shown as mean. a Significant p-values are shown in bold. b Only considering participants that 
underwent rehabilitation. c Only one participant with low breathlessness burden was admitted to pulmonary 
rehabilitation in year 1, so no confidence interval could be calculated. d Some or all bootstrap sample results 
are missing, so no bootstrap estimation has been performed. e Only considering participants that used LTOT. 
Abbreviations: LTOT, long-term oxygen therapy.
Pulmonary rehabilitation
Within the two years, 30 participants were again admitted to the assessment prior 
to a comprehensive PR program. In the first year, 1/82 (1.2%) participants with 
low breathlessness burden and 5/96 (5.2%) participants with high breathlessness 
burden were re-admitted (p=0.142). In the second year, 5/82 (6.1%) participants with 
low breathlessness burden and 19/96 (19.8%) participants with high breathlessness 
burden were re-admitted (p=0.008). In total nine participants only completed the 
baseline assessment, and 21 participants started the PR program (five with low 
breathlessness burden and 16 with high breathlessness burden). Costs for PR were 
€12,977 per participant for the first year and €20,383 per participant for the second 
year, only taking into account the participants who attended PR. Per year, costs for 
participants with low or high breathlessness burden were not different (Table 3 and 
Supplemental Table S2). Rehabilitation costs for patients with high breathlessness 
burden were higher in the second year compared to the first year (p=0.008; Table 3).
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Prescribed medication
A total of 5291 medication prescriptions within the drug reimbursement system 
were registered, 2890 for respiratory diseases and 2401 for other diseases. This 
equals 16.2 prescriptions for respiratory medication and 13.5 prescriptions for other 
medication per participant (p=0.056). Participants with high breathlessness burden 
used significantly more respiratory medication compared to other medication (19.0 
vs. 14.1, p=0.003), which was not the case for participants with low breathlessness 
burden (13.0 vs. 12.7, p=0.590; Table 2).
At baseline, 97.2% of participants was treated with a long-acting bronchodilator, 
86.5% was treated with a short-acting bronchodilator, and 91.6% was treated with 
an inhaled corticosteroid (ICS). The frequency of use of medication for participants 
with low and high breathlessness burden during the follow-up is presented in Table 
2. The use of short-acting bronchodilators was higher for participants with high 
breathlessness burden compared to participants with low breathlessness burden 
(82.3% vs. 61.0%, p=0.002). All other types of medication were used equally often 
by participants with low and high breathlessness burden (Table 2).
In the first year, medication costs were €1616 for participants with low breathlessness 
burden and €1867 for patients with high breathlessness burden (p=0.008; Table 3). 
In the second year, these costs were €1772 and €2028, respectively (p=0.114; Table 
3). Costs did not differ between groups (Table 3 and Supplemental Table S2).
Long-term oxygen therapy
LTOT was used by 84 participants for on average 26.4 (17.7) weeks per participant 
per year. 32/82 (39.0%) participants with low breathlessness burden and 52/96 
(54.2%) participants with high breathlessness burden used LTOT (p=0.044; Table 2). 
Costs per participant were not different for both groups, taking into account only 
the participants that used LTOT (€566 vs. €629 for the first year and €713 vs. €681 
for the second year; Table 3 and Supplemental Table S2). Costs for participants with 
high breathlessness burden were higher in the second year compared to the first 
year (p=0.020; Table 3).
Costs per subgroup
Total healthcare costs in the first year were €9155 per participant and in the second 
year €12,122 per participant (Figure 2). In the first year costs of participants with 
low breathlessness burden were lower (€7302) compared with participants with 
high breathlessness burden (€10,738; Table 3 and Supplemental Table S2). Also, in 
the second year, costs of participants with low breathlessness burden were lower 
(€8830) than costs of participants with high breathlessness burden (€14,933; Table 3 
and Supplemental Table S2). Costs for participants with high breathlessness burden 
and for the total study population were higher in the second year compared to the 
first year (Figure 2 and Table 3).
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Figure 2. Healthcare costs per participant per year.
Notes: * Significant difference. Abbreviations: BB, breathlessness burden; HCP, health care professional.
Figure 3. Cost components of healthcare resource use. (A) Patients with low breathlessness 
burden in year 1; (B) Patients with low breathlessness burden in year 2; (C) Patients with high 
breathlessness burden in year 1; (D) Patients with high breathlessness burden in year 2.
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For participants with low breathlessness burden, the largest cost components were 
contacts with other healthcare professionals (36% in year 1 and 32% in year 2), 
medication (22% in year 1 and 20% in year 2) and hospitalizations (20% in year 1 
and 19% in year 2; Figure 3). For participants with high breathlessness burden, the 
largest cost components differed per year. For year 1, these were hospitalizations 
(34%), contact with other healthcare professionals (27%) and medication (17%), while 
for year 2 these were rehabilitation (28%), hospitalization (24%) and contact with 
other healthcare professionals (21%; Figure 3).
Costs outside the healthcare sector
Impact on daily activities
About 90.2% of participants with low breathlessness burden and 99.0% of 
participants with high breathlessness burden was unable to perform daily 
activities during the two years of follow-up (p=0.008; Table 2). Participants with 
low breathlessness burden were unable to perform daily activities on 30.0 (42.9) 
days, while participants with high breathlessness burden were unable to perform 
daily activities on 75.5 (84.2) days (p<0.001; Table 2). For participants with low 
breathlessness burden, the costs were €339 per participant in year 1 and €493 
per participant in year 2 (p=0.485), while for participants with high breathlessness 
burden the costs were €1153 per participant in year 1 and €963 per participant in 
year 2 (p=0.553; Table 3 and Supplemental Table S2). For both groups, inability was 
more often due to breathing problems than other health problems (Table 2).
About 18.3% of informal caregivers of participants with low breathlessness burden 
and 30.2% of informal caregivers of participants with high breathlessness burden 
had to interrupt their daily activities to take care of the participants (p=0.066; Table 
2). This was on 3.1 and 8.1 days per participant per year, respectively (p=0.064). 
Costs were €49 in the first year and €27 in the second year for informal caregivers 
of participants with low breathlessness burden (p=0.280) and €23 in the first year 
and €204 in the second year for informal caregivers of participants with high 
breathlessness burden (p=0.001; Table 3 and Supplemental Table S2).
Over-the-counter medication
A total of 286 over-the-counter medications were registered, 113 for respiratory 
disease and 173 for other diseases (p=0.004). The number of medications per 
participant was equal for participants with low and high breathlessness burden 
(1.4 vs. 1.8, p=0.137).
Over-the-counter medication costs per participant were €189 for low breathlessness 
burden and €242 for high breathlessness burden in the first year and €212 for low 
breathlessness burden and €181 for high breathlessness burden in the second year 
(Table 3 and Supplemental Table S2). Costs for participants with high breathlessness 
burden were higher in year 1 compared to year 2 (p=0.027; Table 3).




Annual transportation costs were €101 per participant for low breathlessness 
burden and €105 per participant for high breathlessness burden. Transportation 
costs in both groups were not different for the first and second year (Table 3 and 
Supplemental Table S2).
Total societal costs
Total societal costs differed between participants with low and high breathlessness 
burden in both years (Table 3 and Supplemental Table S2). Costs of participants 
with low breathlessness burden amounted €7985 in the first year and €9660 in 
the second year, while costs of participants with high breathlessness burden were 
€12,258 in the first year and €16,390 in the second year. There was no difference 
between the years (Table 3).
Healthcare costs were weakly correlated with FEV1, both for low breathlessness 
burden (Spearman ρ −0.103, p=0.357 for year 1 and Spearman ρ −0.241, p=0.029 for 
year 2) and for high breathlessness burden (Spearman ρ −0.061, p=0.555 for year 
1 and Spearman ρ −0.067, p=0.515 for year 2). For societal costs, the correlations 
were similar (low breathlessness burden year 1: Spearman ρ −0.119, p=0.288; high 
breathlessness burden year 1: Spearman ρ −0.080, p=0.438; low breathlessness 
burden year 2: Spearman ρ −0.224, p=0.043; high breathlessness burden year 2: 
Spearman ρ −0.095, p=0.358).
Sensitivity analysis
Table 4 and Supplemental Table S3 show the results of the sensitivity analyses. None 
of the analyses influenced the total societal costs to such extent that conclusions 
were altered, in both years costs for participants with high breathlessness burden 
were higher compared to costs of participants with low breathlessness burden. 
In the scenario of highest medication prices, the costs for participants with high 
breathlessness burden were higher in the second year compared to the first year 
(p=0.035), while in the other scenarios there was only a trend (Table 4).
Furthermore, scenarios with lowest costs and scenarios with highest costs were 
combined. The scenario with lowest costs equals the scenario in which impact 
on daily activities of informal caregivers was excluded. The scenario with highest 
costs included highest medication prices and valuing impact on daily activities of 
participants based on baseline employment status. Both scenarios had no influence 
on the differences between the groups, while in the scenario with the highest costs 
the costs for participants with high breathlessness burden were higher in the second 
year compared to the first year (p=0.030; Table 4).
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Year 1 Year 2 p-valuea Year 1 Year 2 p-valuea
Base-case
Total societal costs 7985 9660 0.441 12,258 16,390 0.059
Highest medication prices
Total societal costs 9099 10,709 0.266 13,359 17,779 0.035
Impact on daily activities participant according to baseline employment status
Total societal costs 8422 10,144 0.487 12,536 16,735 0.052
Impact on daily activities informal caregiver excluded
Total societal costs 7936 9632 0.443 12,235 16,186 0.072
Combining all scenario’s with highest costs
Total societal costs 9536 11,193 0.347 13,637 18,124 0.030
Notes: Data are shown as mean. a Significant p-values are shown in bold.
Discussion
The CIROCO study provided an overview of healthcare and non-healthcare resource 
utilization and costs of patients with COPD who completed a comprehensive PR 
program during two years. This secondary analysis showed that high breathlessness 
burden in COPD patients is associated with high healthcare and non-healthcare 
costs. Total annual societal costs of participants with low breathlessness burden 
(mMRC<2) were €7985 (€7047-€9087) in year 1 and €9660 (€8045-€11,537) in year 2 
vs. €12,258 (€10,573-€14,321) in year 1 and €16,390 (€13,255-€19,865) in year 2 for 
participants with high breathlessness burden. The difference between low and high 
breathlessness burden applied to almost all cost categories, except for outpatient 
care, diagnostics and medication.
Hospitalization, medication and contact with other healthcare professionals were 
the main cost drivers in this study. Previous cost analyses have shown similar results 
for hospitalization and medication.9-13,20,21 The large contribution of contact with 
other healthcare professionals can be explained by the inclusion of participants 
immediately after completing a PR program. Although not registered, it can be 
assumed that the vast majority of the reported visits was with the physiotherapist. 
These patients are encouraged to continue training with a physiotherapist to retain 
the results of the PR program.
Patients with advanced COPD often have multimorbidity and experience multiple 
symptoms.22 The current results show that medical specialists are consulted mainly 
for breathing problems, and these visits are probably more on a scheduled basis, 
151445_Cindy_van_den_Berg_BNW-def.indd   101 13-9-2021   12:34:42
102
Chapter 3
given the results that medical specialists are visited almost equally often by patients 
with low and high breathlessness burden. Family doctors are consulted for all 
kinds and more emergent problems, since they are visited almost equally often 
for breathing and other health problems, but more often by patients with high 
breathlessness burden than by patients with low breathlessness burden.
Almost as many respiratory tests were performed as visits to the chest physician. 
Furthermore, standard treatment with long-acting bronchodilators and 
inhaled corticosteroids is used by almost all participants. Participants with high 
breathlessness burden subsequently use short-acting bronchodilators as attempt 
to minimize symptoms. When these attempts fail, a new PR program is considered, 
given the results that significantly more patients with high breathlessness burden 
attend a PR program in the second year compared to the first year. Furthermore, PR 
programs in the second year are more often inpatient, leading to higher costs. This 
makes the PR program the largest cost component for this group in the second year.
Breathlessness burden appears not to be a strong predictor of specialist visit 
frequency, deployed diagnostics or costs of applied pharmacological treatment. 
However, it can be assumed that this patient group requires another management 
approach. Given the multifactorial nature of breathlessness, a holistic approach 
should be considered.23,24 When patients still experience severe breathlessness 
burden in daily life after completion of a comprehensive PR program, more focus 
should be on palliation of their breathlessness. This is emphasized by clinical 
practice guidelines.25,26 Opioids have an important place in palliation of refractory 
breathlessness,27 but results of the current study show that only 4.2% of patients 
with high breathlessness burden uses opioids for breathing problems. In a Swedish 
study observing patients with COPD needing LTOT, a similar low prescription rate 
was shown.28
Costs outside the healthcare sector only comprised 8.6% of total societal costs for 
participants with low breathlessness burden and 10.4% for participants with high 
breathlessness burden. This is much lower compared to other studies including 
patients with COPD in general12,13 or participating in a disease management 
program.9 However, compared to these studies the employment rate in our study 
population at baseline was much lower (12.4% compared to 25.6-67.1%). This is 
probably due to the population included in our study that is generally older and 
has more severe COPD.
Indeed, all patients in our study completed a PR program, reflecting that they 
experienced limitations in their daily life. Still, the amount of days patients were 
unable to perform daily activities was 2.52 times higher in patients with high 
breathlessness burden compared to patients with low breathlessness burden. These 
patients were not able to perform their daily activities, which may have a major 
impact on their quality of life.29 When a patient is unable to perform household 
work, the informal caregiver may take over such activities. This is illustrated by 
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the significant higher number of days informal caregivers of patients with high 
breathlessness burden were unable to perform daily activities, especially in 
the second year. This emphasizes the additional burden on informal caregivers 
accompanied with increased breathlessness burden.
This study has several strengths and limitations. First, this is the first study of 
prospective patient-reported data in COPD with a follow-up of two years and a short 
recall period of three months. Second, patients with optimal pharmacological and 
non-pharmacological treatment have been included, since all patients completed 
a PR program. Third, several sensitivity analyses were performed, confirming that 
the base-case results were robust.
Some limitations of the study have to be considered. First, the stratification 
of breathlessness burden was based on the mMRC grade at baseline, while 
mMRC grade was assessed during each follow-up visit. Patients showed various 
breathlessness burden profiles, which has been shown in Supplemental Table S1. 
About 35.4% of participants showed a variable mMRC grade over time. Second, this 
study fully relied on patient report and was not underpinned with patient file data, 
except for rehabilitation and prescribed medication. This means that study results 
may be influenced by recall bias. However, participants knew they had to report 
their healthcare utilization every three months, and several participants kept notes 
in these periods. Third, calculation of costs was based on several assumptions. 
When it was not clear if a contact had taken place for breathing or other health 
problems, the frequency was equally divided over these components. Over-the-
counter medication was only registered if patients mentioned it and is therefore 
probably not complete. The mode of transportation was not collected, and therefore 
transportation costs were estimated based on transportation by car. Employment 
status of the participants was reported at baseline of the CIROCO study and had to 
be extrapolated to baseline of this analysis based on data on long-term sick leave. 
Employment status of informal caregivers was not known at all. Therefore, valuing 
of impact on daily activities was done conservatively, using prices for household 
work. However, the sensitivity analyses showed that valuation based on the baseline 
employment status did not significantly affect the total societal costs. Fourth, 
the data used for this analysis were collected between 2008 and 2013. However, 
reference prices for 2019 were used to value healthcare costs. In the intervening 
years, treatment guidelines have changed.1 Fifth, patients included in this study 
recently completed a PR program and were instructed to continue training with the 
physiotherapist. Also, patients have been educated in symptom recognition and 
therefore might contact a family doctor or medical specialist sooner. Therefore, the 
current results cannot be extrapolated to the general population of patients with 
COPD. Finally, the CIROCO study included some invasive tests for which patients 
had to come to CIRO. Therefore, it might be assumed patients for whom this was 
difficult (due to disease severity or due to employment) declined to participate.




Patients with high breathlessness burden show higher healthcare and societal costs 
compared to patients with low breathlessness burden, and this cost difference 
increases over time. Breathlessness is a complex symptom, which asks for a 
personalized holistic approach. Each approach of proactive palliative care that 
improves breathlessness burden might also influence healthcare-related costs. 
A recent systematic review showed the effectiveness of holistic breathlessness 
services on breathlessness, anxiety, depression and costs in patients with cancer.30 
These services included education, psychosocial support, self-management 
strategies and other appropriate interventions. Furthermore, these services include 
the informal caregivers and/or family and the home situation. The management 
of patients with high breathlessness burden should shift more to these holistic 
approaches in order to relieve symptoms and decrease the economic burden on 
society.
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Supplementary Material
Supplemental Methods 1 – Cost questionnaires
Baseline cost questionnaire
Healthcare
1. During the past 3 months, did you call a family doctor? □ Yes □ No
If yes: 1.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
2. During the past 3 months, did you make any healthcare visits or has any 
healthcare provider visited you at home?
□ Yes □ No
If yes: Please answer Question 3-16 else go to Question 17
3. During the past 3 months, did you visit a family doctor? □ Yes □ No
If yes: 3.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
4. During the past 3 months, did you visit a specialist? □ Yes □ No
If yes: 4.1 What was the cause? (Please choose all that apply)
□   Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
5. During the past 3 months, did you make any other healthcare visits? □ Yes □ No
Other healthcare includes visits to the nurse, occupational therapist, physiotherapist 
etc (excluding physician visits).
If yes: 5.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
6. During the past 3 months, did a family doctor visit you at home? □ Yes □ No
If yes: 6.1 What was the cause? (Please choose all that apply)
□   Breathing problems
□   Other health problems
If yes
If yes
How many times? _____
How many times? _____
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7. During the past 3 months, did other healthcare providers visit you at home? □ Yes □ No
Other healthcare includes visits to the nurse, occupational therapist, physiotherapist 
etc (excluding physician visits).
If yes: 7.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
8. During the past 3 months, did you need ambulance transport? □ Yes □ No
If yes: 8.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
9. During the past 3 months, were you hospitalized overnight with intensive 
care?
□ Yes □ No
If yes: 9.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
10. During the past 3 months, were you hospitalized overnight with general care? □ Yes □ No
If yes: 10.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
11. During the past 3 months, did you visit first aid/emergency care? □ Yes □ No
If yes: 11.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
12. During the past 3 months, have you performed a spirometry test? □ Yes □ No
If yes: How many times? _____
13. During the past 3 months, have you performed an advanced pulmonary test? □ Yes □ No
If yes: How many times? _____
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14. During the past 3 months, have you undergone a plain chest X-ray? □ Yes □ No
If yes: How many times? _____
15. During the past 3 months, have you undergone a computer tomography for 
chest?
□ Yes □ No
If yes: How many times? _____
16. During the past 3 months, have you been using oxygen at home? □ Yes □ No
If yes: How many weeks? _____
Employment
17. What is your current occupation?
□  Full-time employed (paid employment, including self-employment)
□  Part-time employed (less than full-time paid employment, including self-
employment)
□  House-person (subject whose main occupation is running his/her own 
home and family (more than 50%))
□  Retired (retired due to age or other reason)
□  Unemployed (currently not in paid employment)
□  Long-term sick leave (on sick leave more than 4 weeks)
If you are part- or full-time employed:
17.1 How many hours per week do you normally work? ______ hours
If you are on long-term sick leave:
17.2 Since how many months? ______ months
17.3 What is the cause? □  Breathing problems
□  Other health problems
18. During the past 3 months, have you been unable to perform you usual daily 
activities?
□ Yes □ No
(Daily activities include: employment work or house-work, not hobbies nor sports)
If yes: 18.1 What was the cause? (Please choose all that apply)
□  Breathing problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
□  Other health problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
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19. During the past 3 months, has a caregiver been unable to perform his/her 
usual daily activities due to your illness?
□ Yes □ No
(Caregiver is a person who has stayed home from work to assist you)
If yes: 19.1 What was the cause? (Please choose all that apply)
□  Breathing problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
□  Other health problems If yes How many half days (≤ 4 hours)?





1. During the past 3 months, did you call a family doctor? □ Yes □ No
If yes: 1.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
2. During the past 3 months, did you make any healthcare visits or has any 
healthcare provider visited you at home?
□ Yes □ No
If yes: Please answer Question 3-16 else go to Question 17
3. During the past 3 months, did you visit a family doctor? □ Yes □ No
If yes: 3.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
4. During the past 3 months, did you visit a specialist? □ Yes □ No
If yes: 4.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
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5. During the past 3 months, did you make any other healthcare visits? □ Yes □ No
Other healthcare includes visits to the nurse, occupational therapist, physiotherapist 
etc (excluding physician visits).
If yes: 5.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
6. During the past 3 months, did a family doctor visit you at home? □ Yes □ No
If yes: 6.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
7. During the past 3 months, did other healthcare providers visit you at home? □ Yes □ No
Other healthcare includes visits to the nurse, occupational therapist, physiotherapist 
etc (excluding physician visits).
If yes: 7.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
8. During the past 3 months, did you need ambulance transport? □ Yes □ No
If yes: 8.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
9. During the past 3 months, were you hospitalized overnight with intensive care? □ Yes □ No
If yes: 9.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
10. During the past 3 months, were you hospitalized overnight with general care? □ Yes □ No
If yes: 10.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
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11. During the past 3 months, did you visit first aid/emergency care? □ Yes □ No
If yes: 11.1 What was the cause? (Please choose all that apply)
□  Breathing problems
□  Other health problems
If yes
If yes
How many times? _____
How many times? _____
12. During the past 3 months, have you performed a spirometry test? □ Yes □ No
If yes: How many times? _____
13. During the past 3 months, have you performed an advanced pulmonary test? □ Yes □ No
If yes: How many times? _____
14. During the past 3 months, have you undergone a plain chest X-ray? □ Yes □ No
If yes: How many times? _____
15. During the past 3 months, have you undergone a computer tomography for 
chest?
□ Yes □ No
If yes: How many times? _____
16. During the past 3 months, have you been using oxygen at home? □ Yes □ No
If yes: How many weeks? _____
Employment
17. During the past 3 months, have you been unable to perform you usual daily 
activities?
□ Yes □  No
(Daily activities include: employment work or house-work, not hobbies nor sports)
If yes: 17.1 What was the cause? (Please choose all that apply)
□  Breathing problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
□  Other health problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
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18. During the past 3 months, has a caregiver been unable to perform his/her usual 
daily activities due to your illness?
□ Yes □ No
(Caregiver is a person who has stayed home from work to assist you)
If yes: 18.1 What was the cause? (Please choose all that apply)
□  Breathing problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
□  Other health problems If yes How many half days (≤ 4 hours)?
How many full days (> 4 hours)?
_____ half days
_____ full days
19. Are you on long-term sick leave? □ Yes □ No
If yes: 19.2 Since how many months? ______ months
19.3 What is the cause? □ Breathing problems
□ Other health problems
Supplemental Methods 2 – Assumptions




- If a patient answered “yes” to the question if he had contact with a healthcare 
professional, underwent a test or was admitted to the hospital, but for the 
number of days or number of times 0 was filled in, we assumed no contact had 
taken place;
- To convert times of hospitalization to days of hospitalization, the following mean 
hospitalization lengths were used:
- 7.6 days for general care for breathing problems;1
- 5.2 days for general care for other health problems; 1
- 2.9 days for intensive care for breathing problems;2
- 1.9 days for intensive care for other health problems.2
Cost questionnaire - When a range is given (e.g. 2-3 liters/min), the mean value is used;
- When a comment states frequency is for both lung complaints and other 
complaints, the frequency is divided over lung and other complaints;
Medication in 
general
- When information of the medicine is missing in the start visit, information was 
adopted from the stop visit;
- When information of the medicine in start visit and stop visit didn’t match, 
information from the stop visit was used;
- If patients state to have used more than one medicine from the same medication 
category, only one medication was included. In case of sustained treatment, the 
start visit or stop visit was adjusted so medicines succeeded each other. In case 
of phasing out the medication, only the highest dose was included.
Medication dose - The present information is on total daily dose. Based on FK, this dose is split up 
in a usual dose and number of doses per day;
- In case of unknown or impossible dose, the medication name is leading and the 
usual dose is extracted from FK. When more doses are possible, a mean of these 
doses is used;
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Supplemental Methods 2. Continued




- In case of unknown or impossible route, the usual route is extracted from FK 
based on medication name and dose.
Medication duration - No duration for a course of antibiotics, corticosteroids, antivirals or other 
medication prescribed as a course of treatment was given within the 
database. Therefore, the mean value of a course of the medication was used, 
based on the information in the Farmacotherapeutisch Kompas (FK, www.
farmacotherapeutischkompas.nl), a Dutch database of pharmacology. When 
a medicine is prescribed until 2 days after complaints resolved, the maximal 
treatment duration is used. An overview of the assumptions is stated in the 
appendix;
- Medication data is collected each 3 months. If a patient states to have started 




- The following assumptions were made about frequency of use:
o Daily, at night or daily + prn: 91,25 days per 3 months;
o Prn: 91,25 days per 3 months and usual daily dose;
o During exercise: twice per week/26 days per 3 months;
- In case of topical treatment or treatment with spray or drops, it is assumed that 
one tube, bottle or container is enough for one month
LTOT - When a range is given (e.g. 2-3 liters/min), the mean value is used;
- Amount of hours/day use is divided in 2 categories:
o ≥15 hours/day: continuous user
o <15 hours/day: non-continuous user





- Costs for a rehabilitation program that took place in both year 1 and 2 was 
assigned to the year in which the greater part of the rehabilitation program took 
place
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Note: a These participants showed a stable breathlessness burden during the follow-up, except for the baseline 
visit. So participants within the group of low breathlessness burden showed low breathlessness burden at 
baseline, but stable high breathlessness burden during the remainder of the follow-up.
Abbreviation: PR, pulmonary rehabilitation.
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Dyspnea is one of the most reported symptoms of patients with advanced Chronic 
Obstructive Pulmonary Disease (COPD) and is often undertreated. Morphine has 
proven to be an effective treatment for dyspnea and is recommended in clinical 
practice guidelines, but questions concerning benefits and respiratory adverse 
effects remain. This study primarily evaluates the impact of oral sustained release 
morphine (morphine SR) on health-related quality of life and respiratory adverse 
effects in patients with COPD. Secondary objectives include the impact on exercise 
capacity, the relationship between description and severity of dyspnea and the 
presence of a clinically relevant response to morphine, and cost-effectiveness.
A single-center, randomized, double blind, placebo controlled intervention study will 
be performed in 124 patients with COPD who recently completed a comprehensive 
pulmonary rehabilitation program. Participants will receive 20-30 mg/24 h morphine 
SR or placebo for four weeks. After the intervention, participants will be followed 
for twelve weeks. Outcomes include: the COPD Assessment Test, six minute walking 
test, Multidimensional Dyspnea Scale and a cost diary. Furthermore, lung function 
and arterial blood gasses will be measured. These measures will be assessed during 
a baseline and outcome assessment, two home visits, two phone calls and three 
follow-up assessments. The intervention and control group will be compared using 
uni- and multivariate regression analysis and logistic regression analysis. Finally, an 
economic evaluation will be performed from a societal and healthcare perspective. 
The current manuscript describes the rationale and methods of this study and 
provides an outline of the possible strengths, weaknesses and clinical consequences.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a chronic, often progressive 
disease and a major cause of morbidity and mortality.1,2 Dyspnea is one of the 
most frequently reported symptoms in patients with advanced COPD and many 
patients remain breathless despite optimal treatment of their COPD.3,4 Previously 
was shown that opioids can reduce refractory dyspnea,5-7 and therefore current 
(inter)national guidelines recommend opioids as palliative treatment for refractory 
dyspnea.8,9 Despite these recommendations, only 2% of the outpatients with 
advanced COPD are using opioids.3 Physicians mention uncertainty about benefits, 
fear for respiratory adverse effects and lack of evidence-based guidelines as main 
reasons for their reluctance to prescribe opioids.10-12 Furthermore, a previous study 
suggests that one-third of patients don’t show an improvement in dyspnea when 
treated with oral morphine for three months.7 Currently, literature is insufficient to 
overcome the barriers towards opioid prescription for dyspnea.
While opioids can relieve dyspnea in patients with COPD, the effects on health-
related quality of life (HRQL) and exercise capacity remain unknown. The aim of 
palliative care interventions is to improve HRQL,13 but the effect of opioids on HRQL 
has only been assessed in three RCT’s.14-16 Consequently, a recent systematic review 
concerning opioid treatment for dyspnea concluded that a meta-analysis of HRQL 
could not be performed due to study heterogeneity and insufficient data.17 Further, 
the effect of opioids on exercise capacity is unclear. In fact, two meta-analyses 
found no effect on exercise capacity,5,17 mainly due to the administration of small 
and single doses,18 while a recent study suggested a positive effect on exercise 
capacity in COPD.19
Another reported barrier is fear for respiratory adverse effects.10-12 Data from 
patients with COPD are limited and results are conflicting. RCT’s with low dose 
morphine showed no relevant effects on respiratory rate, blood gases or oxygen 
saturation. However, these studies were not designed to assess safety.14,16,20 On 
the other hand, high dose oral morphine during exercise caused increased carbon 
dioxide levels and decreased oxygen levels in patients with COPD.21 A recent 
population-based prospective cohort study showed that lower doses of opioids 
were not associated with increased mortality, while higher doses of opioids were 
associated with increased mortality, independent of partial pressure of CO2.
22
Furthermore, there is no consistent evidence of which patients do and don’t 
benefit from opioid treatment.18 Johnson et al.23 showed that older age and more 
severe dyspnea predict the response to opioids. The American Thoracic Society 
describes three sensory descriptors of dyspnea which may be linked by specific 
physiological processes: sensations of work/effort, tightness and air hunger/
unsatisfied inspiration.24 To date it remains unknown whether these descriptors 
predict a clinical response to morphine. Finally, the cost-effectiveness of morphine 
treatment in patients with COPD is not yet known.
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To conclude, morphine is an effective treatment for dyspnea and is recommended in 
current guidelines. However, questions concerning benefits and respiratory adverse 
effects remain. Furthermore, only two-thirds of the patients benefit from morphine 
treatment. Knowledge about these benefits and respiratory adverse effects is 
lacking and should be complemented to improve treatment for patients with COPD.
Objectives
The MORphine for DYspnea in COPD (MORDYC) study is designed to investigate 
the benefits and respiratory adverse effects of oral sustained release morphine 
(morphine SR) treatment in patients with COPD. This study primarily aims at:
1.1 studying whether and to what extent oral administration of morphine SR 
improves HRQL in patients with COPD;
1.2 exploring whether and to what extent oral administration of morphine SR leads 
to respiratory adverse effects in patients with COPD.
The secondary objectives of the study are:
2.1 to investigate the effect of oral administration of morphine SR on exercise 
capacity in patients with COPD;
2.2 to study the relationship between severity and description of dyspnea and the 
response to oral administration of morphine SR in patients with COPD;
2.3 to analyze the cost-effectiveness of oral administration of morphine SR in 
patients with COPD.
We hypothesize that morphine SR improves HRQL and exercise capacity, does not 
lead to respiratory adverse effects and is cost-effective in patients with COPD. 
Furthermore, we hypothesize that patients with more severe dyspnea are more 
likely to respond to morphine SR. Finally, we hypothesize that the description of 
dyspnea (work/effort, tightness and air hunger/unsatisfied inspiration) may predict 
the response to morphine SR.
The objective of this article is to describe the rationale and methods of the MORDYC 




The MORDYC study is a single-center, randomized, double blind and placebo-
controlled intervention study of morphine SR in outpatients with COPD, followed 
by a prospective cohort study in the same group of patients. A treatment period of 
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four weeks will be sufficient to show results of treatment with morphine SR. Since 
a time horizon of four weeks may be insufficient to obtain valid estimates of the 
cost-effectiveness of the use of morphine SR, the collection of data on costs, health 
status and side effects is prolonged for twelve weeks. However, from an ethical 
perspective, four weeks is considered to be the maximum period to withhold the 
placebo group from recommended treatment. Therefore, after the intervention 
period of four weeks, participants can decide themselves if they will be treated 
with morphine.
Study population
The study population will consist of adults with a confirmed diagnosis of COPD 
based on the Global initiative for Obstructive Lung Disease (GOLD).1 Participants 
are eligible to participate when they experience severe to very severe impairment 
due to dyspnea (modified Medical Research Council [mMRC] Dyspnea grade 3 or 
4)25 despite optimal pharmacological and nonpharmacological treatment of their 
COPD.1 According to the latest GOLD strategy, optimal pharmacological treatment 
for patients with high symptom burden includes treatment with a combination 
of a long-acting muscarinic antagonist and a long-acting β-agonist,1 while optimal 
nonpharmacological treatment includes recent completion of a comprehensive 
pulmonary rehabilitation program.1,26 All participants will be recruited at CIRO, a 
center of expertise for chronic organ failure in Horn, the Netherlands. This center 
offers a state-of-the-art interdisciplinary pulmonary rehabilitation program, 
including education, psychosocial counselling, physical exercise training, nutritional 
counselling, occupational therapy and exacerbation management, consistent with 
the latest American Thoracic Society/European Respiratory Society Statement on 
Pulmonary Rehabilitation.27 The program at CIRO is patient-tailored and lasting for 
8 weeks (inpatient) or 14 weeks (outpatient).
Patients will be excluded from this study if they are aged under 18, are not able 
to read or fill out the questionnaires or diary, are awaiting lung transplantation, 
have a history of medicine misuse, use irreversible MAO blockers or opioids, have 
an allergy for morphine or its constituents, are pregnant or have the potential to 
get pregnant, have a history of convulsions or suffer from renal failure (creatinine 
clearance <15 ml/min), a head injury, intestinal obstruction, gastroparesis or liver 
disease. When a potential participant has suffered an exacerbation within two weeks 
before inclusion, enrolment will be postponed until two weeks after completion of 
the treatment for this exacerbation.
Intervention
Participants in the intervention group will receive morphine SR 10 mg capsules, 
administered twice daily (20 mg/24h). The control group will receive placebo 
capsules, which are identical in look and taste to the intervention medication. This 
ensures that both the participants and study staff won’t be able to distinguish 
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the morphine and placebo capsules. Morphine and placebo will be prescribed 
for four weeks, while meanwhile usual clinical care is continued. The dose can be 
increased to three times per day 10 mg (30 mg/24h) after one or two weeks in 
non-responders. A non-responder is defined as a participant whose severity of 
dyspnea is not improved by one point on a Numeric Rating Scale (NRS) compared to 
baseline.28 Dose increment will only be done if side-effects are acceptable according 
to the patient. To minimize side effects of morphine, all participants will receive a 
prescription for laxatives and anti-emetics with the instruction to use it as needed.
Study procedure
Patients will be informed about the study by the physician in CIRO during the end 
evaluation of their rehabilitation program. If a patient is eligible and shows interest 
in the study, he or she will receive the patient information letter. Participation will be 
verified by a phone call one week later. The baseline assessment will be scheduled 
a few days after this phone call. Between oral informed consent and the baseline 
assessment, participants will be randomized to either the intervention or the control 
group using a web-based random number generator. Minimization will be used to 
guarantee equal allocation distribution between the intervention and the control 
group. Randomization will be stratified for age (<55 years, 55-65 years, 65-75 years 
or >75 years) and impact of dyspnea (mMRC grade 3 or 4).23 At the start of the 
baseline assessment, written informed consent will be obtained. At that moment, 
the participants will receive a jar with the intervention medication. The jars will be 
provided with a blinded label, ensuring that the researcher and the participant will 
not be able to see which intervention is allocated. After the baseline assessment, 
the participant’s general practitioner and chest physician will be informed about 
study participation.
The intervention study consists of six assessments during the four weeks of 
intervention (Figure 1). The baseline (T0) and outcome (T5) assessments will take 
place in CIRO and last for 2.5 to 3 h. The investigator will visit the participants in 
their home environment one (T2) and two (T3) weeks after the baseline assessment, 
which lasts for approximately 1 h. Two days (T1) and four (T4) weeks after the 
baseline assessment, the investigator will call the participants. Furthermore, the 
participants will be asked to complete a weekly prospective cost diary during the 
intervention period.
At the end of the intervention study, the participants continue with the cohort study. 
At that moment, the participants can choose to continue morphine treatment. 
Since unblinding takes place when all participants have completed the intervention 
study, it is possible that participants from the placebo group assume they were in 
the intervention group and prefer to ‘continue’ morphine treatment. The general 
practitioner will be informed about this possibility and will be asked to monitor 
the treatment. The prospective cohort study lasts for twelve weeks after the end 
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of the intervention period. Participants will be followed up and will receive several 
questionnaires by post after four (T6), eight (T7) and twelve (T8) weeks (Table 1).
Figure 1. Study design
Outcomes
Primary outcomes
This study has two primary endpoints. HRQL will be determined using the COPD 
Assessment Test (CAT), which is a short and simple instrument that assesses the 
impact of COPD on HRQL.29,30
Adverse respiratory effects will be assessed by measuring partial pressure of carbon 
dioxide (PaCO2) using arterial blood gas.
Secondary outcomes
Adverse respiratory effects will, in addition to PaCO2 levels, be assessed by the 
following respiratory outcomes: partial pressure of oxygen (PaO2), respiratory rate 
at rest, oxygen saturation (SpO2) and transcutaneous pressure of carbon dioxide 
(PtcCO2) using a digital monitoring system, SO2 during the night using overnight 
pulse oximetry, and lung function, including forced expiratory volume in the first 
second (FEV1), forced vital capacity (FVC), Tiffenau index (FEV1/FVC) and inspiratory-
to-total lung capacity ratio (IC/TLC).
Determination of functional exercise capacity consists of the following two elements. 
The six minute walking test (6MWT)31 will be used to measure exercise capacity. 
Functional capacity will assessed by examining care dependency using the Care 
Dependency Scale32 and general mobility using the Timed ‘Up & Go’ test.33
For the assessment of the relationship between severity and description of dyspnea 
and the response to oral morphine SR, several instruments will be used. Severity 
of dyspnea will be assessed using a 0-10 NRS,34 with 0 = not breathless at all and 
10 = breathlessness as bad as you can imagine. The focus period will be framed as the 
average dyspnea as well as the worst dyspnea during the last 24 h. At T0, the focus 
will also be at the average dyspnea during the last week. Description of sensory and 
affective dimensions of dyspnea will be verified by means of the Multidimensional 
Dyspnea Profile (MDP) with the last 24 h as focus period.35,36 The mMRC scale25 and 
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modified Pulmonary Functional Status and Dyspnea Questionnaire37,38 will be used 
to assess impact of dyspnea.
For the economic evaluation of morphine SR, participants will complete a 
prospective costs diary about their healthcare use, domestic help and absence 
of paid or voluntary work. Generic quality of life will be determined using the 
EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L)39 and HRQL using the CAT. During the 
cohort study, the participants will be asked to fill out the CAT and EQ-5D-5L and a 
retrospective cost questionnaire.
Other outcomes
The following outcomes will be taken from the patient file:
• Demographic characteristics (such as date of birth, gender and marital status);
• Medical history (number of exacerbations and hospital admissions in the 
previous year and the Charlson Comorbidity Index40);
• Smoking history;
• Lung function (including FEV1, FVC, FEV1/FVC);
• Creatinine clearance;
• Use of medication (including use of long-term oxygen therapy and noninvasive 
positive pressure ventilation).
Current smoking behavior and use of medication will be verified with the participant 
during the baseline assessment at CIRO. Change in medication use, compliance and 
occurrence of exacerbations will be recorded during the remaining assessments. 
An exacerbation is defined as an acute event characterized by a worsening of the 
patient’s respiratory symptoms beyond normal day-to-day variations and leading 
to a change in medication.1 In addition, adverse effects will be monitored, including 
nausea, vomiting, drowsiness, constipation and sleeplessness (NRS; average burden 
in last 24 h), sleepiness (Epworth Sleepiness Scale41) and cognition (Montreal 
Cognitive Assessment42).
Table 1 shows the measurements performed during the intervention study and 
the cohort study.
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Table 1. Measurements
T0 T1 T2 T3 T4 T5 T6 T7 T8
Primary outcomes
Health-related quality of life: COPD 
Assessment Test X X X X X X
Respiratory parameters
Arterial blood gas, including PaO2 and 
PaCO2
X X
Respiratory rate at rest, SpO2 and PtcCO2 X X X X
Respiratory rate at rest, SpO2 and PtcCO2 X X
Lung function: FEV1, FVC, FEV1/FVC, IC/
TLC X X
Secondary outcomes
Exercise capacity: six minute walking test X X
Care dependency: Care Dependency Scale X X
Mobility: Timed ‘Up & Go’ test X X X X
Severity of dyspnea: Numeric Rating Scale X X X X X X X X
Description of dyspnea: Multidimensional 
Dyspnea Profile X X
Impact of dyspnea: modified Medical 
Research Council scale X X X X
Impact of dyspnea: Modified Pulmonary 




Prospective cost diary X X X X X
Retrospective cost questionnaire X X X
General quality of life: EuroQol-5 
Dimensions-5 Levels X X X X
Other outcomes
Demographics, including age, gender, 
marital status X
Medical history: Charlson Comorbidity 
Index X
COPD history: number of exacerbations 
and hospital admissions for COPD (< 12 
months)
X
Smoking history and behavior X
Current medication X X X X X X X




Nausea, vomiting, drowsiness, 
constipation and sleeplessness: 
Numeric Rating Scale
X X X X X X X X
Sleepiness: Epworth Sleepiness Scale X X
Cognition: Montreal Cognitive 
Assessment X X
Exacerbations X X X X X X X X
Compliance X X X X X
Abbreviations: FEV1 = forced expiratory volume in the first second; FEV1/FVC = Tiffenau index; FVC = forced vital 
capacity; IC/TLC = inspiratory-to-total lung capacity ratio; PaCO 2  = partial pressure of carbon dioxide; PaO 2 = partial 
pressure of oxygen; PtcCO2 = transcutaneous pressure of carbon dioxide; SpO2 = pulse oxygen saturation.




A total of 54 participants per treatment group are needed to detect a clinically 
relevant change in CAT score of 3.8 points (SD 6.1 points),29,43 based on a significance 
level of 5% and a power of 90%. In addition, in order to detect a change in PtcCO2 
level of 1.0 kPa (SD 0.7 kPa44) 10 participants per treatment group are needed, based 
on a significance level of 5% and a power of 90%. A drop-out rate of about 13% is 
expected,16 and therefore 62 participants will be included per group. Yearly, about 
130 patients with COPD completing the pulmonary rehabilitation program at CIRO 
report an mMRC grade of 3 or 4. About 10% of these patients won’t be eligible 
for this study because of a history of substance misuse, renal failure or because 
patients are already using opioids. Furthermore, based on an ongoing study among 
patients with advanced COPD, we expect a response rate of about 50%. Therefore, 
it seems reasonable to recruit 124 patients within two years.
Data management and statistical analysis
Data will be screened for missing data, which will be handled according to the 
guidelines of the different instruments. In order to minimize missing data, the 
majority of the tests and questionnaires will be performed in the presence of a 
researcher or research assistant. Continuous variables will be checked for normality. 
For all data, point measures and measures of variability will be provided. Baseline 
characteristics will be compared between the intervention and control group using 
descriptive statistics. The independent sample T-test will be used for normally 
distributed continuous variables, the Mann-Whitney U-test for not normally 
distributed continuous variables and the Chi square test for categorical variables.
Mean change in CAT-scores, respiratory parameters, 6MWT results, NRS scores for 
side effects, Epworth Sleepiness Scale scores and Montreal Cognitive Assessment 
scores will be compared between the intervention and control group using 
independent sample T-tests or Mann-Whitney U tests, according to the variable 
distribution. Subsequently, a linear mixed model will be developed to assess 
longitudinal changes according to trial arm. The proportion of exacerbations is 
compared between the intervention and control group using a Chi-squared test. 
Analyses will be done using an intention-to-treat approach.
To explore the relationship between the response to morphine and the severity of 
their dyspnea and the way participants describe their dyspnea, univariate analysis 
will be used, followed by binary logistic regression. Response to opioids (defined as 
a decrease in dyspnea NRS score by one point or more compared to baseline) will 
be included as dependent variable, descriptors of dyspnea (MDP) as independent 
variables and baseline dyspnea (NRS) as a possible confounder. Participants who 
discontinue morphine during the study because of lack of effect and/or intolerable 
adverse effects will be analyzed as non-responders.
A trial-based economic evaluation will be performed from the societal and 
healthcare perspective. The time horizon of the trial-based economic evaluation 
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will be four weeks. The intervention offered in this study is primarily expected to 
affect morbidity, so quality of life is considered as an important outcome in these 
patients. The incremental costs per Quality-Adjusted Life Year based on the EQ-
5D-5L will be expressed in the incremental cost-effectiveness ratio for the societal 
perspective,45 whereas additional patients with a clinically relevant improvement on 
the CAT will be expressed for the healthcare perspective. The cost analyses will be 
performed according to Dutch guidelines for cost calculations,46 and study related 
costs will be excluded. Hospital resource use will be registered using the questions 
about exacerbations and costs outside the hospital will be registered using the cost 
diary and cost questionnaire. Standard sensitivity analyses and bootstrap analysis 
will be performed to investigate the uncertainty surrounding the incremental cost-
effectiveness ratios. Based on the bootstrap results, cost-effectiveness acceptability 
curves will be constructed. These curves show the probability that morphine (in 
addition to usual clinical care) is cost-effective compared to placebo (in addition to 
usual clinical care) for a range of cost-effectiveness threshold values. Data collection 
on costs, quality of life and side effects will be prolonged for twelve weeks since a 
time horizon of four weeks may be insufficient to obtain valid estimates of the cost-
effectiveness of morphine. Additionally, data on long-term costs and effects will be 
estimated using a decision analytical model with a lifelong time horizon.47 Transition 
probabilities, healthcare costs, survival and health utilities will be used as input, 
based on the study results, literature review and, when necessary, expert opinion. 
The economic impact will first be estimated using fixed estimates of probabilities, 
costs and health outcomes. Probabilistic sensitivity analysis will additionally be 
performed to address uncertainty.
Ethical considerations and dissemination
The load for the participants will be minimized by visiting them at home two 
times and contacting them by phone two times. Furthermore, medication will be 
prescribed to prevent the most common adverse effects of morphine. In case of 
questions or concerns, participants can contact the researchers. Participants will 
be able to leave the study at any time for any reason without consequences. The 
investigator can decide to withdraw a subject from the study for urgent medical 
reasons. During interim analysis, the proportion of hospitalized and the proportion 
of deceased patients will be compared between the two groups, without unblinding. 
The code will be broken in case of a statistically significant higher number of hospital 
admissions or deaths in one group, which might be related to the study medication. 
This study will be conducted in accordance with the principles of the Declaration of 
Helsinki and in accordance with the Medical Research Involving Human Subjects Act 
(WMO). Informed consent will be obtained from all participants before participation. 
Monitoring will follow the international ICH-GCP guidelines. The results will be 
published in appropriate well-accepted scientific journals. If desired, participants will 
be informed about the results at the end of the study. The protocol of the present 
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study is approved by the Medical Ethics Committee Maastricht UMC+ (METC152002) 
and is registered at ClinicalTrials.gov (NCT02429050).
Discussion
Morphine is an effective treatment for refractory dyspnea and is recommended in 
clinical practice guidelines.8,9 Although effectiveness for relieve of dyspnea is proven, 
concerns regarding benefits and respiratory adverse effects remain. Due to this 
lack of knowledge, physicians are reluctant in prescribing morphine to patients with 
COPD. As a result, dyspnea that persists despite optimal treatment of the underlying 
disease is undertreated in patient with COPD. The current study is designed to 
provide the knowledge physicians need to optimally treat refractory dyspnea in 
COPD.
Strengths of this study
To date, most studies have been focusing on the effect of opioids on refractory 
dyspnea, with some of them collecting data on respiratory adverse effects and 
HRQL as secondary objective. As a consequence, the sample size calculations of 
these studies were only based on the change in dyspnea score and therefore not 
designed to assess safety of opioids. Moreover, only three RCT’s on oral or parental 
opioids included a measure of HRQL, and their results were conflicting.14-16 A major 
strength of the present study is the intended sample size, which will be based on 
clinical relevant changes in both the CAT score and PtcCO2. This study will therefore 
be able to demonstrate an effect of morphine treatment, if present.
Furthermore, the present study will include measures for the intensity of dyspnea 
and for the description of sensory and affective dimensions of dyspnea. These 
outcomes will be compared between responders and non-responders. Previous 
studies showed conflicting results regarding characteristics of patients with 
COPD that will predict the response to opioids.23,48 This knowledge is necessary 
to select the patients that are likely to respond to morphine without unacceptable 
side effects. When such a subgroup of patients can be indicated, the treatment of 
refractory dyspnea can be individually tailored in the future.
Other strengths are related to the study duration. Previous studies on systemic 
opioids were mostly of short duration, with several studies only prescribing a single 
dose.20,49-51 The treatment period of four weeks in the present study will be sufficient 
to show beneficial effects of morphine SR treatment. In addition, this will create 
an opportunity to increase the dose if initially no relieve of dyspnea is achieved. 
Furthermore, the intervention study is followed by a cohort study of twelve weeks, 
making it possible to ground the model-based economic evaluation.
Finally, including participants at the end of a comprehensive rehabilitation program 
ensures the completion of a state-of-the-art nonpharmacological treatment.27 
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Besides that, CIRO covers the southeastern part of The Netherlands, including 
patients referred from both general and academic hospitals. This will improve the 
generalizability of the study results.
Weaknesses of this study
This study has some potential limitations. First, it is possible that patients are not 
willing to participate. In a study among Dutch chest physicians, resistance of patients 
is one of the mentioned reasons restraining physicians from prescribing opioids 
to patients with advanced COPD.10 It is not known if this is truly the attitude of the 
patient or a perception of the physician. However, Abernethy et al.14 showed that 
including patients with COPD in a study with morphine SR treatment is possible. 
Second, drop-out might take place because of adverse effects like nausea and 
constipation.17 To minimize this risk, participants will receive a prescription for anti-
emetics and laxatives. Since drop-out cannot be prevented completely, a drop-out 
rate of 13% is taken into account in the sample size calculation.16 Third, compliance is 
only monitored by asking participants about their ingestion pattern and by counting 
the remaining capsules at the end of the intervention period. It is possible that 
the compliance is different and forgotten capsules are discarded. However, this is 
comparable to behavior of patients in daily practice. Finally, the sample size might 
be too small to have adequate power to test interaction between severity and 
description of dyspnea and the response to oral administration of morphine SR.
Clinical consequences
The MORDYC study will examine the benefits and possible respiratory adverse 
effects of oral sustained-release morphine in patients with COPD. Currently the 
percentage of patients receiving morphine for refractory dyspnea is very low, despite 
the fact that morphine is recommended in national and international guidelines. 
When morphine proves to have major benefits and only small adverse effects, this 
might abate the barriers for physicians, leading to a more effective treatment for 
patients with COPD with refractory dyspnea despite optimal treatment.
Furthermore, the present study will gain insight in the characteristics of patients 
that do and do not benefit from treatment with morphine SR. This will create the 
opportunity to individually tailor the treatment of these patients, with minimal 
adverse effects. The future focus for patients that do not respond to treatment with 
morphine SR or experience unacceptable adverse effect can shift to the examination 
of other effective treatment.




To conclude, treatment of refractory dyspnea is an important component of the 
management of COPD. Therefore, examining the benefits and respiratory adverse 
effects and determining the characteristics of those that will benefit from treatment 
is essential for the management of patients with this disease.
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Importance: Morphine is used as palliative treatment of chronic breathlessness in 
patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on 
respiratory adverse effects and health status is scarce and conflicting.
Objective: To assess the effects of regular, low-dose, oral sustained-release 
morphine on disease-specific health status (COPD Assessment Test; CAT), 
respiratory outcomes and breathlessness in patients with COPD.
Interventions: Participants were randomly assigned to 10 mg of regular, oral 
sustained-release morphine or placebo twice daily for 4 weeks, with the possibility 
to increase to 3 times daily after 1 or 2 weeks.
Design, setting and participants: The Morphine for Treatment of Dyspnea 
in Patients With COPD (MORDYC) study was a randomized, double-blind and 
placebo-controlled study of a 4-week intervention. Patients were enrolled between 
November 1, 2016 and January 24, 2019. Participants were recruited in a pulmonary 
rehabilitation center and 2 general hospitals after completion of a pulmonary 
rehabilitation program. Outpatients with COPD and moderate to very severe 
chronic breathlessness (modified Medical Research Council [mMRC] breathlessness 
grades 2-4) despite optimal pharmacological and nonpharmacological treatment 
were included. A total of 1380 patients were screened, 916 were ineligible and 340 
declined to participate.
Main outcomes and measures: Primary outcomes were CAT score (higher scores 
represent worse health status) and arterial partial pressure of carbon dioxide 
(PaCO2). Secondary outcome was breathlessness in the previous 24 hours (numeric 
rating scale). Data were analyzed by intention to treat. Subgroup analyses in 
participants with mMRC grades 3 to 4 were performed.
Results: A total of 111 of 124 included participants were analyzed (mean [SD] age, 
65.4 [8.0] years; 60 men [54%]). Difference in CAT score was 2.18 points lower in 
the morphine group (95%CI, −4.14 to −0.22 points; p=0.03). Difference in PaCO2 was 
1.19 mmHg higher in the morphine group (95%CI, −2.70 to 5.07 mmHg; p=0.55). 
Breathlessness remained unchanged.Worst breathlessness improved in participants 
with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95%CI, −2.50 
to −0.16 points; p=0.03). Five participants of 54 in the morphine group (9%) and 1 
participant of 57 in the placebo group (2%) withdrew because of adverse effects. 
No morphine-related hospital admissions or deaths occurred.
Conclusions and relevance: In this randomized clinical trial, regular, low-dose, oral 
sustained-release morphine for 4 weeks improved disease-specific health status in 
patients with COPD without affecting PaCO2 or causing serious adverse effects. The 
worst breathlessness improved in participants with mMRC grades 3 to 4. A larger 
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randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 
4 is warranted.
Introduction
Chronic breathlessness is one of the most frequently reported symptoms of patients 
with advanced Chronic Obstructive Pulmonary Disease (COPD).1,2 The underlying 
pathophysiology is complex, and it has a considerable effect on prognosis and 
health status (defined as the effect of health on the ability to perform and derive 
fulfillment from activities of daily life, including health-related quality of life and 
functional status3).4,5 Breathlessness management is an important treatment goal.6
Previous authors proposed palliative pharmacological treatment with low-dose 
opioids for patients with refractory breathlessness despite optimal pharmacological 
and nonpharmacological treatment.7 This recommendation has been included in 
international and national guidelines.8-10 Evidence for this recommendation is still 
limited. Two meta-analyses reported small improvements in breathlessness after 
opioid treatment in patients with different life-limiting illnesses.11,12 Analyses in 
patients with COPD treated for at least 4 days showed an improvement of 5 to 12 
points on a 0 to 100 visual analog scale.11,12 No effect on health status or functional 
performance could be shown because only a few studies included small populations. 
A recent study by Currow et al13 prescribing regular, low-dose, oral sustained-
release morphine for 1 week to patients with chronic breathlessness due to several 
conditions also showed no change in health status and suggested morphine will only 
reduce breathlessness in patients with severe chronic breathlessness.
Moreover, physicians remain reluctant to prescribe opioids for breathlessness in 
COPD for fear of respiratory depression.14,15 A recent systematic review found no 
evidence for respiratory adverse effects after treatment with low-dose opioids 
for chronic breathlessness.16 However, most studies were small and only a few 
measured arterial blood gases. To our knowledge, no large randomized clinical 
trials (RCTs) adequately powered to measure the effect of opioids on respiratory 
outcomes have yet been conducted.
Therefore, the primary aims of the Morphine for Treatment of Dyspnea in Patients 
With COPD (MORDYC) study17 were to assess (1) whether and to what extent regular, 
low-dose, oral sustained-release morphine improves disease-specific health status 
in patients with moderate to very severe chronic breathlessness due to advanced 
COPD and (2) whether and to what extent regular, low-dose, oral sustained-release 
morphine leads to respiratory adverse effects. Secondary aims were to assess 
the effect of regular, low-dose, oral sustained-release morphine on functional 
performance and breathlessness.





The MORDYC study is a randomized, double blind, placebo-controlled, parallel-arm 
intervention study.17 Participants were treated with regular, low-dose, oral sustained-
release morphine or placebo for 4 weeks. The study protocol was approved by the 
medical ethics committee of Maastricht University Medical Center (METC152002). 
All participants provided written informed consent. Results are reported according 
to the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.
Participants
Adult patients with a confirmed diagnosis of COPD based on the Global Initiative 
for Obstructive Lung Disease (postbronchodilator forced expiratory volume in 1 
second per forced vital capacity ratio of <0.70)6 were recruited from CIRO (a certer 
of expertise for chronic organ failure in Horn, the Netherlands), Zuyderland Hospital 
in Heerlen, the Netherlands and VieCuri Medical Center in Venlo, the Netherlands. 
Inclusion criteria were modified Medical Research Council (mMRC) breathlessness 
grades 2, 3 or 418 despite optimal pharmacological and nonpharmacological 
treatment, including having completed a pulmonary rehabilitation program.6 See 
Supplemental Methods 1 for details.
Randomization and blinding
Randomization was performed by a web-based random number generator using 
minimization and stratification for age (<55 years, 55-65 years, 65-75 years or >75 
years) and mMRC grade.19 Participants and investigators were blinded.
Study procedures
Participants received 10 mg of regular, oral sustained-release morphine or placebo 
twice daily. The dose could be adjusted to 3 times daily after 1 or 2 weeks in non-
responders (<1 point improvement in severity of mean breathlessness on a 0 to 10 
numeric rating scale [NRS] compared with baseline20,21). All participants received a 
prescription for macrogol (13.8 g) once daily and metoclopramide (10 mg) 3 times 
daily, both as needed.
After baseline, participants were contacted by phone after 2 days and 3 weeks. 
Home visits took place after 1 and 2 weeks (Figure 1).
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Figure 1. Study Design
Note: T indicates time.
Outcomes
At baseline, demographic and clinical characteristics were collected from the patient 
file or based on self-report. Disease-specific health status was determined using 
the COPD Assessment Test22,23 (CAT) (higher scores represent worse health status, 
minimal clinical important difference [MCID] 2.0-3.0 points24) at time T0, T2, T3 
and T5. Arterial partial pressure of carbon dioxide (PaCO2) was assessed in arterial 
blood at T0 and T5. A priori, the project group defined a change of 7.5 mm Hg as 
clinically relevant.17
Secondary outcomes included functional performance, respiratory outcomes and 
severity of breathlessness. Functional performance consisted of functional exercise 
performance (6-minute walk test [6MWT]25), general mobility (Timed Up and Go 
[TUG] test26) and care dependency (Care Dependency Scale [CDS]27,28). 6MWT and 
CDS were assessed at T0 and T5, and the TUG test was performed at T0, T2, T3 and 
T5.
Secondary respiratory outcomes included (1) partial arterial pressure of oxygen 
(PaO2), arterial oxygen saturation (SaO2), percentage of time that the overnight pulse 
oxygen saturation (SpO2) was below 90%, mean overnight SpO2 and lung function 
at T0 and T5, and (2) respiratory rate (RR), transcutaneous carbon dioxide pressure 
(PtcCO2) and transcutaneous SpO2 at T0, T2, T3 and T5.
Severity of mean and worst breathlessness in the previous 24 hours was self-
reported at T0 to T5 on a 0 to 10 NRS29, with 0 being not breathless at all and 10 
being the worst imaginable breathlessness.
Morphine-related adverse effects, medication use, and incidence of acute COPD 
exacerbations or hospitalizations were discussed during T0 to T5 (Supplemental 
Methods 2).
Sample size
To detect a mean (SD) change in CAT of 3.8 (6.1) points (at the time of study design 
the estimated MCID22,30), 54 participants per group were needed (significance level 
5%, power 90%). Furthermore, 10 participants per group were needed to detect a 
mean (SD) change in PaCO2 of 7.5 (5.3
31) mm Hg. Considering a dropout rate of 13%,32
62 participants per group needed to be included.




Continuous data were described as mean (SD) or median (interquartile range). 
Categorical data were shown as number (percentage).
Given the longitudinal nature of the data, mean change between the morphine and 
placebo group was assessed, including time by group interaction. For PaCO2, PaO2, 
overnight oximetry, lung function, 6MWT and CDS a linear regression model was 
developed. For CAT, RR, PtcCO2 , SpO2, TUG and NRS, a linear mixed-effects model 
was developed. Different covariance structures were considered (Supplemental 
Table S1) and the best-fitting model was selected using χ2 tests. Mean difference (95% 
CI) between groups was presented. Post hoc subgroup analyses were performed in 
the original study population with mMRC grades 3 to 4 at baseline. Furthermore, 
post hoc analyses of the CAT on item level were performed.
Analyses were performed according to intention to treat but excluding participants 
who withdrew between randomization and exposure to the intervention.33 For the 
analyses, SPSS version 25.0 (IBM Corp) was used. A 2-sided level of significance was 
set at p£0.05. Data were analyzed from September 11, 2019, to May 11, 2020.
Results
Between November 1, 2016 and January 24, 2019, 1380 patients were screened, 
464 patients were eligible, and 124 participants were randomized (response rate 
27%) (Figure 2). Between randomization and baseline assessment, 13 participants 
withdrew. The remaining 111 participants had a mean (SD) age of 65.4 (8.0) years, 
and 60 were men (54%) (Table 1). Participants who enrolled did not differ from those 
who declined to participate regarding age or sex, but participants who enrolled 
experienced more severe breathlessness (41 of 124 participants [33%] had mMRC 
grade 3 and 11 [9%] had mMRC grade 4 vs 59 of 340 nonparticipants [17%] who had 
mMRC grade 3 and 25 [7%] who had mMRC grade 4, p=0.009). The proportion of 
participants completing the treatment was 81% (n=44) in the morphine group and 
89% (n=51) in the placebo group.
Health status
The difference in CAT score between the treatment groups was −2.18 points (95% CI, 
−4.14 to −0.22 points; p=0.03; Table 2) favoring morphine. When examining the CAT 
score on item level, the difference between the groups was significant for walking 
the stairs or hill (−0.43 points; 95% CI, −0.80 to −0.07 points; p=0.02; Table 3).
In the subgroup with mMRC grades 3 to 4, the difference between the treatment 
groups was not significant (−1.17 points; 95% CI, −4.17 to 1.84 points; p=0.44; Table 2), 
as were the scores on item level (Table 3). Results for the CAT scores per assessment 
are shown in Supplemental Table S2.
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Figure 2. Flowchart of the Morphine for Treatment of Dyspnea in Patients With COPD 
(MORDYC) Study
Abbreviations: COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.
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Age, mean (SD), y 65.0 (8.0) 65.7 (8.0) 66.6 (8.1) 64.5 (9.0)
Male 28 (52) 32 (56) 12 (52) 12 (46)
BMI, mean (SD), kg/m2 27.6 (6.6) 27.2 (5.3) 27.5 (6.1) 26.1 (6.2)
Marital status
Single 9 (17) 13 (23) 2 (9) 5 (19)
Married/cohabitation 42 (78) 44 (77) 19 (83) 21 (81)
In relation, but living apart 3 (6) 0 (0) 2 (9) 0 (0)
Medical characteristics
Current smoking 7 (13) 7 (12) 3 (13) 4 (15)
Pack years, median (IQR) 40 (29.8-51.3) 40 (30-50) 40 (30-50) 40 (59-69.3)
CCI, median (IQR), pointsb 1.5 (1-2) 1 (1-3) 1 (1-2) 1 (1-3)
Prior myocardial infarction 7 (13) 4 (7) 4 (17) 1 (4)
Congestive heart failure 2 (4) 6 (11) 2 (9) 4 (15)
Peripheral vascular disease 6 (11) 6 (11) 2 (9) 1 (4)
History of cerebrovascular 
disease
4 (7) 4 (7) 0 (0) 3 (12)
Rheumatologic disease 1 (2) 3 (5) 0 (0) 2 (8)
Peptic ulcer disease 0 (0) 1 (2) 0 (0) 1 (4)
Mild liver disease 1 (2) 2 (2) 0 (0) 2 (4)
Diabetes mellitus 9 (17) 7 (12) 6 (26) 1 (4)
Moderate-to-severe renal 
disease
2 (4) 1 (2) 0 (0) 1 (4)
Diabetes mellitus with 
chronic complications
1 (2) 0 (0) 1 (4) 0 (0)
Cancer without 
metastases, leukemia or 
lymphoma
5 (9) 9 (16) 2 (9) 4 (15)
Exacerbations <12 months, 
median (IQR)
2 (1-4) 2 (0-3.5) 3 (2-4) 4 (1-4)
Hospital admissions <12 
months, median (IQR)
0 (0-1) 0 (0-1) 1 (0-1) 0 (0-1)
Treatment used
LAMA 52 (96)c 57 (100) 23 (100) 26 (100)
LABA 53 (98)c 57 (100) 23 (100) 26 (100)
ICS 43 (80) 45 (79) 18 (78) 21 (81)
LTOT 22 (41) 25 (44) 10 (43) 13 (50)
NIV 12 (22) 12 (21) 3 (13) 5 (19)
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FEV1, L 0.99 (0.71-1.31) 0.95 (0.64-1.25) 0.87 (0.66-1.02) 0.88 (0.58-1.18)
FEV1, % predicted 38 (29-53) 34 (25-49) 30 (24-42) 35 (23-51)
FVC, L 2.88 (2.39-3.74) 2.92 (2.32-3.66) 2.72 (2.03-3.66) 2.71 (2.22-3.39)
FEV1/FVC 0.32 (0.27-0.41) 0.31 (0.25-0.42) 0.29 (0.27-0.34) 0.32 (0.26-0.44)
IC/TLC, mean (SD) 0.31 (0.09)d 0.31 (0.10)e 0.29 (0.07)d 0.30 (0.11)d
ITGV, mean (SD), L 4.79 (1.26)d 5.08 (1.53)f 5.02 (1.34)d 5.06 (1.85)
Clinical characteristics
mMRC grade at T0
2 31 (57) 31 (54) 0 (0) 0 (0)
3 20 (37) 19 (33) 20 (87) 19 (73)
4 3 (6) 7 (12) 3 (13) 7 (27)
CAT score, mean (SD) 22.8 (6.3) 21.4 (7.4) 23.2 (5.8) 24.0 (6.5)
6MWT, mean (SD), m 354 (85)d 343 (114)d 332 (84)d 285 (114)d
PaCO2, median (IQR), mm Hg 40.6 (37.6-44.5) 41.4 (36.8-45.9) 42.9 (35.3-45.9) 39.9 (36.7-47.9)
SaO2, median (IQR), % 93.1 (91.4-94.5) 93.8 (89.9-95.3) 94.2 (92.5-95.1) 93.1 (89.2-95.5)
Notes: a Values are written as No. (%) unless otherwise indicated. b None of the participants had dementia, 
hemiplegia, moderate or severe liver disease, metastatic solid tumor or acquired immunodeficiency syndrome. 
c One patient only used LABA therapy, and 1 patient had LAMA-LABA therapy prescribed but stopped using this 
on their own initiative. d Test not performed in 1 participant. e Test not performed in 3 participants. f Test not 
performed in 4 participants. Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; CCI, Charlson 
Comorbidity Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity; IC/TLC, inspiratory capacity to total lung capacity ratio; ICS, inhaled corticosteroids; ITGV, 
intrathoracic gas volume; IQR, interquartile range; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic 
antagonist; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council; 6MWT, 6-minute walk 
test; NIV, noninvasive positive pressure ventilation; PaCO2, arterial partial pressure of carbon dioxide; SaO2, 
arterial oxygen saturation.
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Table 2. Mean difference in outcomes for total study population and subgroup of participants 




Subgroup with mMRC grades 3-4
(n=49)
Variable Mean difference (95% CI) p-value Mean difference (95% CI) p-value
Primary outcomes
CAT score −2.18 (−4.14 to −0.22) 0.03 −1.17 (−4.17 to 1.84) 0.44
PaCO2, mm Hg  1.19 (−2.70 to 5.07) 0.55  1.84 (−4.95 to 8.64) 0.59
Secondary outcomes
PaO2, mm Hg −3.79 (−9.70 to 2.12) 0.21 −5.92 (−15.73 to 3.90) 0.23
SaO2, % −1.09 (−2.93 to 0.75) 0.24 −1.72 (−5.02 to 1.58) 0.30
Respiratory rate −1.46 (−2.84 to −0.09) 0.04 −0.73 (−2.79 to 1.34) 0.49
PtcCO 2, mm Hg  1.39 (−0.65 to 3.42) 0.18  1.02 (−1.78 to 3.82) 0.47
SpO2, % −0.33 (−0.95 to 0.29) 0.29 −0.09 (−1.09 to 0.91) 0.86
% time overnight SpO2 below 
90%
−0.04 (−19.61 to 19.52)c >0.99 10.84 (−19.64 to 41.32)a 0.48
Overnight SpO2, %  0.16 (−1.48 to 1.81)
c 0.84 −0.03 (−2.90 to 2.85)a 0.99
FEV1, L −0.02 (−0.29 to 0.26) 0.91  0.04 (−0.34 to 0.42) 0.83
FEV1, % predicted −0.27 (−9.92 to 9.38) 0.96  2.57 (−12.07 to 17.22) 0.73
FVC, L −0.15 (−0.68 to 0.38) 0.57 −0.17 (−0.96 to 0.63) 0.68
FEV1/FVC  0.02 (−0.05 to 0.08) 0.60  0.04 (−0.06 to 0.14) 0.42
IC/TLC  0.02 (−0.04 to 0.07)e 0.58  0.03 (−0.06 to 0.11)b 0.56
IC, L −0.03 (−0.49 to 0.42)d 0.88 −0.07 (−0.74 to 0.61)a 0.85
ITGV, L −0.42 (−1.27 to 0.44)d 0.34 −0.65 (−2.17 to 0.88)a 0.40
Functional exercise 
performance (6MWT)
−5.07 (−61.38 to 51.20)a 0.86  1.49 (−87.47 to 90.46)a 0.97
General mobility (TUG) −0.04 (−0.54 to 0.47)b 0.89  0.00 (−0.87 to 0.87)a 0.99
Care dependency (CDS) −0.33 (−3.34 to 2.69) 0.83 −1.56 (−6.65 to 3.52) 0.54
Breathlessness previous 24 
h (NRS)
Mean −0.60 (−1.55 to 0.35) 0.21 −1.31 (−2.80 to 0.17) 0.08
Worst −0.56 (−1.41 to 0.28) 0.19 −1.33 (−2.50 to −0.16) 0.03
Notes: a Test not performed in 3 participants. b Test not performed in 1 participant. c Test not performed in 5 
participants. d Test not performed in 2 participants. e Test not performed in 4 participants. Abbreviations: CAT, 
COPD Assessment Test; CDS, Care Dependence Scale; COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; IC/TLC, inspiratory capacity to total 
lung capacity ratio; ITGV, intrathoracic gas volume; mMRC, modified Medical Research Council; 6MWT, 6-minute 
walk test; NRS, numeric rating scale; PaCO2, arterial partial pressure of carbon dioxide; PaO2, partial arterial 
pressure of oxygen; PtcCO2, transcutaneous carbon dioxide pressure; SaO2, arterial oxygen saturation; SpO2, 
pulse oxygen saturation; TUG, Timed Up and Go Test.
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Table 3. Mean difference in CAT item scores for total study population and subgroup of 




Subgroup with mMRC grades 3-4
(n=49)
Score item Mean difference (95% CI) p-value Mean difference (95% CI) p-value
Total score −2.18 (−4.14 to −0.22) 0.03 −1.17 (−4.17 to 1.84) 0.44
Coughing −0.31 (−0.70 to 0.08) 0.12 −0.12 (−0.74 to 0.49) 0.70
Phlegm −0.12 (−0.49 to 0.25) 0.52 −0.13 (−0.64 to 0.38) 0.61
Chest tightness −0.06 (−0.55 to 0.44) 0.83  0.59 (−0.09 to 1.27) 0.09
Walking stairs or hill −0.43 (−0.80 to −0.07) 0.02 −0.45 (−0.96 to 0.05) 0.08
Activities at home −0.11 (−0.58 to 0.35) 0.63 −0.33 (−1.04 to 0.37) 0.35
Confidence leaving home −0.31 (−0.86 to 0.25) 0.28  0.14 (−0.79 to 1.08) 0.76
Sleeping −0.16 (−0.78 to 0.45) 0.60 −0.30 (−1.34 to 0.75) 0.57
Energy −0.45 (−1.07 to 0.16) 0.15 −0.22 (−1.22 to 0.78) 0.66
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; mMRC, modified 
Medical Research Council.
Respiratory outcomes
Change in PaCO2 did not differ significantly or clinically between the treatment 
groups (1.19 mm Hg; 95% CI, −2.70 to 5.07 mm Hg; P=0.55; Table 2). The subgroup 
with mMRC grades 3 to 4 also showed no significant or clinically relevant difference 
in PaCO2 (1.84 mm Hg; 95% CI, −4.95 to 8.64 mm Hg; p=0.59; Table 2).
The difference in RR between the treatment groups was significant favoring 
morphine (−1.46; 95% CI, −2.84 to −0.09; p=0.04; Table 2). In the subgroup with 
mMRC grades 3 to 4 no difference in RR was seen (−0.73; 95% CI, −2.79 to 1.34; 
p=0.49; Table 2). Differences in PaO2, SaO2, PtcCO2, SpO2, overnight SpO 2, the amount 
of time SpO2 was below 90% during the night and all lung function parameters were 
not significant (Table 2).
Functional performance
No difference in distance walked in the 6MWT was observed between the treatment 
groups in the total study population (−5.07 m; 95% CI, −61.38 to 51.20 m; p=0.86) 
and in the subgroup with mMRC grades 3 to 4 (1.49 m; 95% CI, −87.47 to 90.46 m; 
p=0.97). The TUG time and CDS scores also did not differ significantly (Table 2).
Breathlessness
There was no significant or clinically relevant change in mean or worst 
breathlessness in the previous 24 hours between the treatment groups (Table 2). 
Within the morphine group, 21 of 44 participants (48%) responded to the treatment 
(improvement of 1.0 point on NRS mean breathlessness); within the placebo group, 
18 of 51 participants (36%) responded (p=0.25). In the subgroup with mMRC grades 
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3 to 4, the difference in mean breathlessness between the treatment groups was 
not significant (−1.31; 95% CI, −2.80 to 0.17; p=0.08; Table 2). Change in worst 
breathlessness in the previous 24 hours differed between the treatment groups 
(−1.33; 95% CI, −2.50 to −0.16; p=0.03; Table 2). Results of NRS scores for each 
assessment are shown in Supplemental Table S2.
Intervention and adverse effects
In 68 of 106 participants (64%) who were still in the study at time T2, treatment 
dose was increased to 3 times daily at T2 or T3; 27 of 51 (53%) in the morphine 
group and 41 of 55 (75%) in the placebo group (p=0.06). In 1 participant (2%) in the 
morphine group and 3 participants (5%) in the placebo group treatment dose was 
increased at T2 but decreased at T3 again because of adverse effects. The final 
mean (SD) number of capsules in the morphine group was 2.55 (0.50) capsules and 
in the placebo group 2.73 (0.45) capsules (P=0.07); 24 participants of 44 (55%) in 
the morphine group and 37 participants of 51 (73%) in the placebo group used 3 
capsules/day at T5 (p=0.07; Supplemental Table S3).
Self-reported compliance was 67%, with a median number of forgotten capsules 
of 2 (interquartile range, 1-5). Both the proportion of noncompliant participants 
and the number of forgotten capsules were equal between the treatment groups 
(p=0.51 and p=0.44, respectively). Reasons for not taking study medication included 
forgetting to take the medication (n=28; 25%), feeling the medication was not helping 
(n=1; 1%) and experiencing adverse effects (n=6; 5%).
A total of 53 of 111 (48%) participants guessed correctly whether they received 
morphine or placebo (20 [37%] in the morphine group and 33 [58%] in the placebo 
group). A total of 20 of 111 (18%) had no idea what intervention they received (12 
[22%] in the morphine group and 8 [14%] in the placebo group).
The number of participants experiencing 1 or more adverse effects of interest 
(nausea, vomiting and retching, drowsiness, constipation and sleeplessness) 
did not differ between the morphine group and placebo group (43 of 53 [81%] 
vs 40 of 57 [70%]; p=0.49). Change in constipation NRS scores between baseline 
and T5 between the treatment groups was significant (1.53 points; 95% CI, 0.44 
to 2.62 points; p=0.006; Supplemental Table S4). Detailed results of participants 
experiencing adverse effects and change in NRS scores are shown in Supplemental 
Tables S4 and S5. Other spontaneously reported adverse effects did not differ 
between the treatment groups.
Eighteen of 111 participants (16%) experienced a moderate-to-severe COPD 
exacerbation (a worsening of symptoms treated with antibiotics and/or 
corticosteroids6): 7 (13%) in the morphine group and 11 (19%) in the placebo group 
(p=0.41). Three hospital admissions (all for COPD exacerbation) occurred, 1 of 54 
(2%) in the morphine group and 2 of 57 (4%) in the placebo group (p=0.57). No 
morphine-related deaths occurred.
151445_Cindy_van_den_Berg_BNW-def.indd   150 13-9-2021   12:34:55
151
Effect of sustained-release morphine on patients with COPD and refractory breathlessness
5
Discussion
In patients with moderate to very severe chronic breathlessness due to COPD, 
disease-specific health status improved after administering regular, low-dose, oral 
sustained-release morphine. These effects were obtained without any change in 
respiratory outcomes or functional performance. Regular, low-dose, oral sustained-
release morphine for 4 weeks was well tolerated, with only mild opioid-related 
adverse effects.
To our knowledge, this is the first study powered to detect a change in respiratory 
outcomes of morphine treatment. Our study clearly illustrates that fear of 
respiratory depression or other respiratory adverse effects cannot be substantiated. 
Respiratory rate decreased without a change in PaCO 2 or PaO2, indicating no 
clinically relevant differences in alveolar ventilation. Low-dose morphine treatment, 
therefore, seems to be safe even in this group of patients with moderate to very 
severe COPD. These results suggest that fear of respiratory depression, mentioned 
by physicians,14,15 might be unfounded and are in accordance with our previous 
meta-analysis.16
Our results show a significant and clinically relevant improvement in CAT after 
morphine treatment. This improvement did not reach the predetermined MCID 
of the CAT as originally used for the sample size calculation.30 However, this MCID 
was reassessed by Smid et al in 201724 and is now defined as a change of 2.0 to 3.0 
points. Therefore, we conclude that the reported differences in CAT are on the lower 
bound of clinical relevance for this population.
Previous reviews on opioid treatment showed an effect on breathlessness, but not 
on health status.11,12 Otherwise, Currow et al.13 recently published a RCT in which 284 
patients with chronic breathlessness due to several conditions were treated with 
regular, low-dose, oral sustained-release morphine. No effect on mean or worst 
breathlessness in the previous 24 hours, current breathlessness, health status or 
functional capacity was shown after 1 week of treatment. Where our total study 
population also did not show an effect on breathlessness, our subgroup with mMRC 
grades 3 to 4 showed an improvement on worst breathlessness of 1.33 points at 4 
weeks. Moreover, the effect on mean breathlessness was 1.31 points at 4 weeks, 
which did not reach the level of significance, possibly due to a lack of power.
Interestingly, the morphine group reported CAT improvement on walking the stairs 
or hill compared with the placebo group. We cannot exclude that this improvement 
in daily life activities masks the expected effect on breathlessness. Indeed, palliative 
treatment may allow patients to be more active in daily living.34 Patients will be 
able to do more before reaching the same level of breathlessness. Previous studies 
exploring the effect of breathlessness treatment (morphine, supplemental oxygen) 
on exercise capacity in laboratory settings have shown similar results.35
However, this suggested improvement in daily functioning was not reflected in an 
objectifiable change of functional performance as assessed in this study.
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Morphine treatment was well tolerated by the participants of this study. The 
mean difference in NRS scores between the morphine and placebo group was 
only significant for constipation, which was consistent with other studies.11,13 The 
complaints resolved after symptom treatment or early study termination. In this 
group of patients with COPD, there were no hospital admissions for or deaths due 
to morphine-related adverse effects. A large observational study on patients with 
COPD who are oxygen dependent also showed no association between low-dose 
opioids and increased hospital admissions or deaths.36
Strengths and limitations
Our study has several strengths and limitations. First, to our knowledge, this 
study is the first double blind, placebo-controlled, parallel-arm RCT with a 4-week 
morphine treatment for chronic breathlessness in patients with COPD. Second, to 
our knowledge, this is the first RCT including CAT and PaCO2 as primary outcomes. 
Moreover, a thorough assessment of adverse respiratory effects by means of 
14 outcomes was performed. Third, all participants completed a comprehensive 
pulmonary rehabilitation program ensuring treatment was both pharmacologically 
and nonpharmacologically optimized.
Some limitations need to be recognized. The main limitation is the large number 
of patients who were unwilling to participate, contributing to insufficient inclusion 
of our original target population. Where we expected a response rate of 50%, only 
27% of eligible patients gave informed consent. As a result, we had to expand the 
inclusion criteria to participants with mMRC grade 2. Currow et al.13 experienced a 
delayed inclusion as well, also leading to the expansion of the inclusion criteria to 
mMRC grade 2. As concluded by Johnson et al.,19 patients with less severe chronic 
breathlessness are less likely to benefit from opioid treatment. In future studies, 
only patients with mMRC grades 3 to 4 should be included. Second, the predefined 
sample size was not reached for the CAT. The prior MCID of 3.8 was estimated by 
an anchor-based method and was the best estimate for our patient population at 
the time of study design.30 The MCID was re-estimated by Smid et al.24 by combining 
all known MCIDs from anchor-based and distribution-based estimations, making 
this MCID of 2.0 to 3.0 more accurate. Therefore, we are confident that our findings 
are clinically relevant. Third, functional performance was assessed by a standard 
battery of tests. At least, it can be questioned whether these forms of exercise 
testing are appropriate in this stage of the disease to assess daily functional 
performance. Direct assessment of low-grade daily life activities probably would be 
more appropriate.35 Physical activity is heterogeneous, and physical activity patterns 
fluctuate.37 Combining activity monitoring with, for example, Ecological Momentary 
Assessment can give more insight into the fluctuation of breathlessness and its 
effect on physical activity and quality of life over the day.38 Fourth, the occurrence 
of adverse effects and the fact that participants were not blinded to laxative use 
might have compromised blinding. The occurrence of adverse effects was equal 
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between treatment arms, but intensity of constipation was significantly different. 
However, because only 48% of participants guessed their treatment (morphine 
or placebo) correctly, we assume blinding was only minimally compromised. In 
addition, although this study was one of the first with a trial duration of more than 
1 week, the long-term effects of morphine and possible adverse effects remain 
unknown.
Conclusion
In conclusion, this study has shown that regular, low-dose, oral sustained-release 
morphine for 4 weeks may have a positive effect on disease-specific health status in 
patients with moderate to very severe breathlessness. Also, regular, low-dose, oral 
sustained-release morphine does not appear to lead to respiratory adverse effects. 
However, our results should be confirmed in a future RCT only including patients 
with severe to very severe chronic breathlessness and optimized pharmacological 
and nonpharmacological treatment of their COPD. Given the low response rate, 
a multicenter approach should be considered. Furthermore, to confirm and 
substantiate the results on CAT score, the study should include a measure of daily 
physical activity. Finally, to assess long-term effects and safety, more than 4 weeks 
of follow-up are needed.
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Supplementary Material
Supplemental Methods 1 – Participant eligibility criteria and re-
cruitment
Inclusion criteria
• Diagnosis of COPD according to the current Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease (GOLD);1
• Optimal pharmacological treatment, including treatment with a combination of 
a long-acting muscarinic antagonist (LAMA) and a long-acting β-agonist (LABA);1
• Grade 2, 3 or 4 dyspnea on the modified Medical Research Council (mMRC) 
Scale;2
o This criterion was expanded to moderate breathlessness (mMRC grade 2) to 
allow enrollment of predefined patient numbers.
• Optimal nonpharmacological treatment defined as completed a comprehensive 
pulmonary rehabilitation program.3,4
Exclusion criteria
• History of substance misuse;
• Exacerbation of COPD within two weeks of study enrolment;
• Waiting list for lung transplantation;
• Pregnant or childbearing potential not using contraception;
• Renal failure (creatinine clearance <15mL/min);
• Age under 18;
• Not being able to read or fill in the questionnaires or diary;
• Allergy for morphine or its excipients;
• Concomitant use of irreversible MAO blockers;
• Use of opioids;






Initially, participants were recruited in CIRO, Horn, The Netherlands, after 
completion of a PR program.4 Due to delayed participant enrollment, participants 
were also recruited in Zuyderland Hospital, Heerlen and VieCuri Hospital, Venlo, 
The Netherlands after completion of an outpatient PR program.
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Supplemental Methods 2 – Description of outcome measures
Health status
Health status was determined using the COPD Assessment Test (CAT). The CAT is a 
short and simple instrument that assesses the impact of COPD on health status.5,6 
The questionnaire consists of eight questions, assessing the symptoms on a scale 
from 0 to 5. The total score ranges from 0 to 40, with higher scores representing 
worse health status. The minimal clinical important difference (MCID) for the CAT 
is 2.0 to 3.0 points.7 The CAT was completed on paper by the participants at T0, T2, 
T3 and T5.
Respiratory adverse effects
The primary respiratory outcome was arterial partial pressure of carbon dioxide 
(PaCO2). PaCO2 was assessed by arterial blood gas drawn from the radial artery 
at T0 and T5. Also, arterial partial pressure of oxygen (PaO2) and arterial oxygen 
saturation (SaO2) were assessed in the arterial blood. A priori, the project group 
defined a change of 7.5 mm Hg in PaCO2 as clinically relevant.
8
Overnight pulse oxygen saturation (SpO2) and the time SpO2 was below 90% during 
the night was assessed at T0 and T5 using a WristOx2 3150 pulse oximeter (Nonin 
Medical, Plymouth, USA).
Transcutaneous partial pressure of carbon dioxide (PtcCO2) and transcutaneous 
SpO2 were assessed at T0, T2, T3, and T5 using a SenTec Digital Monitoring System 
(SenTec, Therwil, Switzerland) with an earlobe clip. Respiratory rate (RR) was 
assessed at T0, T2, T3, and T5. Finally, lung function consisted of a flow-volume 
measurement and a body box measurement at T0 and T5. During the flow-volume 
measurement, forced expiratory volume in the first second (FEV1) and forced vital 
capacity (FVC) were assessed, of which the Tiffenau index (FEV1/FVC) was calculated. 
During the body box measurement, inspiratory capacity (IC), total lung capacity 
(TLC) and intra thoracic gas volume (ITGV) were assessed and afterwards the IC/
TLC ratio was calculated.
Functional performance
Functional performance consisted of three tests. The 6-minute walk test (6MWT) is 
a valid and reliable measure to estimate functional exercise capacity in patients with 
chronic respiratory diseases.9 Participants cover as many distance as possible in 6 
minutes. The test was performed according to the ERS/ATS guidelines.9 The MCID 
for the 6MWT is 30 m.10 The 6MWT was performed at T0 and T5.
General mobility was examined using the Timed ‘Up & Go’ (TUG) test.11 This simple 
test requests patients to stand up from a chair, walk 3 meters in a comfortable 
pace, turn, walk back and sit down on the chair again. During the test, the time is 
recorded. Participants performed this test twice and the best time was used for 
analysis.12 The TUG test is valid and responsive in patients with COPD with a MCID 
of 0.9 to 1.4 sec.13 The TUG test was performed at T0, T2, T3 and T5.
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Care dependency was examined using the Care Dependency Scale (CDS).14,15 This 
instrument consists of 15 items regarding basic and instrumental activities of daily 
living, which are each scored on a 5-point Likert Scale. Higher scores indicate less 
care dependency. The CDS was completed on paper by the participants at T0 and T5.
Severity of breathlessness
Severity of breathlessness was assessed using a Numeric Rating Scale (NRS) ranging 
from 0 to 10, with 0 being not breathless at all and 10 being the worst imaginable 
breathlessness.16 The participants completed these items verbally. During all 
assessments, the mean and worst breathlessness in the last 24 hours was recorded. 
At baseline, the mean breathlessness in the last week was also determined to 
estimate if the day of the baseline assessment was an average day of that week. 
The MCID for the NRS for breathlessness is estimated at 1.0 points.17
Other outcomes
At baseline, the following other outcomes were recorded: demographic 
characteristics (age, gender, Body Mass Index and marital status), medical history 
(Charlson Comorbidity Index (CCI)18 and number of exacerbations and hospital 
admissions in the previous 12 months19,20), smoking history, current smoking 
behavior, use of medication, use of long-term oxygen therapy (LTOT) and use 
of noninvasive positive pressure ventilation (NIV). At T1, T2, T3, T4 and T5, data 
on change in medication use, LTOT and NIV, compliance to study intervention, 
exacerbations and adverse effects were collected.
The CCI was completed based on the patient file and further discussed with the 
participant for completeness. Compliance to study intervention was recorded 
by asking the participant during each assessment if they missed a capsule since 
the prior assessment. Furthermore, if study medication was handed in at T5, the 
remaining capsules were counted. The occurrence of exacerbations was assessed 
by asking the participant if they experienced a worsening of their COPD since 
the prior assessment.21 If so, the symptoms were recorded together with given 
medication and possible contact with a health care professional or admission to 
the hospital. Collection of adverse effects included nausea, vomiting and retching, 
drowsiness, constipation, sleeplessness, sleepiness and cognition. Nausea, vomiting 
and retching, drowsiness, constipation and sleeplessness were recorded during 
all assessments using a NRS (average burden in last 24 hours). The participants 
completed these items verbally.
At the end of the intervention study, the participants were asked which intervention 
they assumed to have received.




Table S1. Covariance structures
Random Intercept Random Intercept + Random 
Slope
Unstructured
CAT Chosen Considered Considered
Respiratory rate Chosen Not applicable Considered
PtcCO2 Considered Not applicable Chosen
SpO2 Considered Not applicable Chosen






Chosen for both groups Considered for total group
Not applicable for subgroup
Considered for both groups
Abbreviations: CAT, COPD Assessment Test; NRS, Numeric Rating Scale; PtcCO2, transcutaneous partial pressure 
of carbon dioxide; SpO2, pulse oxygen saturation; TUG, Timed Up & Go test.
Table S2. Mean difference in CAT score and breathlessness scores per assessment for total 




Subgroup with mMRC grades 3-4
(n=49)
Variables Mean difference (95% CI) p-value Mean difference (95% CI) p-value
CAT
T2 −1.45 (−3.33 to 0.44) 0.13 −0.34 (−3.16 to 2.48) 0.81
T3 −1.83 (−3.74 to 0.08) 0.06 −1.82 (−4.67 to 1.04) 0.21
T5 −2.18 (−4.14 to −0.22) 0.03 −1.17 (−4.17 to 1.84) 0.44
Mean breathlessness (NRS)
T2 −0.11 (−0.84 to 0.62) 0.76 −0.41 (−1.46 to 0.63) 0.43
T3 −0.55 (−1.35 to 0.26) 0.18 −0.90 (−2.10 to 0.29) 0.14
T5 −0.60 (−1.55 to 0.35) 0.21 −1.31 (−2.80 to 0.17) 0.08
Worst breathlessness (NRS)
T2 −0.02 (−0.83 to 0.80) 0.97 −0.63 (−1.73 to 0.46) 0.26
T3 −0.20 (−1.02 to 0.62) 0.63 −0.44 (−1.55 to 0.67) 0.43
T5 −0.56 (−1.41 to 0.28) 0.19 −1.33 (−2.50 to −0.16) 0.03
Abbreviations: CAT, COPD Assessment Test; NRS, Numeric Rating Scale
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Increase T2 13 (27) 30 (55) 0.001
Increase T3 14 (29) 11 (20) 0.28
Decrease T3 1 (2) 3 (5) 0.38
Number of capsules per day after T2, mean (SD) 2.26 (0.44) 2.55 (0.50) 0.002
Number of capsules per day after T3, mean (SD) 2.53 (0.50) 2.69 (0.47) 0.10
Final number of capsules per day at T5, mean (SD) 2.55 (0.50) 2.73 (0.45) 0.07
Participants using 3 capsules per day at T5 24 (55) 37 (73) 0.07
Note: a Values are written as No. (%) unless otherwise indicated.
Table S4. Numeric Rating Scores for adverse effects for total study population
Morphine vs placebo
Baseline to final assessment for 
total study population (n=111)
Maximal difference for total study 
population (n=111)
Variables Mean difference (95% CI) p-value Mean difference (95% CI) p-value
Nausea −0.61 (−1.57 to 0.35) 0.21 −0.61 (−1.57 to 0.35) 0.21
Vomiting and retching −0.27 (−0.69 to 0.14) 0.20 −0.43 (−1.01 to 0.14)a 0.14
Drowsiness −0.11 (−1.24 to 1.01) 0.84  1.23 (0.16 to 2.31)b 0.30
Constipation  1.53 (0.44 to 2.62) 0.006  1.53 (0.44 to 2.62) 0.006
Sleeplessness −0.44 (−1,67 to 0.80) 0.48 −0.49 (−1.52 to 0.55)b 0.36
Notes: a Reached at T1. b Reached at T2.








Nausea 16 (30) 13 (23) 0.48
Vomiting and retching 8 (15) 10 (18) 0.72
Drowsiness 27 (50) 21 (37) 0.29
Constipation 25 (46) 17 (30) 0.16
Sleeplessness 16 (30) 23 (40) 0.34
Note: A worsening was defined as ≥2 points on the NRS score.
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Background: Chronic breathlessness is a frequent symptom in advanced chronic 
obstructive pulmonary disease (COPD) and has major impact on quality of life, daily 
activities and healthcare utilization. Morphine is used as palliative treatment of 
chronic breathlessness. The aim is to analyze cost-effectiveness of regular, low-
dose morphine in patients with advanced COPD from a healthcare and societal 
perspective.
Methods: In a randomized controlled trial, participants with advanced COPD were 
assigned to 10 mg regular, oral sustained-release morphine or placebo twice daily 
for four weeks. Quality of life (COPD Assessment Test; CAT), quality-adjusted life 
years (QALY’s; EQ-5D-5L), healthcare costs, productivity and patient and family costs 
were collected. Incremental cost-effectivity ratios (ICERs) using healthcare costs 
and CAT scores and incremental cost-utility ratios (ICURs) using societal costs and 
QALY’s were calculated.
Results: Data of 106 of 124 participants were analyzed, of which 50 were in the 
morphine group (mean [SD] age 65.4 [8.0] years, 58 [55%] male). Both the ICER 
and ICUR indicated dominance for morphine treatment. Sensitivity analyses 
substantiated these results. From a healthcare perspective, the probability that 
morphine is cost-effective at a willingness to pay €8000 for a minimal clinically 
important difference of 2.0 points increase in CAT score is 63%. From a societal 
perspective, the probability that morphine is cost-effective at a willingness to pay 
€20,000 per QALY is 78%.
Conclusion: Morphine for four weeks is cost-effective regarding the healthcare and 
the societal perspective. To estimate the long-term costs and effects of morphine 
treatment, a study of longer follow-up should be performed.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by symptoms like 
breathlessness, fatigue and cough.1,2 COPD is often presented with comorbidities 
and has a major impact on morbidity and mortality.2 Worldwide, COPD was the 
ninth and sixth leading cause of loss of disability-adjusted life years in men and 
women, respectively, in 2017.3
Chronic breathlessness – breathlessness that persists despite optimal treatment 
of the underlying disease4 – is one of the most frequently reported symptoms in 
COPD. Chronic breathlessness has a major impact on quality of life and daily life 
activities like work or household activities.4-7 As chronic breathlessness worsens 
over time with progression of the COPD,1,4,8 patients need increasing help from 
healthcare professionals and informal caregivers. Several longitudinal and 
cross-sectional studies in patients with COPD have shown that with increasing 
breathlessness disability or disease severity, both healthcare and societal costs 
increase.9-13 These increased costs were mainly driven by exacerbations, hospital 
admissions, comorbidities and loss of productivity.9-11,13,14 Therefore, treatment of 
chronic breathlessness is important in the management of COPD.2
Opioids have proven to be an effective palliative treatment of chronic breathlessness 
in patients with COPD.15-17 However, the effect of opioids on health-related quality 
of life is conflicting. Two reviews reported an unclear effect of opioids on quality 
of life,16,17 with three included studies reporting no effect on quality of life,18-20 one 
study reporting a beneficial effect21 and one study reporting a negative effect.22
Meta-analyses could not be performed due to study heterogeneity and insufficient 
data. Subsequently, a large randomized controlled trial on the effect of morphine 
for breathlessness showed no effect.23 Study populations were mixed, with the 
majority of patients being patients with COPD. Three studies had a duration of four 
to five days,18-21 one study had a duration of one week,23 one study a duration of two 
weeks19 and one study a duration of six weeks.22
Although the effectiveness of morphine is known and treatment is included 
in national and international guidelines,24-26 information on cost-effectiveness 
of morphine treatment for breathlessness is absent. Therefore, the aim of this 
study was to analyze the cost-effectiveness of regular, low-dose oral sustained-
release morphine in patients with advanced COPD from a healthcare and societal 
perspective.





The current analysis is part of the Morphine for Treatment of Dyspnea in patients 
with COPD (MORDYC) study. The MORDYC study is a randomized, double blind, 
placebo-controlled, parallel-arm intervention study.27,28 For this analysis, only 
relevant aspects will be described briefly. The study was approved by the Medical 
Ethics Committee Maastricht UMC+ (METC152002) and registered on ClinicalTrials.
gov (NCT02429050). All subjects gave their written informed consent before study 
start.
Participants
The study population consisted of adults with a confirmed diagnosis of COPD 
based on the Global initiative for Obstructive Lung Disease (GOLD).2 Participants 
were eligible when experiencing moderate to very severe impairment due to 
breathlessness (modified Medical Research Council (mMRC) breathlessness grade 
2, 3 or 429) despite optimal pharmacological and non-pharmacological treatment 
of their COPD, including completion of a comprehensive pulmonary rehabilitation 
program. In addition to the exclusion criteria of the MORDYC study, which are 
described in detail elsewhere,27 patients that did not complete the cost diary were 
excluded from this analysis.
Intervention
Participants in the intervention group received 10 mg regular, oral sustained-
release morphine capsules twice daily for four weeks (20 mg/24 h), while the control 
group received placebo capsules with identical look and taste twice daily for four 
weeks. The dose was increased to three times daily (30 mg/24 h) after one or two 
weeks in non-responders (defined as <1 point improvement in severity of mean 
breathlessness on a 0 to 10 numeric rating scale [NRS] compared to baseline30,31). 
To minimize adverse effects of morphine, all participants received a prescription 
for laxatives and anti-emetics with the instruction to use it as needed.
Study procedures
Patients were informed about the study by the physician after completion of a 
pulmonary rehabilitation program. Between oral informed consent and baseline, 
participants were randomized to either the intervention or the control group using 
a web-based random number generator. Randomization was stratified for age (<55 
years, 55–65 years, 65–75 years or >75 years) and impairment due to breathlessness 
(mMRC grade 2, 3 or 429).
After baseline, the participants were visited twice in their home. Furthermore, the 
participants were asked to complete a weekly prospective cost diary (Figure 1).
151445_Cindy_van_den_Berg_BNW-def.indd   184 13-9-2021   12:35:06
185
Cost-effectiveness of sustained-release morphine for breathlessness
7
Figure 1. Study design of the MORDYC study
Measures
At baseline, information on demographics and clinical characteristics was collected 
from the patient file or based on self-report. This included: age, gender, body mass 
index (BMI), marital status, smoking behavior, comorbidities using the Charlson 
Comorbidity Index (CCI),32 exacerbations and hospital admissions in the previous 
12 months, lung function and functional exercise performance using the 6 minute 
walk distance (6MWD).33
Disease-specific health-related quality of life was assessed using the COPD 
Assessment Test (CAT).34,35 The CAT is an eight-question instrument that assesses 
the impact of COPD on health-related quality of life. The impact is scored on a 0 to 
5 differential scale, with higher scores indicating worse health-related quality of life. 
The CAT was completed at T0, T2, T3 and T5.
Generic health-related quality of life was assessed using the EuroQoL-5 Dimensions-5 
Levels (EQ-5D-5L).36,37 The EQ-5D-5L is a preference-based measure, including five 
domains of health: mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. Each domain is scored on five levels. Using a crosswalk set, a utility score 
was generated applying to the Dutch population.38,39 The EQ-5D-5L also contains a 
visual analog scale (VAS) scoring the current health from 0 (worst imaginable health) 
to 100 (best imaginable health). The EQ-5D-5L was completed at T0 and T5.
During the four weeks of study, participants completed a comprehensive prospective 
cost diary at home covering employment status at baseline, healthcare utilization, 
medication use, household aid, absenteeism and inability to perform daily activities. 
All questions applied to resource use due to the COPD.
Resource use and costing
This economic evaluation was performed according to the cost manual of the 
Dutch National Healthcare Institute.40 A cost-effectiveness analysis from the 
healthcare perspective and a cost-utility analysis from the societal perspective were 
performed. The following costs related to COPD and morphine treatment were 
included: intervention costs, other healthcare costs, costs for patient and family 
and productivity costs.
The resource use as registered by the participants was valued using reference prices 
obtained from the Dutch cost manual.40 For resource use not covered by the Dutch 
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cost manual, the rate list first-line diagnostics41 and the rate list general practitioner 
and multidisciplinary care42 of the Dutch Healthcare Authority were used. Costs of 
medication were determined using the medication database by the Dutch National 
Healthcare Institute.43 Delivery costs by the pharmacist were accounted for for 
medication within the drug reimbursement system. For the base case analysis, the 
lowest medication price was used.40 A sensitivity analysis was performed using the 
highest medication prices. Costs for long-term oxygen therapy (LTOT) and non-
invasive ventilation (NIV) were derived from the medication and medical device 
database of the Dutch National Healthcare Institute44 and from Westfalen Medical 
(Deventer, the Netherlands).
Costs were calculated by multiplying the volume of resource use by the related 
cost price. Relevant costs prices are shown in Supplemental Table S1. All costs 
were indexed to 2019. Since the study duration was four weeks, no discounting 
was performed.
Healthcare costs
Healthcare utilization included intervention costs, contact with a general practitioner, 
medical specialist, nurse specialists or other healthcare professionals, use of 
prescribed medication, use of LTOT or NIV, hospitalization and use of professional 
home care.
Intervention costs included the use of morphine in the intervention group and the 
use of laxatives and anti-emetics in both groups. For this purpose, the number 
of study medication capsules, laxatives and anti-emetics used was gathered 
throughout the study. Since normally morphine is prescribed and followed-up by 
the general practitioner, a sensitivity analysis was performed including two extra 
consults by the general practitioner for the intervention group (one visit to the 
general practitioner for prescription and one telephone consult for follow-up).
Data on contact with healthcare professionals and use of professional home 
care were collected in the cost diary. Use of LTOT and NIV were discussed at T0 
and T5. Medication use was discussed during each assessment. Information on a 
hospitalization was collected when applicable. When a participant was admitted to 
the hospital, participation in the study was terminated. However, the participant 
was followed-up until the event had resolved using telephone calls. For hospital 
admissions, only the costs for the days that would have been within the four weeks 
of study were included in the base case analysis. A sensitivity analysis including the 
costs for the complete event was performed.
Patient/family costs
Patient and family costs included medication costs not covered by the health 
insurance, over the counter medication, informal care, paid household aid and 
transportation. Costs for over the counter medication and paid household aid was 
registered directly in the cost diary. Transportation was calculated by using a mean 
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distance to the healthcare professional or hospital from the Dutch cost manual,40
multiplied by costs for transportation based on the mode of transportation 
registered by the participant.
Productivity costs
Costs for productivity losses included absenteeism from paid work and absenteeism 
from voluntary work. Absenteeism from paid work was valued using the friction 
cost method, as recommended in the Dutch cost manual.40 The friction cost method 
assumes that all absent or long-term sick employees are replaced after a certain 
friction period. This period is based on the mean time an employer needs to replace 
a sick or absent employee. In 2019 in the Netherlands, a period of 85 days was 
recommended. After this period, no costs for absenteeism are generated anymore. 
Absence of voluntary work (i.e. volunteering in a care home, a school or a community 
club) was valued according to the costs for informal care.
Analysis
Continuous data were presented as mean (SD) or median (interquartile range). 
Categorical data were presented as number (percentage). Cost data were presented 
as mean (bootstrapped BCa 95% confidence interval). Missing data on effects and 
resource use were imputed using single imputation, as only 4.5% of data was 
missing. Imputation of diary data was based on baseline clinical characteristics and 
the first week of diary data. Medication data in patients that dropped out during 
the four weeks of intervention were imputed by continuing counting until 28 days.
CAT scores were analyzed using a linear mixed effects model, including time by 
group interaction and considering a random intercept. EQ-5D-5L utility scores and 
VAS scores were analyzed using a linear regression model, including time by group 
interaction. Quality-adjusted life years (QALYs) were assessed based on EQ-5D-5L 
utility scores by calculating the area under the curve.45
Incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios 
(ICURs) were calculated using the formula (Cm – Cp) / (Em – Ep). C represents the 
average costs per participant for the four-week period and E represents the effect 
on health-related quality of life in these four weeks for the morphine group (Cm and 
Em ) and the placebo group (Cp and Ep). For the ICER, healthcare costs (healthcare 
perspective) and results of the CAT were included. In the base case analysis of 
the ICER, the T5 scores of the CAT were included. A sensitivity analysis using the 
difference between T0 and T5 for the CAT scores was conducted. For the ICUR, all 
costs (societal perspective) and QALYs were included.
To quantify the uncertainty around the ICER and ICUR, nonparametric bootstrapping 
was performed calculating 1000 simulated ICERs and ICURs. Results were plotted 
in cost-effectiveness planes. These planes give a visual representation of the 
probability that morphine is cost-effective compared to placebo by showing the 
distribution of simulated ICERs and ICURs in four quadrants: 1) more costly and less 
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effective (northwest [NW] quadrant); 2) more costly and more effective (northeast 
[NE] quadrant); 3) less costly and less effective (southwest [SW] quadrant); and 4) 
less costly and more effective (southeast [SE] quadrant).45 An ICER or ICUR in the 
SE or NW quadrant shows respectively a dominant or a dominated (i.e. inferior) 
intervention. An ICER or ICUR in the SW or NE quadrant shows an intervention that 
is only favorable when the ICER or ICUR is respectively below a maximum willingness 
to pay (WTP) for gain in effect or beyond a minimum willingness to accept (WTA) for 
a loss in effect. Cost-effectiveness acceptability curves (CEAC) were created for both 
a minimal clinically important difference of 2.0 points improvement in CAT and for 
a QALY gain. These curves show the probability that the intervention is favorable 
for different hypothetical WTPs. In the Netherlands, the Council for Public Health 
and Health Care has proposed a WTP €20,000 to €80,000 per QALY, depending on 
the burden of disease.46 No maximum WTP for an improvement in CAT is available.
Analyses were performed according to intention-to-treat, but excluding participants 
that withdrew between randomization and exposure to the intervention47 and 
excluding participants that generated no cost data. For the analyses, SPSS version 
25.0 (IBM Corp, Armonk, NY) and Excel 2016 (Microsoft, Redmond, WA) were used.
Results
Participants
Between November 1st 2016 and January 24th 2019, 1380 patients with COPD 
were assessed for eligibility, 464 patients were eligible and 124 patients were 
randomized (Figure 2). Between randomization and baseline assessment, 13 
patients withdrew participation, eight in the morphine group and five in the placebo 
group. Furthermore, no cost data were available for five participants, four in the 
morphine group and one in the placebo group. Therefore, data of 106 participants 
were included in the current analysis, 50 in the morphine group and 56 in the 
placebo group (Figure 2).
Baseline characteristics are shown in Table 1. No baseline differences were observed 
in the demographic or clinical characteristics. Employment status was different 
at baseline. In the morphine group, seven participants were employed, of whom 
three were on long-term sick leave. In the placebo group, three participants were 
employed, who were all on long-term sick leave. All participants that were on long-
term sick leave were sick longer than the friction periods of 85 days and therefore 
generated no costs for absenteeism.
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Figure 2. Flow chart
Clinical effectiveness
Table 2 shows the results of the CAT and the EQ-5D-5L. On the CAT, the morphine 
group scored 22.92 (7.02) points at T0 and 19.71 (7.21) points at T5. The placebo 
group scored 21.50 (7.02) points at T0 and 20.47 (7.13) points at T5. The total QALYs 
over the time horizon of four weeks were 0.050 (0.012) for the morphine group and 
0.047 (0.015) for the placebo group.
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Age, mean (SD), y 65.4 ± 8.0 65.1 ± 8.0 65.6 ± 8.0
Male, No (%) 58 (55) 27 (54) 31 (55)
BMI, mean (SD) 27.6 ± 5.9 28.2 ± 6.6 27.1 ± 5.3
Marital status, No (%)
   Single 22 (21) 9 (18) 13 (23)
   Married/cohabitation 82 (77) 39 (78) 43 (77)
   In relation, but living apart 2 (2) 2 (4) 0 (0)
Medical characteristics
Current smoking, No (%) 14 (13) 7 (14) 7 (13)
Pack years, median (IQR) 40.0 (30.0-50.0) 40.0 (30.0-56.3) 40.0 (30.0-50.0)
CCI, median (IQR), pointsa 1.5 (1.0-2.0) 1.5 (1.0-2.0) 1.5 (1.0-3.0)
Exacerbations <12 months, median (IQR) 2.0 (1.0-4.0) 3.0 (1.0-4.0) 2.0 (0.0-3.8)
Hospital admissions <12 months, median (IQR) 0.0 (0.0-1.0) 0.0 (0.0-1.0) 0.0 (0.0-1.0)
Participants using LTOT, No (%) 44 (42) 20 (40) 24 (43)
Participants using NIV, No (%) 24 (23) 12 (24) 12 (21)
Pulmonary function
FEV1, median (IQR), l 0.96 (0.70-1.27) 1.00 (0.72-1.31) 0.93 (0.61-1.26)
FEV1, median (IQR), %pred 35.5 (26.8-50.8) 37.5 (28.5-53.4) 34.5 (25.0-49.5)
FEV1/FVC, median (IQR) 0.31 (0.26-0.41) 0.32 (0.27-0.41) 0.31 (0.24-0.42)
Clinical characteristics
mMRC grade at T0, No (%)
   2 59 (58) 29 (58) 30 (54)
   3 37 (35) 18 (36) 19 (34)
   4 10 (9) 3 (6) 7 (12)
6MWD, mean (SD), m 347 ± 101a 354 ± 85 342 ± 114a
Employment
Paid work, No (%) 10 (9) 7 (14) 3 (5)
Hours employment/week, median (IQR) 34.0 (23.0-48.8) 32.0 (20.0-60.0) 36.0 (32.0-40.0)
Days/week, median (IQR) 5.0 (4.0-5.0) 5.0 (4.0-5.0) 5.0 (4.0-5.0)
Sick leave, No (%)b 6 (60) 3 (43) 3 (100)
Notes: p>0.05 for all comparisons between morphine and placebo group. a Test not performed in 1 participant. b % 
of participants with paid work. Abbreviations: 6MWD, 6 minute walk distance; BMI, body mass index (calculated as 
weight in kilograms divided by height in meters squared); CCI, Charlson Comorbidity Index; FEV1, forced expiratory 
volume in 1 second; LTOT, long-term oxygen therapy; NIV, non-invasive positive pressure ventilation.
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Cost-effectiveness
Table 3 shows the costs for both treatment groups. Total healthcare costs for four 
weeks were €610.82 for the morphine group and €721.27 for the placebo group. 
Besides the intervention costs, this difference is largely explained by the difference in 
hospital admission costs. Costs for patient and family were higher for the morphine 
group (€173.46) than for the placebo group (€147.88), which was mainly due to the 
difference in informal care and paid household aid. Costs for productivity losses 
were completely generated by absenteeism from voluntary work, as all patients with 
a paid job were either on long-term sick leave or were not absent from their job.
For both the healthcare perspective and the societal perspective, costs in the 
morphine group were lower than costs in the placebo group. Combining these costs 
with the effects of the CAT or the QALYs resulted in both the ICER and ICUR pointing 
towards dominance for treatment with morphine (Table 4).
Table 2. Results of clinical outcomes (mean [SD])
Morphine Placebo
T0 T5 T0 T5
CAT 22.92 (7.02) 19.71 (7.21)a 21.50 (7.02) 20.47 (7.13)a
EQ-5D-5L utility 0.60 (0.19) 0.68 (0.17) 0.58 (0.22) 0.61 (0.21)
Total QALY’s 0.050 (0.012) 0.047 (0.015)
EQ-5D-5L VAS 61.44 (16.76) 64.07 (17.74) 59.55 (18.50) 56.06 (19.25)
Notes: a significant difference between the groups at 5% level. Abbreviations: CAT, COPD Assessment Test; EQ-
5D-5L, EuroQoL-5 Dimensions-5 Levels; QALY, quality-adjusted life year; VAS, visual analog scale.
The distribution of bootstrapped costs and effects for both perspectives over the 
four quadrants are shown in Table 4 and the cost-effectiveness planes in Figure 
3a and 3c. For both perspectives, the majority of ICERs and ICURs is located in the 
SE quadrant indicating dominance for morphine treatment. For the bootstrapped 
ICERs, this was 51% and for the ICURs this was 64%.
The probability that the intervention is cost-effective given certain WTPs is shown 
in the CEACs in Figure 3b and 3d. At a WTP €0 for a minimal clinically important 
difference of 2.0 points increase in CAT score, the probability that morphine is cost-
effective is 79%. This probability decreases to 68% with a WTP €1000 and eventually 
to 63% with a WTP €8000 or higher (Figure 3b). At a WTP €0 for one QALY gained, the 
probability that morphine is cost-effective is 69%. At a WTP €20,000, the probability 
rose to 78% and at a WTP €80,000 to 87% (Figure 3d).
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Intervention costs €10.86 €0.00
Laxatives/anti-emetics €2.78 €2.29
General practitioner €18.46 €27.65
Medical specialist €37.10 €59.36
Nurse specialist €32.96 €24.90
Other healthcare professionals €121.76 €143.32
Hospitalization €19.89 €115.45




Professional home care €109.89 €101.92
Other healthcare costs €9.43 €11.07
Total healthcare costs €610.82 (€489.66 - €764.11) €721.27 (€549.60 - €936.05)
Patient and family costs
Prescribed medication, not covered by 
insurance
€7.22 €9.17
Over the counter medication €1.07 €1.25
Informal care €95.99 €58.08
Paid household aid €14.04 €5.89
Transportation €9.09 €11.03
Absenteeism household work €44.82 €52.82
Other patient and family costs €1.21 €9.65
Total patient and family costs €173.46 (€113.71-€235.39) €147.88 (€89.64-€218.79)
Productivity costs
Absenteeism paid work €0.00 €0.00
Absenteeism voluntary work €16.41 €2.12
Total productivity costs 16.41 (€1.34-€44.32) €2.12 (€0.32-€4.58)
Total costs €800.69 (€646.68-€972.12) €871.27 (€679.23-€1121.86)
Sensitivity analyses
Table 4 shows the cost-effectiveness for the different sensitivity analyses. All of the 
sensitivity analyses resulted in ICERs and ICURs indicating dominance for morphine 
treatment.
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Discussion
To our knowledge, this is the first cost-effectiveness analysis of regular, low-dose, 
oral sustained-release morphine treatment for chronic breathlessness in patients 
with COPD. Our study showed that the intervention reduced healthcare and societal 
costs. Both from a healthcare as from a societal perspective, regular, low-dose, 
oral sustained-release morphine treatment was cost-effective. Sensitivity analyses 
showed that these results were robust.
CAT scores improved in both groups with the effect in the morphine group being 
larger, as was reported before by the authors.28 This improvement was both 
significant and clinically relevant48 and reported after four weeks. Previous studies 
that showed no effect of oral opioids on quality of life all had a duration of four days 
to two weeks.18-20,23 One study showed a negative effect of oral morphine on mastery 
after six weeks.22 This study included a similar patient population as the MORDYC 
study and disease-specific quality of life was the primary outcome. However, the 
number of included patients was much smaller, which could have explained the 
negative effect. Also, the baseline level of quality of life was unknown.
EQ-5D-5L scores showed results in the same direction as CAT scores, indicating that 
morphine has a positive effect on generic health-related quality of life as well after 
four weeks of treatment. However, this effect was rather small. It is not known if this 
positive effect on generic and disease-specific health-related quality of life persists 
for the longer term. So a study of longer duration is needed.
Both healthcare costs and societal costs were lower in the morphine group 
compared to the placebo group, although these differences were not significant. The 
largest difference in healthcare costs was shown for hospital admissions. Previous 
studies have shown that hospital admissions are main cost drivers for patient with 
COPD and high breathlessness burden.9-13 Hospital admissions are events that 
generate large costs in a short period. The current study was of short duration, in 
which it can be expected that little hospital admissions take place. The sensitivity 
analysis showed that inclusion of costs for the complete hospitalization, instead of 
only the days that were within the study duration, had no major influence on the 
probability that morphine is cost-effective.
Main cost drivers in the current study were medication use and contact with 
healthcare professionals. Since maintenance medication generates constant costs, 
medication use is a known cost driver.10-12 For a population of post-rehabilitation 
patients, who are advised to continue exercising under supervision of a 
physiotherapist, it has been shown that contact with other healthcare professionals 
is a cost driver.13
Morphine is often prescribed by the general practitioner in the Netherlands, while 
general practitioners have a paramount role in palliative care provision.49 Close 
follow-up of morphine treatment is necessary to observe possible adverse effects 
in the first period of treatment and to prevent possible dependence. We considered 
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this follow-up was mainly performed by telephone consult. A sensitivity analysis 
was performed including costs for one practice visit and telephone consult, which 
showed this did not affect the dominance of the ICER and ICUR.
Productivity costs were singly determined by absenteeism from voluntary work. 
Only 9% of our population was still employed, which is common in this disabled 
population.10,12,13 Those patients that were employed were either on long-term sick 
leave or were not absent from work. Since we used the friction cost method, no 
costs were calculated for patients on long-term sick leave. In many countries, the 
human capital method is more widely applied.50 This method includes all costs for 
loss of work due to illness and related treatments. In the case of a follow-up longer 
than the friction period, this would lead to considerable different results.51 However, 
since the MORDYC study had a follow-up period of four weeks, patients with a paid 
job were already absent at study inclusion and employment status did not change 
during the follow-up, applying the human capital method would only reflect the 
costs of COPD and would not be related to treatment effects.
In the Netherlands, the WTP threshold for a gain in one QALY is €20,000 to €80,000. 
At a WTP threshold of €20,000, the probability that morphine is cost-effective is 
78%. Concerning the CAT, at a WTP €0 for a gain of the minimal clinically important 
difference of 2.0 points the probability that morphine is cost-effective is 79%, since 
this is the amount of ICERs that falls in the SE and SW quadrants (all cost saving 
or dominant). With increasing WTP thresholds, the probability that morphine is 
cost-effective gradually decreases down to 63% at a WTP threshold of €8000. This 
indicates that even with a low, conservative WTP morphine is cost-effective, although 
there is no accepted WTP threshold for a minimal clinically important difference of 
2.0 points improvement in CAT score. This WTP threshold is expected to be much 
lower than that of the QALY, suggesting that morphine has a high probability of 
being cost-effective.
Strengths and limitations
This study has several strengths and limitation. First, to our knowledge this was 
the first cost-effectiveness and cost-utility analysis of oral morphine treatment for 
chronic breathlessness in patients with COPD. Since these analyses were part of a 
randomized controlled trial, participants were blinded to treatment allocation. Also, 
participants were optimally treated for their COPD, including having completed a 
comprehensive pulmonary rehabilitation program. Second, both the societal and the 
healthcare perspective are covered. Morphine is a treatment for breathlessness and 
therefore assumed to decrease healthcare utilization. However, due to the major 
impact of breathlessness on daily life activities,4-7 covering the complete spectrum 
of societal costs gives a better picture of the effects of morphine treatment. 
Furthermore, the implementation of the societal perspective in the design of the 
study may be considered a strength. Since a big part of the patients with COPD are 
retired or unable to perform a paid job, only including work-related productivity 
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costs would lead to an underestimation of societal costs. Therefore, costs for 
inability to perform voluntary work or daily life activities were included as well. 
Finally, several sensitivity analyses were performed in order to ground the base case 
analysis. This included a sensitivity analysis that mimics usual care by considering 
costs for consults by the general practitioner for prescription and follow-up of 
morphine treatment.
Several limitations have to be considered. First, the data collection was only for four 
weeks. Although this is one of the first and longest randomized controlled trials of 
opioid treatment for chronic breathlessness in COPD, the long-term effects and costs 
of morphine treatment remain unknown. It has been shown that hospitalizations 
are one of the main cost drivers in patients with COPD and severe breathlessness.9-13
In this short follow-up, three patients were admitted to the hospital. A recent 
observational study in the Netherlands showed 0.73 hospital admissions per patient 
per year for breathing problems in patients with COPD and high breathlessness 
burden (mMRC 2 to 4). Converting this to our study would have meant six hospital 
admissions. Therefore, healthcare costs might be underestimated. Furthermore, it 
is not known if the effect of morphine on health-related quality of life persists after 
four weeks. A study with longer follow-up should be considered to estimate the long-
term costs and effects of morphine treatment in these patients. Second, no baseline 
data on healthcare utilization and activities of daily life were collected. Therefore, 
we cannot be certain that the difference in cost data between the morphine and 
placebo group was created by the morphine treatment. Especially in the case of 
informal care and voluntary work, which were the main differences in costs for 
patient and family and productivity costs. However, due to the randomization of 
treatment allocation, we may assume groups are equal at baseline. Third, results 
of this analysis are only applicable for patients who completed a comprehensive 
pulmonary rehabilitation program. However, since low-dose, oral, sustained-release 
morphine is indicated in chronic breathlessness despite optimal treatment of the 
underlying disease and pulmonary rehabilitation is indicated to optimize symptoms 
of COPD, results are generalizable to the patients in which low-dose morphine is 
indicated for chronic breathlessness. Finally, clinical effectiveness differed between 
the longitudinal regression model and the cost-effectiveness analysis. In the cost-
analysis data were imputed and afterwards the mean of T5 scores was calculated, 
while in the regression model the data of all four assessments were taken into 
account. Longitudinal regression modelling showed that morphine treatment for 
four weeks improves health-related quality of life significant and clinically relevant.28
Conclusion
In conclusion, this study has shown that regular, low-dose, oral sustained-release 
morphine treatment for four weeks has a positive effect on disease-specific 
and generic health-related quality of life and healthcare and societal costs and 
therefore can be considered cost-effective in patients with advanced COPD and 
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chronic breathlessness. Given the prevalence and burden of chronic breathlessness 
in patients with advanced COPD, morphine treatment should be considered in 
this patient population when optimal pharmacological and non-pharmacological 
treatment does not provide adequate relief. To estimate the long-term cost-
effectiveness of morphine treatment, a model-based analysis should be considered.
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Supplementary Material
Table S1. Overview of most important cost categories with unit prices.













Visit GP practice €34 Dutch cost manual2
Home visit €52 Dutch cost manual2
Consult by phone €18 Dutch cost manual2
Repeated prescription €0 Dutch cost manual2
Visit GP center €173 Rate list general practitioner and 
multidisciplinary care of the Dutch Healthcare 
Authority (Nederlandse Zorgautoriteit)3
Medical specialist
Visit €95 Dutch cost manual2
Consult by phone €49 (calculated from) Dutch cost manual2
Nurse specialist
Visit €95 (calculated from) Dutch cost manual2
Consult by phone €49 (calculated from) Dutch cost manual2
Other healthcare professionals
Visit physiotherapist €34 Dutch cost manual2
Home visit physiotherapist €52 (calculated from) Dutch cost manual2
Visit dietician €34 (calculated from) Dutch cost manual2
Home visit dietician €52 (calculated from) Dutch cost manual2
Visit psychologist €67 Dutch cost manual2
Visit speech therapist €31 Dutch cost manual2
Visit nurse practitioner €34 (calculated from) Dutch cost manual2
Hospitalization (day) €497 Dutch cost manual2
Prescribed medication, covered by 
insurance
Variable Medicijnkosten.nl1
LTOT (day) €2,96 Westfalen Medical (Deventer, the Netherlands)
NIV (day) €0.97 Medication and medical device database 
of the Dutch National Healthcare Institute 
(Zorginstituut Nederland)4








Nursing and caring (hour) €21 Dutch cost manual2
Household activities (hour) €52 Dutch cost manual2
Other healthcare costs Variable Reported by participants in cost diary
Patient and family costs
Prescribed medication, not covered by 
insurance
Variable Medicijnkosten.nl1
Over the counter medication Variable Reported by participants in cost diary
Informal care (hour) €14.63 Dutch cost manual2
Paid household aid Variable Reported by participants in cost diary
Transportation
By car or public transportation €0.20 Dutch cost manual2
Parking costs hospital €3.13 Dutch cost manual2
By taxi, base rate €3.08 Dutch cost manual2
By taxi, rate per km €2.78 Dutch cost manual2
Absenteeism household work (hour) €14.63 Dutch cost manual2
Other patient and family costs Variable Reported by participants in cost diary
Productivity costs
Absenteeism paid work (hour) €36.31 Dutch cost manual2
Absenteeism voluntary work (hour) €14.63 Dutch cost manual2
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Breathlessness is the most common symptom in advanced chronic lung 
disease or chronic heart failure (CHF).1 Opioids are recommended for palliative 
treatment of breathlessness persisting despite optimal pharmacological and non-
pharmacological treatment.2,3 However, physicians don’t always consider opioids for 
chronic breathlessness4,5 and experience barriers when considering opioids, such 
as resistance of patients.6 This can limit effective palliative treatment. Qualitative 
studies in patients with COPD and CHF revealed fear of dependence and fear of 
imminent death as the most important barriers to opioid use. The reason to start 
treatment was to do as much as possible.7-9 These qualitative studies were only 
conducted in small patient populations. Therefore, our aims were 1) to assess 
the willingness of patients with chronic lung disease or CHF to use opioids for 
breathlessness, irrespective of a current indication for opioid treatment and 2) to 
assess their barriers towards opioid use and reasons to use opioids. Finally, we 
aimed to compare willingness differences according to sex, age, educational level, 
diagnosis and breathlessness severity.
An exploratory convenience sample of 175 patients referred for a baseline 
assessment prior to pulmonary or heart failure rehabilitation was recruited, 
independent of their level of breathlessness. Patients were excluded when they 
could not read or write, had not mastered Dutch, aged <18 years or were unable to 
give informed consent. The Maastricht University Medical Centre (MUMC+) medical 
ethical committee (Maastricht, the Netherlands), reviewed the study protocol and 
concluded that the study didn’t fall under the Medical Research Involving Human 
Subjects Act (METC 2018-0790). Patients completed a survey including: demographic 
characteristics, educational level, previous and current opioid use (opioid, dosage 
and reason for prescription) and willingness to use opioids for breathlessness. 
Patients willing to use opioids and patients who had experience with opioids were 
asked to indicate their reasons to use opioids; patients unwilling to use opioids 
were asked to indicate their barriers. Patients who were indecisive were asked to 
indicate their barriers against and the reasons to use opioids. In addition, patients 
were invited to report reasons other than those predefined using a free-text 
field. The predefined reasons were selected based on previous research,7-9 expert 
opinion of the project group and experience from patient inclusion for an opioid trial 
(MORDYC).10 Disease characteristics (diagnosis, disease history, lung function, 6-min 
walk distance [6MWD]11) and breathlessness severity (modified Medical Research 
Council [mMRC] scale)12 were recorded using chart review.
151445_Cindy_van_den_Berg_BNW-def.indd   208 13-9-2021   12:35:20
209

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































151445_Cindy_van_den_Berg_BNW-def.indd   209 13-9-2021   12:35:20
210
Chapter 8
Data were described using mean±SD or median (interquartile range [IQR]) 
for continuous variables and n (%) for categorical variables. We compared the 
willingness to use opioids between sexes, age (<65 years or ≥65 years), educational 
level (lower education, defined as having finished secondary vocational education 
versus higer education, defined as having finished at least Higher General Secondary 
Education),13 diagnosis and mMRC score (<2 or ≥2 points) using Chi-squared test or 
Fisher-Freeman-Halton test, as appropriate.
Between November 2018 and May 2019, 237 patients were eligible and 175 patients 
(50% male), median age 65 years (IQR 57 to 70 years), completed the survey 
(response rate 74%). Patients were diagnosed with COPD (n=124, 71%), CHF (n=18, 
10%), asthma (n=17, 10%), interstitial lung disease (n=8, 5%), COPD-asthma overlap 
syndrome (n=3, 2%), pulmonary hypertension (n=3, 2%) and other (n=2, 1%). Median 
mMRC score was 2.5 points (IQR 2 to 3 points), 6MWD was 393±107 m and 141 (81%) 
patients completed lower education only. Nonresponders were 45% male and aged 
median 66 years (IQR 59 to 71 years; both p>0.05 compared to responders).
72 (41%) out of 175 patients previously used one or more different opioids (49 [68%] 
for pain, 10 [14%] for breathlessness, eight [11%] for both pain and breathlessness, 
five [7%] for drug dependence and six [8%] for unknown reasons). Opioids used 
were morphine (n=45, 63%), oxycodone (n=30, 42%), fentanyl (n=7, 10%), methadone 
(n=6, 8%) and buprenorphine (n=3, 4%). At the time of the survey, 14 (8%) out of 
175 patients used an opioid (seven [50%] for pain, five [36%] for breathlessness, 
one [7%] for both pain and breathlessness and one [7%] for drug dependence). Six 
(43%) patients used morphine, four (29%) patients used fentanyl, four (29%) patients 
used oxycodone and one (7%) patient used methadone. Median daily morphine 
equivalent dose was 27.5 mg (IQR 16.25 to 30.00 mg) with an outlier of 480 mg 
(dependence).
In total, 64 (37%) patients were willing to use opioids for breathlessness, 44 (25%) 
patients were unwilling and 67 (38%) patients were indecisive. Patients unwilling to 
use opioids were older compared to patients willing to use opioids and indecisive 
patients (66 versus 63 and 62 years, respectively; p<0.01). Sex, educational level, 
diagnosis, mMRC score and previous opioid use were comparable between groups 
(p=0.79, p=0.06, p=0.42, p=0.06 and p=0.07, respectively).
Main reasons to use opioids were on physician’s recommendation (89 [68%] out of 
131) and doing as much as possible to feel better (79 [60%] out of 131). Main reasons 
not to use opioids were concerns about adverse effects (49 [44%] out of 111) and fear 
of dependence (47 [42%] out of 111). Differences existed between decisive patients 
and indecisive patients (Table 1). Free-text considerations were not being familiar 
with opioids, fear of getting high and fear of weight increase.
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This study assessed attitudes towards opioid treatment in patients with chronic 
breathlessness with or without an indication for palliative treatment with opioids. 
The results showed that attitudes towards opioids are mixed, with only a quarter 
of the patients unwilling to use opioids. These results do not correspond with 
physicians’ assumptions, who indicate that they do not prescribe opioids because 
patients are resistant 6. Three-quarters of the indecisive patients indicated that they 
rely on physicians’ positive advice, and one-third indicated that thet rely on negative 
advice. So the physician is an important source of information, and open and 
honest communication is important.8 Since physicians state that they are insecure 
in prescribing opioids because of a lack of knowledge,6,8 more emphasis should be 
on educating physicians about when and how to treat breathlessness with opioids.
The main barriers against and reasons to use opioids mentioned in this study were 
consistent with previous studies.7-9 Concerns related to adverse effects and fear of 
dependence are the main reasons not to use opioids or to be indecisive. Qualitative 
studies show that patients experience that small improvements in breathlessness 
can have a big impact on the quality of life,9 which fits with the attitude of being 
willing to do as much as possible.
This study’s results have also shown that there are as many opinions as people, 
which also applies to the way patients gather information to form this opinion. 
Therefore, a proper provision of information for patients using different channels 
is necessary.
Low-dose opioids appear to be effective and safe in patients with severe chronic 
breathlessness.14-16 However, adverse effects might occur.15 Therefore, physicians 
and patients should discuss benefits and possible harms when considering low 
dose opioids.
A limitation of this study is that the convenience sample consisted of only 175 
patients referred to one centre. Another limitation is that not all included patients 
had an indication for opioid treatment. However, there was no difference in attitude 
between patients with mild (mMRC<2) and severe breathlessness, indicating 
that forming an opinion about opioids is irrespective of breathlessness severity 
and therefore information should be suitable and accessible to all patients with 
chronic breathlessness. Nevertheless, opioids should be reserved for patients 
with chronic breathlessness, persisting despite optimal pharmacological and non-
pharmacological treatment.17,18
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Palliative care is an approach that improves quality of life, provides relief from 
distressing symptoms and intends neither to hasten nor postpone death. 
It includes an early identification and correct assessment and treatment of 
distressing symptoms and complications and support of the patient’s wishes and 
needs. Palliative care is applicable early in the course of illness and requires a 
multidisciplinary and integrated management.1,2 As the course of chronic obstructive 
pulmonary disease (COPD) is unpredictable, with acute deteriorations and no 
distinct terminal phase, early recognition of palliative care needs and treatment 
of distressing symptoms is crucial.2-4 Chronic breathlessness is one of the most 
common symptoms in patients with advanced COPD and palliation of this distressing 
symptom is an important treatment goal.5
Recently, oral sustained-release morphine was licensed for the management of 
chronic breathlessness in Australia.6 However, as described in chapter 1, several 
aspects of low-dose, oral sustained-release morphine remained unclear. Therefore, 
the central aim of this thesis was to review breathlessness management with 
low-dose, oral sustained-release morphine. In this chapter, the main findings will 
be discussed in depth. First, I will discuss the effects of opioids in patients with 
advanced COPD on health-related quality of life and chronic breathlessness. Also, 
I will discuss impeccable assessment, the safety profile and the willingness of 
patients to use opioids. Next, the methodological considerations of this thesis will 
be discussed. I will conclude with the role of low-dose morphine in palliative care 
of patients with advanced COPD, including future directions for clinical care and 
research.
Enhancing quality of life
The most important aim of palliative care is the enhancement of quality of life. 
Few studies have previously assessed the effect of breathlessness management 
with opioids on health-related quality of life.7-11 These studies included small 
patient populations with different conditions and several only reported the results 
on health-related quality of life in words. Therefore, no meta-analysis could be 
performed.12,13 Of these studies, three reported no effect on quality of life,7,8,10 one 
reported a beneficial effect9 and one reported a negative effect.11 Last year, one of 
the largest randomized controlled trials (RCT) assessing the effect of opioids on 
chronic breathlessness was published. Currow et al.14 treated 284 patients with 
moderate to very severe chronic breathlessness (modified Medical Research Council 
[mMRC] breathlessness grade 2 to 4) due to several conditions with 20 mg oral 
sustained-release morphine or placebo for seven days. Secondary outcome was 
the effect on health-related quality of life, assessed by the European Organization 
for Research and Treatment of Cancer-Quality of Life Questionnaire Core 15 PAL.15
Results showed no effect on health-related quality of life. The MORDYC study
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assessed the effect of 20 to 30 mg oral sustained-release morphine for four weeks 
in 111 patients with COPD and moderate to very severe chronic breathlessness 
(mMRC grade 2 to 4, chapter 4). Results showed a significant and clinically relevant 
improvement of health-related quality of life, as assessed by the COPD Assessment 
Test (CAT, chapter 5).16,17 This effect was only reached after four weeks; no significant 
or clinically relevant improvement was seen after one or two weeks. As the majority 
of previous clinical trials only lasted for two weeks or less, it can be questioned if 
these studies lasted long enough to properly assess the effect of breathlessness 
improvement on quality of life.7-10,14 The only study so far with a follow-up longer than 
four weeks was the study by Poole et al.11, who studied low-dose, oral sustained-
release morphine treatment for six weeks in 16 patients with advanced COPD. 
Results showed no effect on the total score or the dyspnea, fatigue or emotional 
subscales of the Chronic Respiratory Disease Questionnaire (CRQ).18 The mastery 
subscale in the morphine group slightly deteriorated, while the scores in the placebo 
group improved, leading to a significant and clinically relevant difference favoring 
placebo. However, the included patient population was small and the baseline CRQ 
scores were unknown.
Interestingly, when reviewing the effects on health-related quality of life in the 
MORDYC study on item level, the significant and clinically relevant effect was mainly 
driven by an improvement on the item ‘walking the stairs or hill’. As suggested in 
chapter 5, it is possible that patients experienced an improvement in breathlessness 
and seized the opportunity to be more active in daily life until they reached a 
similar level of breathlessness. As patients experience difficulty accepting that daily 
activities, their independence and their role in a family changes when breathlessness 
worsens, small changes can have big impact on quality of life.19-21 However, this was 
not reflected in the measures of functional performance included in the MORDYC 
study – the 6 Minute Walk Test (6MWT), Care Dependency Scale (CDS) and Timed 
Up&Go (TUG) test. It can be questioned if these measures are suitable measures 
to capture the effect of morphine treatment in this population. Previously, patients 
with moderate to very severe COPD indicated walking, household activities and stair 
climbing most frequently as problematic daily life activities. Patients were the least 
satisfied with the performance of dressing/undressing, transfers and showering 
and bathing.22 Of these, only walking and transfers are captured by the 6MWT 
and the TUG test. The CDS captures several of these activities (mobility, dressing/
undressing, hygiene and household activities). However, the CDS is designed for 
patients in nursing homes, who are care dependent in daily life to a certain extent. 
The population included in the MORDYC study was generally not care dependent at 
baseline, leaving no room to improve. Therefore, monitoring meaningful activities 
over the day in combination with the level of breathlessness would be more 
insightful to assess the combined effect of morphine on breathlessness, health-
related quality of life and functional performance.




Relief of chronic breathlessness
Data on the effect of opioid treatment on breathlessness remain conflicting. Indeed, 
insufficient knowledge of positive effects and lack of expertise were the main 
barriers reported by physicians.21,23,24 While moderate-level evidence showed that 
opioids significantly reduce chronic breathlessness,12,13,25,26 recently this evidence 
has been brought into question. Meta-analyses have indicated a standardized mean 
difference of 0.28 to 0.36, corresponding to an effect of 0.52 to 0.66 points on a 
0-10 numeric rating scale (NRS) when using the baseline standard deviation of the 
MORDYC study. These meta-analyses included a wide range of patient populations 
with their severity of breathlessness ranging from moderate to very severe. In 
patients with COPD the most consistent evidence was shown for opioids given at 
steady state with a standardized mean difference of 0.42 (corresponding to 0.77 
points on the 0-10 NRS).13 Although these results were significant, they were not 
considered clinically relevant.27 Recently, Currow et al.14 showed no effect on their 
primary outcome ‘breathlessness now’ or the secondary outcomes mean, worst 
or best breathlessness in the previous 24 hours. The magnitude of the effects was 
less compared to the results of the meta-analyses, which can in part be explained 
by the fact that the use of rescue medication was allowed in both the morphine 
and the placebo group. The MORDYC study showed a magnitude of effect similar 
to the meta-analyses on mean and worst breathlessness in the previous 24 hours 
(chapter 5). Both the MORDYC study and the study by Currow et al.14 performed a 
subgroup analysis in the patients with mMRC grade 3 or 4, although these analyses 
were underpowered. Where Currow et al.14 showed a trend for improvement in 
worst breathlessness, the MORDYC study showed a significant and clinically relevant 
improvement of worst breathlessness and a trend for improvement of mean 
breathlessness.
Few studies have been performed on the effect of other opioids or routes of 
administration on chronic breathlessness. The studies on other opioids were 
mainly small and only dihydrocodeine showed a beneficial effect.12 Recently, Ferreira 
et al.28 studied the effect of 15 mg oral, controlled-release oxycodone for seven 
days in 155 patients with different conditions and showed no effect on intensity 
of ‘breathlessness now’, unpleasantness of ‘breathlessness now’, or intensity 
of worst, best or mean breathlessness. Even, the placebo group showed better 
results on all outcomes except for worst breathlessness. Although the study was 
underpowered and the use of rescue medication in both the oxycodone and placebo 
group was allowed, the authors concluded that oxycodone does not improve chronic 
breathlessness. Furthermore, meta-analyses have consistently demonstrated 
no effect of nebulized opioids on breathlessness.12,13,25 Recently, Janowiak et al.29
assessed the effect of 2.0% nebulized morphine. Breathlessness improved in 11 
patients with COPD after four days. However, since they did not assess systemic 
uptake, a central effect cannot be excluded. Therefore, until now evidence shows the 
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best implications for oral morphine in the management of chronic breathlessness. 
As was shown in a dose increment and pharmacovigilance study, an effect of oral 
morphine should be observed after one week and upward titration until 30 mg per 
day within one week may be needed.30,31 When no improvement is observed at 30 
mg per day, treatment should be stopped.
Although oral morphine treatment does not improve breathlessness to a 
clinically relevant extent at group level, it has been suggested that several patient 
characteristics are related to a positive response.32,33 First, a pooled analysis 
of effectiveness studies with different patient populations has identified worse 
breathlessness intensity as a possible characteristic of positive response,32 with an 
odds ratio of 1.04 on a 0 to 100 visual analogue scale. Smaller studies were not able 
to identify breathlessness intensity as a relevant characteristic.30,33 The MORDYC 
study also showed an association between response to morphine and worse 
breathlessness intensity (chapter 6). For each point increase in breathlessness 
intensity on a 0 to 10 NRS, the odds of a positive effect increased with 1.55, which 
is similar to the pooled analysis.32 Also, as discussed above, both the MORDYC study 
and the study by Currow et al.14 showed more improvement in breathlessness 
in the subgroup of patients with mMRC grade 3 or 4. Therefore, breathlessness 
intensity should be taken into account when considering morphine treatment for 
breathlessness.
Second, younger age was suggested as possible characteristic. Two smaller studies 
that dichotomized age with 75 years as cut-off point found no association between 
age and response to opioid treatment.30,33 Subsequently, a large pooled analysis 
identified younger age as predictor when included as continuous outcome.32 The 
MORDYC study could not confirm these results, which was possibly due to a lack 
of power, but showed a similar magnitude of effect (chapter 6). For each year of 
aging, the odds of a positive effect to morphine treatment decreases with 1.04 
to 1.08. It can be questioned if this is an effect of the process of ageing or the 
existence of long breathlessness trajectories that comes with age. Perception 
of breathlessness is influenced by priors, formed by experiences and learned 
behaviors.34,35 When breathlessness trajectories are long established, strong priors 
have been formed.36 This process of anticipatory learning is associated with less 
responsiveness to morphine therapy.37 When considering morphine treatment for 
breathlessness, age should be considered. Also, the association between response, 
age and breathlessness trajectories should be studied in a future study.
Third, a favorable effect is suggested in patients describing breathlessness as air 
hunger,32,38 but not as breathing work/effort.39 However, as patients with different 
conditions choose different descriptors for their breathlessness,40-42 the attribution 
of sensory description on a beneficial response to morphine in COPD is unclear. In 
the MORDYC study none of the descriptors of breathlessness could be indicated as 
predictor of a beneficial response to morphine (chapter 6), which is probably due 




to a lack of power. Responders to morphine treatment chose air hunger as most 
accurate descriptor, while non-responders chose various descriptors. This could 
indicate air hunger as a predictor of positive response to morphine in COPD, which 
should be examined in a properly powered study.
Fourth, as stated in chapter 1, negative affective states such as anxiety and 
depression can amplify the perception of breathlessness.43 A small study indicated 
that opioid responsiveness is decreased when anxiety or depression worsens, even 
with subtle worsening.37 As is known from opioid treatment for pain, anxiety or 
depression can lead to dose escalation and difficulty with tapering off treatment.44
The presence of anxiety or depression was not reported in the MORDYC study and 
other studies concerning opioids for breathlessness.12,14 Therefore, the association 
between responsiveness to morphine for breathlessness and anxiety or depression 
should be studied in a future study. When this association is confirmed, symptoms 
of anxiety or depression should be managed first before considering morphine 
treatment for breathlessness.
Finally, the MORDYC study indicated higher body mass index (BMI) as a strong 
predictor for a beneficial response (chapter 6). As morphine metabolism decreases 
with increasing weight, the positive association might be due to increased levels of 
morphine metabolites.45-47 Also, as patients with overweight or obesity show an 
increased perception of breathlessness compared to patients with normal weight, 
patients with overweight or obesity might have more room to improve.48,49 However, 
since this study was the first study to indicate BMI as characteristic related to a 
beneficial response to morphine and the explanations are only hypothetical, the 
relationship and the underlying mechanism should be further studied.
Impeccable assessment
As described in chapter 1, measurement of breathlessness can serve different 
purposes, of which we addressed the purpose of evaluation of the effectiveness of 
an intervention over time. Breathlessness is a multidimensional symptom involving 
different mechanisms and pathways.50 Therefore, a unidimensional measure of 
breathlessness might not be justified in measuring the effectiveness of morphine 
on breathlessness.51,52 Therefore, in addition to mean breathlessness, worst 
breathlessness and breathlessness unpleasantness should be assessed.51 Patients 
with worse breathlessness have more room to improve. Morphine might have the 
most revealing effect on the active moments during the day, which is reflected in the 
measure of worst breathlessness. Patients refer to this as ‘the edges are off’. When 
only the average breathlessness during the day is assessed, these peak moments 
might be faded out and the effect of morphine might then be harder to assess.20,21
In the MORDYC study worst baseline breathlessness showed an improvement in 
patients with mMRC grade 3 or 4, where mean breathlessness only showed a trend 
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(chapter 5), indicating the need to assess both aspects of breathlessness. Also, as 
intensity and unpleasantness can vary independently,50 both dimensions should be 
assessed. Limbic areas like the hippocampus and amygdala are activated when an 
efferent-afferent mismatch arises, areas in which opioid receptors are abundantly 
present. In healthy volunteers, the strong opioid remifentanil interfered with both 
breathlessness pathways and the process of anticipatory learning, leading to an 
effect on breathlessness unpleasantness but not on breathlessness intensity.53 
Currow et al.14 showed a trend for improvement of breathlessness unpleasantness 
in the subgroup of patients with mMRC grade 3 or 4. 
A second important dimension of breathlessness assessment is the beneficial effect 
on daily life. Results of the MORDYC study suggested that patients are able to do 
more in daily life before reaching a comparable level of breathlessness (chapter 
5). This was not reflected in the used assessments of functional performance. 
As both breathlessness and physical activity patterns fluctuate over the day,54,55 
continuous and direct assessment of meaningful daily life activities and symptoms 
is more appropriate.56 Activity monitoring would be a proper measurement of 
physical activity patterns during the day. This simple and noninvasive assessment 
would give more insight in changes of daily life activities.57,58 Activity monitoring 
can subsequently be combined with Ecological Momentary Assessment (EMA).59 
EMA is a method to obtain momentary accounts of symptoms, activities or quality 
of life. When EMA is used on an electronic device, patients are asked to answer 
questions on this device on random moments during the day. This combination 
allows to give insight in real-time symptom burden and the effect of morphine 
treatment. Also, collected data are not subject to recall bias and give insight in the 
breathlessness and daily activity patterns of patients in their natural environment.60 
Although EMA has not been applied for breathlessness assessment, it is used to 
assess the fluctuation in fatigue61 or applied in rehabilitation for chronic illnesses.62
Safety
Both physicians and patients mention fear of serious adverse effects as a major 
barrier of opioid treatment.19-21,23,63-65 A retrospective observational study performed 
in Canada suggested that new opioid prescription has been associated with 
increased emergency department visits and 30-day mortality in patients with COPD, 
regardless of opioid dose.66 However, data on patients who received opioids as 
palliative treatment were excluded. Also, as this was an observational study, there 
is no information on cause or effect. The increased risk for emergency department 
visits and mortality may as well be a marker of disease severity: patients who receive 
opioids have higher symptom burden and are therefore just more ill. Actually, a 
large registry study in patients with advanced oxygen-dependent COPD found 




no association between low dose opioids (≤30 mg oral morphine equivalent) and 
hospital admission or mortality after four years of follow-up.67
Within morphine treatment, serious adverse effects mainly concern the occurrence 
of respiratory depression. Fear of respiratory depression is not restricted to 
treatment of breathlessness, but is also mentioned as barrier in and probably 
originates from experiences in pain treatment.23 In COPD, ventilatory responses to 
hypercapnia and hypoxia are abated,68,69 which can even be obtunded by opioids.70
Evidence on respiratory adverse effects of low-dose opioid treatment for chronic 
breathlessness is limited and conflicting. The respiratory outcomes most reliable 
to assess respiratory depression are partial arterial pressure of carbon dioxide 
(PaCO2) and partial arterial pressure of oxygen (PaO2).
71 Systematic reviews assessing 
the effect of opioids on breathlessness have indicated no effects on PaCO2, partial 
end-tidal pressure of carbon dioxide (PETCO2) or arterial oxygen saturation (SaO2), 
but meta-analyses were not conducted. Also, the included studies reported no 
cases of respiratory depression.12,13,72 On the contrary, observational studies have 
reported five cases of respiratory depression in patients treated with opioids for 
breathlessness.73-75 Three cases were reported in an observational study to the 
effect of subcutaneous oxycodone for pain and/or breathlessness. The mean dose 
reported was 44.6 mg per day (oral morphine equivalent 133.8 mg per day), but the 
specific dose or indication of the patients that experienced a respiratory depression 
was not mentioned.74 The fourth case was in a patient treated for cancer-related pain 
with 30 mg continue-release morphine per day needing additional treatment for 
breathlessness with nebulized morphine.73 The fifth case was a patient treated with 
15 mg sustained-release morphine who additionally used a high dose of immediate-
release morphine.75
To systematically assess the occurrence of respiratory adverse effects of opioids 
when prescribed for chronic breathlessness, we performed a systematic review 
and meta-analysis (chapter 2). In line with previous systematic reviews, this review 
showed that there was no evidence of clinically relevant respiratory adverse effects. 
However, the quality of the included studies was low, the studies were small and 
used a variety of treatment regimens and patient populations, and the studies were 
not designed to examine the safety of opioids. Further, several included studies 
assessed the occurrence of a respiratory depression, but did not quantify which 
outcomes were used to assess a respiratory depression.
Only a few of the studies in chapter 2 included relevant respiratory outcomes 
and none of the studies were powered to assess these outcomes. The MORDYC 
study included PaCO2 as primary outcome and 13 other respiratory outcomes as 
secondary outcome, including outcomes on overnight oximetry and lung function 
parameters (chapter 4). Also, the study included a larger study population and had 
a longer duration compared to the majority of included studies in chapter 2. The 
results, as described in chapter 5, showed that respiratory rate decreased without 
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a change in PaCO2 or any of the other respiratory outcomes. In a subgroup-analysis 
in patients with mMRC grade 3 or 4, none of the included outcomes changed.
Currow et al.14 also assessed respiratory adverse effects, albeit as secondary 
outcome, and found no effects of morphine treatment on respiratory rate, 
peripheral oxygen saturation (SpO2) and PETCO2. Results of our systematic review, 
the MORDYC study and the study by Currow et al.14 are of comparable magnitude 
and similar direction. These results indicate that no clinically relevant differences 
in alveolar ventilation occur after low-dose morphine treatment.
Another concern is the effect of opioids on respiration during sleep, including central 
sleep apnea, hypoventilation and oxygen desaturation.70 Within opioid treatment 
for pain, a dose-response relationship was shown with the apnea-hypopnea 
index. The majority of the patients received high-dose opioids.76,77 It is not known 
if this conclusion can be drawn for low-dose opioids as well.78 A recent overview of 
Cochrane reviews of opioid therapy for chronic pain found no case of respiratory 
depression, sleep apnea or sleep-disordered breathing.79 Since the effect in patients 
with COPD was unknown, we included overnight pulse oximetry in the MORDYC 
study. Results showed no effect on the time SpO2 was below 90% nor the mean SpO2 
during the night (chapter 5). These results are consisted with the Cochrane review 
on opioids for chronic pain79 and are indicative for the dose-response relationship. 
Hence, these results emphasize the relationship between high-dose opioids and 
increased risk for serious adverse effects and therefore warrant to distinguish 
between low- and high-dose opioid treatment and confine treatment for chronic 
breathlessness to low-dose opioids.
Not only respiratory adverse effects, but also gastrointestinal adverse effects as 
nausea and vomiting, constipation and drowsiness are a concern of morphine 
treatment.63,65 Indeed, low-dose morphine treatment comes with several adverse 
effects.12,13,43 A systematic review and meta-analysis showed that patients using 
opioids are 4.7 times more likely to experience nausea and vomiting, 3.0 times 
more likely to experience constipation and 2.9 times more likely to experience 
drowsiness.12 Adverse effects were generally mild, as only 12 patients across all 
studies dropped out. In the MORDYC study, the number of participants experiencing 
adverse effects was not different between the groups, although the severity of 
constipation was worse in the morphine group (chapter 5). Five participants in the 
morphine group and one participant in the placebo group had to withdraw from the 
study due to adverse effects including constipation, nausea, vomiting, dizziness and 
hallucinations. Currow et al.14 showed similar results, although participants in the 
morphine group reported more often and more severe constipation and vomiting. In 
all studies the adverse effects resolved quickly after termination of the intervention 
or treatment of the symptom. These results clearly indicate that adverse effects 
occur in morphine treatment, but are mild and responsive to symptom treatment.





As breathlessness in the palliative phase of a disease might be difficult to control, 
healthcare utilization increases. As discussed in chapter 1, breathlessness burden 
is associated with healthcare costs. When breathlessness burden increases, 
healthcare utilization might increase as well as was shown previously.80-83 However, 
these studies were retrospective or cross-sectional studies and used claims data or 
long recall periods. Our prospective study using patient-reported data with a short 
recall period confirmed these results (chapter 3). This study showed that in patients 
with high breathlessness burden despite optimal treatment of advanced COPD, 
healthcare and non-healthcare costs were higher compared to patients with low 
breathlessness burden. The main cost driver in patients with high breathlessness 
burden in the first year after pulmonary rehabilitation was hospitalization, indicating 
that these patients often attend the hospital, with corresponding high costs. The 
main cost driver in the second year was pulmonary rehabilitation, indicating 
that when controlling breathlessness with arbitrary interventions fails, a second 
pulmonary rehabilitation program is initiated. In the view of these high healthcare-
related costs of high breathlessness burden, assessment of cost-effectiveness 
of palliative interventions should be a regular and significant component when 
interventions demonstrate to be effective. However, assessing all relevant costs 
in palliative care is challenging, as informal care is a major component of palliative 
care.84 To date, cost-effectiveness analyses for palliation of chronic breathlessness 
are scarce and limited to holistic breathlessness support services.85,86 In chapter
7 we conducted a cost-effectiveness analysis of low-dose, sustained-release oral 
morphine, which showed that four weeks morphine treatment decreased both 
healthcare and societal costs. As morphine treatment improved health-related and 
general quality of life, the intervention showed to be cost-effective. This simple and 
inexpensive intervention reduced healthcare and societal costs within a foreseeable 
period, which is an important aspect of the effectiveness of morphine treatment. 
We also showed that conducting a cost-effective analysis in palliative care along 
a RCT is feasible and therefore encourage others to assess cost-effectiveness of 
palliative interventions.
Willingness of patients
Unwillingness of patients to use opioids is mentioned as one of the reasons 
restraining physicians from prescribing opioids.63 As described in chapter 5, the 
major challenge of the MORDYC study was the unwillingness of patients to participate. 
Due to disappointing recruitment rates, inclusion criteria were expanded to mMRC 
grade 2 to 4. This was also the case in the study by Currow et al.14 Main reasons for 
unwillingness of patients eligible to participate in the MORDYC study were related 
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to morphine (28%) and to the burden of the project (24%). Barriers to start opioid 
treatment have been reported before. Small qualitative studies indicate fear of 
dependence and fear of imminent death as most important barriers.19-21 However, 
these studies were mainly conducted in patients with experience with opioid 
treatment21 or in patients that agreed to participate in an opioid-trial.20 We assessed 
these reasons for willingness or unwillingness to start opioid treatment in a survey 
among patients with chronic lung or heart disease, as described in chapter 8. The 
patients surveyed did not necessarily have an indication for opioid treatment for 
breathlessness and were not necessarily informed by a physician about opioids. 
About one third of patients surveyed was willing to use opioids for breathlessness 
and another one third was indecisive. In line with previous studies, main barriers 
were concerns about adverse effects and fear of dependence, where the main 
reason to start opioids was to do as much as possible to feel better.19-21 Fear of 
imminent death was only mentioned by three patients. Important result of the 
survey was that the physician plays an important role in the decision of patients. 
For indecisive patients, recommendation of their physician is the most important 
reason to start opioid treatment and a negative advice of their physician is the most 
important reason not to start. These results were irrespective of previous opioid 
use, sex, educational level, diagnosis and breathlessness burden. This indicates that 
proper information and communication by physicians and shared decision making 
is very important. To overcome the physicians’ lack of knowledge and expertise, 
proper education and information should be emphasized.
One of the barriers reported was the fear of dependence,19-21 which is a legitimate 
concern given the opioid epidemic surrounding over-prescription and drug-misuse 
of opioids for pain management. As patients live with chronic breathlessness for 
many months or years, misuse may occur. Should we use the lessons learned 
from the world of analgesics when considering opioid treatment for chronic 
breathlessness? A systematic review published in 2015 concluded that for some 
harms, including dependence, “higher opioid doses are associated with increased 
risk”.87 With analgesia, high doses and dose escalation titrating against severity 
of pain are usual practice, but patients with breathlessness are usually treated 
with low-dose opioids (≤30 mg oral morphine equivalents a day30). Therefore, it 
is questionable whether the knowledge of analgesia can be extrapolated to the 
treatment of chronic breathlessness with low-dose opioids. Responders in a long-
term effectiveness study (mean of 209.5 patient-days per participant) used a mean 
of 14 mg per day, of which only 7.7% used the highest dose of 30 mg per day to gain 
benefit.30 In participants needing a dose increment up to 30 mg per day to gain 
benefit, improvement continued without further dose titration over the following 
seven days, a phenomenon not described in pain response.31 However, although 
the doses for breathlessness treatment are lower than doses associated with 
dependence, intended or unintended misuse can still occur.75,88 Misuse is less likely 
with morphine compared to other opioids89 and with sustained-release opioids 




compared to immediate-release opioids.90 Therefore, sustained-release morphine 
treatment should be the first choice opioid for breathlessness treatment. Also, 
proper and timely monitoring of patients is important to prevent misuse.
Not being able to drive a vehicle was one of the main reasons patients declined 
to participate in the MORDYC study and was also indicated as a barrier in chapter 
8. Driving is an activity related to freedom and independence for many adults, 
especially when being single.91 For patients with COPD, driving is also essential to 
attend therapy or go to a doctor’s appointment.92,93 Due to possible adverse effects 
as dizziness, patients are advised against driving during therapy initiation or upward 
dose titration. Where high doses can impair driving,94 patients receiving stable low-
dose morphine and their caregivers don’t experience impairment of driving skills of 
the patient.93 However, as this is not assessed in a clinical trial, care must be taken. 
This issue and the consequences should be discussed by the patient and physician 
before morphine treatment is initiated.
Methodological considerations
This thesis has several strengths. First, we conducted a broad analysis of the effects 
of low-dose, oral sustained-release morphine. Chapter 2 gives an overview of the 
current knowledge on respiratory adverse effects, also including observational 
studies and case reports. As these studies are closer to daily practice, the results 
gave insight in what happens and can happen outside laboratory settings. Also, we 
performed meta-analyses of five respiratory outcomes. The MORDYC study (chapter 
4) was powered to estimate health-related quality of life and respiratory adverse 
effects. In chapter 5 we assessed 14 respiratory outcomes, including overnight 
oximetry. To conclude, we performed a cost-analysis (chapter 7), which was the 
first cost-effectiveness analysis on opioids for breathlessness. Second, we included 
optimally treated patients. Palliative care is indicated in patients experiencing 
breathlessness refractory to disease-modifying management.95 Patients in chapters 
3, 5, 6 and 7 all recently completed a comprehensive pulmonary rehabilitation 
program, ensuring state-of-the-art pharmacological and nonpharmacological 
management.96 This enables the generalizability of results to patients to whom 
this palliative management of breathlessness is intended. Third, we conducted a 
thoroughly-conducted cost-analysis of COPD and of morphine treatment. Both 
chapter 3 and chapter 7 included the healthcare and societal perspective. 
Breathlessness has a major impact on the daily life of patients,97,98 placing more 
burden on informal caregivers.82,99 Covering all cost aspects of breathlessness gives 
a proper overview of the consequences of this distressing symptom and the effects 
of its management. Also, results were grounded by several sensitivity analyses. 
Finally, the MORDYC study was one of the first RCTs with a study duration of more 
than one week.12,13 This enabled us to increase the treatment dose after one week, 
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as is usual in clinical practice. Also, it enabled us to show the impact of morphine on 
health-related quality of life. Although it is only theoretical, this gave insight in the 
combined effect on breathlessness, functional ability and quality of life.
This thesis has several limitations which should be considered when interpreting 
the results. First, we did not reach the intended sample size of 124 participants for 
the MORDYC study. Of the patients that consented to participate, thirteen patients 
dropped out between consent and study start. In the majority of patients this was 
because of recurring acute exacerbations of COPD, for which some were prescribed 
morphine. Second, the sample size calculation of the MORDYC study was based on two 
of the assessed outcomes, the CAT for assessing health-related quality of life and 
PaCO2 for assessing impact on respiratory outcomes. The study was therefore not 
powered to assess the other outcomes. Breathlessness was not included as primary 
outcome, as at trial design several systematic reviews indicated that morphine 
improves breathlessness. However, a large RCT published after completion of the 
MORDYC study brought this into question.14 Also, the study was not powered to 
determine the interaction between severity and description of breathlessness and 
response to morphine. The five known descriptors of breathlessness could only 
be included in the regression analysis one by one. Also, only age, breathlessness 
severity and BMI could be included. Third, chapters 3 and 7 were based on several 
assumptions. Although the costs questionnaires were designed to the best 
knowledge at the time of study design, not all information was gathered. In chapter 
3, assumptions had to be made regarding transportation and employment status. 
To minimize missing data, we contacted patients to complement the questionnaires, 
but this was not possible in each patient. Finally, although the MORDYC study was 
one of the longest studies to date, long-term effects, adverse effects and cost-
effectiveness remain unknown. The only medium- or long-term data to date are 
from observational studies that have shown that the benefit of low-dose morphine 
was maintained for three months in one-third of patients30 and that low-dose 
opioids are not associated with increased hospital admissions rates or mortality.67,100 
Data on long-term cost-effectiveness are lacking.
Conclusions and future directions
This thesis has indicated the prominent role of low-dose, oral sustained-release 
morphine in the palliation of chronic breathlessness in patients with advanced 
COPD.
For clinical practice, this thesis has the following implications. First, low-dose, oral 
sustained-release morphine has a prominent place in palliative breathlessness 
management, as it enhances quality of life, relieves breathlessness in part of the 




patients, is safe and is cost-effective. As the sustained-release formulation induces 
the lowest peaks and highest troughs, this formulation will lead to the least adverse 
effects and is therefore the preferred formulation. However, when not available, 
immediate-release formulations at a fixed schedule can be prescribed as well.101
An effect should be perceived within one week.30,31 When no effect is perceived, 
treatment dose can be increased up to 30 mg per day in intervals of one week. When 
a patient perceives no effect at the maximal dose of 30 mg or perceives intolerable 
adverse effects, the treatment should be stopped. Second, a broader assessment 
of breathlessness is indicated. Up until recently, only breathlessness in general was 
used to assess the effectiveness of morphine treatment. However, breathlessness 
is a multidimensional symptom and these different dimensions should be taken 
into account. Results have shown worst breathlessness and breathlessness 
unpleasantness are more responsive to morphine treatment compared to mean 
breathlessness. Third, as patients can live with chronic breathlessness for years and 
the long-term effectiveness and safety profile is still unclear, morphine treatment 
should only be considered as palliative treatment in patients whose breathlessness 
remains severe (mMRC grade 3 or 4) and refractory to optimal treatment of the 
COPD. As response is also more likely in younger patients, age should be taken 
into account as well. Fourth, physicians and patients should always discuss 
the possible benefits and harms when considering low-dose morphine. When 
preferred, loved ones should be involved in this conversation. Patients primarily 
rely on the information and recommendation of their physician. However, each 
patient gathers information in their own way. Therefore, proper information should 
be available, suitable and accessible via different channels to all patients with 
chronic breathlessness. Finally, when the joint decision is made to start morphine 
treatment, proper monitoring of the effect is crucial. This also accounts for upward 
dose titration. Although adverse effects are generally mild and the occurrence of 
respiratory adverse effects is minimal, it is unknown in which patients they occur.
Although this thesis has given insight in several aspects of low-dose, oral sustained-
release morphine, some aspects remain unclear. Future research should therefore 
focus on the mechanism in which morphine improves breathlessness and improves 
health-related quality of life. Based on the results of the MORDYC study, we 
hypothesized that improvement of breathlessness leads to the ability to do more 
in daily life, which improved quality of life. However, this is only a theory, which 
should be confirmed in a future study including measures to monitor symptom 
fluctuation and daily activities.
In addition, the role of several patient characteristics in COPD remains unclear, 
including age, sensory description of breathlessness, BMI and symptoms of anxiety 
and depression. These characteristics should be investigated in more detail, in order 
to give the right treatment to the right patient. For age, it should be determined 
if the possible disadvantageous response in older age originates in the process of 
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ageing or in established priors. Different sensory descriptors should be addressed 
to determine if air hunger is indeed a predictor of response in COPD. As the MORDYC 
study was the first study to indicate increased BMI as a characteristic associated with 
beneficial response, this association should be confirmed in a well-powered study. 
The association with symptoms of anxiety and depression and a disadvantageous 
response to morphine should be mapped.
Lastly, the long-term effectiveness, safety profile and cost-effectiveness remain 
unclear. Therefore, a study with a longer follow-up should be considered.
When designing a future RCT, the following aspects should be taken into account:
• Given the low willingness of patients to participate in a morphine-trial, a 
multicenter trial is recommended;
• When assessing the effect on breathlessness, including a multidimensional 
set of outcomes with at least mean breathlessness, worst breathlessness and 
unpleasantness of breathlessness is recommended;
• When assessing the interplay between breathlessness, daily life activities 
and health-related quality of life, continuous and direct assessment of these 
outcomes, for instance by means of activity monitoring in combination with 
Ecological Momentary Assessment, is recommended. This continuous and direct 
assessment enables researchers to link changes in daily life activities to changes 
in breathlessness and quality of life in the patient’s natural environment.
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Chronic breathlessness is a common symptom in patients with advanced chronic 
obstructive pulmonary disease (COPD) with major consequences. Opioids have been 
suggested as effective palliative treatment for chronic breathlessness, with the 
best evidence for low-dose, oral sustained-release morphine. Palliative care is an 
approach that improves quality of life, provides relief from distressing symptoms and 
intends to neither hasten nor postpone death. Several of these aspects are unclear 
for low-dose, oral morphine. The effects on quality of life, breathlessness, functional 
performance and respiratory outcomes remain conflicting. Also, prospective data 
on the long-term economic burden of chronic breathlessness are scarce, as are 
data on long-term effectiveness and cost-effectiveness of oral morphine treatment. 
Therefore, the main aim of this thesis was to provide a comprehensive understanding 
of the effects of low-dose, oral morphine for breathlessness. In addition, we have 
given insight in the economic burden of chronic breathlessness and the willingness 
of patients towards use of opioids for breathlessness (chapter 1).
In chapter 2 a systematic review and meta-analysis were performed to study the 
respiratory adverse effects of opioids for chronic breathlessness. Several databases 
were searched for studies that assessed the effect of opioids on respiratory 
outcomes. We included original research articles such as randomized controlled 
trials, nonrandomized trials, case-control studies, cohort studies, chart reviews, 
case reports and case studies. We assessed six outcomes: arterial carbon dioxide 
tension (PaCO2), arterial oxygen tension (PaO2), arterial oxygen saturation (SaO2), 
respiratory rate, end-tidal carbon dioxide tension (PETCO2) and occurrence of 
respiratory depression. Meta-analyses were performed using randomized data 
for all continuous outcomes. We included 63 articles describing 67 studies. The 
meta-analysis showed a statistically significant, but clinically irrelevant increase in 
PaCO2 in patients using opioids for breathlessness compared to placebo. No other 
significant changes were shown in the meta-analyses or the other included studies. 
A respiratory depression occurred in four patients after a high or unknown opioid 
dose. Based on these results, we concluded that low-dose opioids do not cause 
clinically relevant respiratory adverse effects. However, the included studies used 
a heterogeneity of study designs and the quality was low, indicating the need for a 
larger, adequately powered study.
Healthcare utilization in patients with COPD increases with increasing disease 
severity and the presence of comorbidities. However, the impact of breathlessness 
burden on healthcare utilization and daily activities is unclear. In chapter 3, the 
impact of breathlessness burden on healthcare utilization and economic burden 
is assessed. This observational study followed patients with COPD for 24 months 
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after completion of a comprehensive pulmonary rehabilitation program. Every 
three months, participants completed a cost questionnaire, covering healthcare 
utilization, employment status and impact on daily activities for both breathing 
problems and other health problems. The results were compared between 
participants with low (modified Medical Research Council [mMRC] breathlessness 
grade <2) and high breathlessness burden (mMRC grade ≥2). Main cost drivers for 
the total study population were hospitalizations, contact with other healthcare 
professionals (mainly physiotherapists) and pulmonary rehabilitation. Patients with 
high breathlessness burden showed higher costs for inpatient care, pulmonary 
rehabilitation and informal care compared to patients with low breathlessness 
burden. This study highlights the relevance of adequate breathlessness relief in 
order to reduce healthcare utilization and economic burden of patients with COPD.
While the effect of opioids on health-related quality of life and respiratory adverse 
effects remained unclear, the MORDYC study was designed (chapter 4). This single-
center, randomized, double blind, placebo-controlled intervention study assessed 
the effect of low-dose, oral, sustained-release morphine in 124 patients with COPD 
and moderate to very severe chronic breathlessness despite optimal treatment 
of their COPD. These patients were randomly assigned to either 10 mg morphine 
or placebo twice daily for four weeks, with the possibility to increase to three 
times daily after one or two weeks in patients who did not experience a clinically 
relevant improvement of breathlessness. Assessed outcomes were disease-specific 
health-related quality of life, respiratory outcomes, functional performance, 
breathlessness, adverse effects and costs.
Chapter 5 describes the results of the MORDYC study on health-related quality of 
life, respiratory outcomes, functional performance, breathlessness and adverse 
effects. Health-related quality of life improved statistically significant and clinically 
relevant in the morphine group compared to the placebo group. Respiratory 
outcomes, functional performance and breathlessness remained unchanged. In the 
subgroup of patients with severe to very severe breathlessness (mMRC grade 3 or 
4), worst breathlessness improved, while other outcomes remained unchanged. No 
serious adverse effects occurred. These results showed that four weeks treatment 
of low-dose, oral sustained-release morphine may improve disease-specific 
health-related quality of life in patients with COPD and moderate to very severe 
breathlessness, without affecting respiratory outcomes or causing serious adverse 
effects. Breathlessness improved in patients with severe to very severe chronic 
breathlessness.
Not all patients experience a clinically meaningful improvement of breathlessness 
from morphine treatment. The aim of chapter 6 was to assess the relationship 
between a beneficial response to morphine treatment, sensory breathlessness 




description and demographics using the results of the MORDYC study. Higher baseline 
breathlessness and higher body mass index were associated with a beneficial 
response to morphine, while age and the sensory breathlessness descriptors were 
not. Morphine treatment should therefore be considered in patients with COPD 
with severe breathlessness. As this was the first study indicating body mass index 
as a predictor, this relationship should be further studied.
High breathlessness burden is associated with increased healthcare utilization 
and healthcare-related costs. Adequate breathlessness relief in order to reduce 
economic burden in patients with COPD and severe chronic breathlessness is 
therefore relevant. The aim of chapter 7 was to analyze the cost-effectiveness of 
regular, low-dose morphine using the data of the MORDYC study. Both healthcare 
and societal costs were higher in the placebo group compared to the morphine 
group. As quality of life improved, morphine treatment was dominant from a 
healthcare perspective and from a societal perspective. Several sensitivity analyses 
substantiated these results. Based on these results, we concluded that low-dose, 
oral morphine for four weeks is cost-effective regarding the healthcare and the 
societal perspective.
Although opioids are recommended for patients with optimal pharmacological 
and nonpharmacological treatment of the underlying causes of breathlessness, 
physicians experience barriers to prescribe opioids. One of the barriers mentions by 
physicians is the resistance of patients. This can limit effective palliative treatment of 
breathlessness. In chapter 8, we assessed the willingness to start opioid treatment 
in 175 patients with chronic lung or heart disease, irrespective of a current indication 
for opioid treatment. Attitudes towards opioid treatment were mixed, with one 
quarter of patients being unwilling to start opioid treatment. Of the remaining 
patients, half of the patients was willing to use opioids and half of the patients was 
indecisive. Willingness was only related to age, with older patients more often being 
unwilling to use opioids. The main reason to be unwilling was fear of adverse effects 
and the main reason to be willing was to do as much as possible to feel better. The 
physician is an important source of information for indecisive patients. So, proper 
provision of information for patients is necessary. Patients and physicians should 
discuss the benefits and possible harms when considering low-dose opioids.
Finally, in chapter 9 the main findings of this thesis were discussed in depth in 
relation to previously published studies. We have concluded that low-dose, oral 
sustained-relief morphine treatment has a prominent role in the palliation of 
chronic breathlessness in patients with advanced COPD. Morphine enhances health-
related quality of life, is safe and is cost-effective. In addition, morphine relieves 
breathlessness in part of the patients and should therefore be considered in patients 
with severe to very severe breathlessness. Patients and physicians should always 
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discuss the benefits and possible harms of treatment before initiation in order to 
make a joint decision. However, not all aspects of morphine treatment are evident. 
Therefore, future studies are crucial in order to assess the long-term effectiveness 
and cost-effectiveness and to further explore characteristics associated with a 
beneficial response.





Chronische kortademigheid is een veelvoorkomende klacht bij patiënten met 
gevorderde COPD en heeft grote psychische en sociale gevolgen. Opioïden worden 
beschouwd als effectieve palliatieve behandeling van chronische kortademigheid, 
met de beste resultaten voor lage dosis orale morfine met langdurige afgifte. 
Palliatieve zorg heeft als doel kwaliteit van leven te verbeteren en symptoomlast te 
verminderen, zonder de dood uit te stellen of te versnellen. Uit eerdere studies bleek 
dat voor lage dosis orale morfine verschillende van deze aspecten van palliatieve 
zorg onduidelijk zijn. Zo zijn het effect op kwaliteit van leven, kortademigheid, 
fysiek functioneren en respiratoire parameters (uitkomtmaten van longfunctie- en 
bloedonderzoek) tegenstrijdig. Daarnaast is onduidelijk wat de economische impact 
van chronische kortademigheid op de lange termijn is en of morfine kosteneffectief 
is. Tot slot zijn de lange-termijn effectiviteit en kosteneffectiviteit van morfine niet 
bekend. Daarom is het belangrijkste doel van dit proefschrift om een uitvoerig beeld 
te geven van de effecten van lage dosis orale morfine. Daarnaast geef ik inzicht 
in de economische impact van chronische kortademigheid op de lange termijn 
en de bereidheid van patiënten om opioïden te gebruiken voor kortademigheid 
(hoofdstuk 1).
In hoofdstuk 2 beschrijven we een systematische review en meta-analyse die we 
hebben uitgevoerd om de effecten van opioïden voor chronische kortademigheid 
op respiratoire parameters in kaart te brengen. In diverse databases is gezocht 
naar studies die de effecten van opioïden op respiratoire parameters hebben 
gemeten. Hierbij hebben we originele studies geïncludeerd, zoals gerandomiseerde 
interventiestudies, niet-gerandomiseerde interventiestudies, case-control studies, 
cohortstudies, dossierstudies, case reports en casestudies. We keken naar 6 
parameters: koolstofdioxidedruk in arterieel bloed (PaCO2), zuurstofdruk in 
arterieel bloed (PaO2), zuurstofsaturatie in arterieel bloed (SaO2), ademfrequentie, 
koolstofdioxidedruk in de uitgeademde lucht (PETCO2) en het optreden van een 
ademdepressie. Meta-analyses zijn uitgevoerd met data uit de gerandomiseerde 
interventiestudies voor alle continue uitkomstmaten. We includeerden 63 artikelen, 
waarin 67 studies werden beschreven. Uit de meta-analyse kwam naar voren dat 
PaCO2 statistisch significant toenam bij patiënten die opioïden gebruikten voor 
kortademigheid in vergelijking met placebo. Deze toename was echter niet klinisch 
relevant. Op de andere parameters werd zowel in de meta-analyses als in de overige 
studies geen significant effect gezien. Bij 4 patiënten werd een ademdepressie 
gerapporteerd. Zij werden echter behandeld met een hoge of onbekende dosis 
opioïden. Op basis van deze resultaten kunnen we concluderen dat een lage 
dosis opioïden niet leidt tot klinisch relevante respiratoire bijwerkingen. Echter, 
de geïncludeerde studies gebruikten verschillende methoden, wat de vergelijking 
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moeilijk maakt. Daarnaast was de kwaliteit van de studies vaak laag. Daarom is er 
behoefte aan een grotere en langere studie.
Bij patiënten met COPD neemt het zorggebruik toe wanneer de ernst van de ziekte 
toeneemt en bij de aanwezigheid van meer aandoeningen dan alleen de COPD 
(comorbiditeiten). Het is tot nu toe onduidelijk wat de invloed is van de ernst van 
kortademigheid op zorggebruik en op dagelijkse activiteiten. Daarom hebben we dit 
in hoofdstuk 3 vastgesteld. In deze observationele studie zijn patiënten met COPD 
24 maanden gevolgd na het afronden van een longrevalidatieprogramma. Elke drie 
maanden vulden deze patiënten een kostenvragenlijst in. Daarin werd gevraagd 
naar zorggebruik en het kunnen uitvoeren van werk en dagelijkse activiteiten. 
Vervolgens werd gevraagd of dit een gevolg was van hun ademhalingsproblemen 
of van eventuele andere gezondheidsproblemen. De resultaten werden vergeleken 
tussen patiënten met milde (modified Medical Research Council [mMRC] graad 0 
of 1) en ernstige kortademigheid (mMRC graad 2 tot 4). In de totale patiëntengroep 
waren ziekenhuisopnames, contact met overige zorgprofessionals (met name 
fysiotherapeuten) en longrevalidatie de belangrijkste kostenposten. Patiënten 
met ernstige kortademigheid hadden hogere kosten voor intramurale zorg, 
longrevalidatie en informele zorg in vergelijking met patiënten met milde 
kortademigheid. De andere kostenposten waren gelijk voor patiënten met milde 
en ernstige kortademigheid. Deze studie toont aan dat het belangrijk is om 
kortademigheid te verlichten, zodat zorgkosten worden verminderd. 
Aangezien het effect van opioïden op gezondheid-gerelateerde kwaliteit van 
leven en op bijwerkingen op de ademhaling onduidelijk was, is de MORDYC-studie 
opgezet (hoofdstuk 4). De MORDYC-studie was een single-center, gerandomiseerde, 
dubbelblinde, placebogecontroleerde interventiestudie. Het doel van de studie was 
het vaststellen van het effect van lage dosis orale morfine met langdurige afgifte bij 
124 patiënten met COPD en matige tot zeer ernstige kortademigheid (mMRC graad 
2 tot 4), ondanks optimale behandeling van de COPD. 
Deze patiënten werden willekeurig verdeeld over een groep die behandeld werd 
met tweemaal daags 10 mg morfine of een groep die behandeld werd met placebo. 
Patiënten werden voor vier weken behandeld. Bij patiënten die geen klinisch 
relevante verbetering van hun kortademigheid ervaarden na een of twee weken kon 
de dosering opgehoogd worden naar driemaal daags. Uitkomstmaten van de studie 
waren het effect op ziekte-specifieke kwaliteit van leven, respiratoire parameters, 
fysiek functioneren, kortademigheid, het optreden van bijwerkingen en kosten. 
Hoofdstuk 5 beschrijft de resultaten van de MORDYC-studie op ziekte-specifieke 
kwaliteit van leven, respiratoire parameters, fysiek functioneren, kortademigheid 
en het optreden van bijwerkingen. In de totale studiegroep verbeterde de kwaliteit 
van leven significant en klinisch relevant in de morfinegroep in vergelijking met 




de placebogroep. De respiratoire parameters, het fysiek functioneren en de 
kortademigheid bleven gelijk in beide groepen. Daarnaast werd ook gekeken naar 
de effecten van lage dosis morfine in een subgroep van patiënten met ernstige 
tot zeer ernstige kortademigheid (mMRC graad 3 of 4). In deze groep verbeterde 
de ergste kortademigheid over de dag in de morfinegroep in vergelijking met de 
placebogroep, terwijl alle andere uitkomsten gelijk bleven. In de studie werden geen 
ernstige bijwerkingen vastgesteld. De resultaten van de MORDYC-studie laten zien dat 
behandeling met lage dosis orale morfine met langdurige afgifte voor vier weken 
de ziekte-specifieke kwaliteit van leven kan verbeteren bij patiënten met COPD en 
matige tot zeer ernstige kortademigheid, zonder te leiden tot ernstige bijwerkingen. 
De kortademigheid verbeterde alleen bij de subgroep van patiënten met ernstige 
tot zeer ernstige kortademigheid.
Eerder onderzoek heeft laten zien dat niet alle patiënten een klinisch relevante 
verbetering van de kortademigheid ervaren na behandeling met morfine. Het doel 
van hoofdstuk 6 was om de relatie vast te stellen tussen een klinisch relevante 
verbetering, de manier waarop de patiënt het gevoel van kortademigheid omschrijft 
en demografische eigenschappen van de patiënt. Dit werd gedaan met behulp van 
de resultaten van de MORDYC-studie. Hieruit bleek dat ernstigere kortademigheid 
aan het begin van de studie en een hogere body mass index samenhangen met een 
klinisch relevante verbetering van de kortademigheid. De leeftijd van de patiënt 
en de manier waarop het gevoel van kortademigheid omschreven wordt hingen 
niet samen met een klinisch relevante verbetering. Daarom zou behandeling met 
morfine alleen overwogen dienen te worden bij patiënten met COPD en ernstige 
kortademigheid. Aangezien dit de eerste studie was die body mass index als 
voorspellende eigenschap aantoonde, dient deze samenhang verder onderzocht 
te worden.
Ernstige kortademigheid hangt samen met de toename van zorggebruik en 
zorgkosten. Om de economische impact van patiënten met COPD en ernstige 
kortademigheid te verminderen is een goede behandeling van kortademigheid 
belangrijk. Het doel van hoofdstuk 7 was om de kosteneffectiviteit van lage dosis 
orale morfine met langdurige afgifte vast te stellen. Dit werd gedaan met behulp 
van de resultaten van de MORDYC-studie. Hieruit bleek dat zowel de zorgkosten als 
de maatschappelijke kosten hoger waren in de placebogroep in vergelijking met 
de morfinegroep. Kwaliteit van leven verbeterde, waardoor morfinebehandeling 
dominant was vanuit een gezondheidszorgperspectief en een maatschappelijk 
perspectief. Verschillende sensitiviteitsanalyses bevestigden deze resultaten. 
Op basis van deze resultaten concluderen we dat lage dosis orale morfine met 
langdurige afgifte kosteneffectief is vanuit zowel het gezondheidszorgperspectief 
als het maatschappelijk perspectief.
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Opioïden worden aanbevolen voor patiënten die ondanks een optimale behandeling 
van hun COPD kortademigheid ervaren. Toch ervaren artsen barrières om opioïden 
voor te schrijven. Een van de barrières die zij benoemen is weerstand van de 
patiënt. Dit kan optimale palliatieve behandeling beperken. In hoofdstuk 8 hebben 
we de bereidheid van patiënten om te starten met opioïdenbehandeling in kaart 
gebracht. 175 patiënten met een chronische longaandoening of hartaandoening 
werden gevraagd naar hun bereidheid, onafhankelijk van een indicatie voor deze 
behandeling. De houding ten aanzien van opioïdenbehandeling was wisselend. Een 
kwart van de patiënten was niet bereid om opioïden te gebruiken. Van de overige 
patiënten was de ene helft bereid om opioïden te gebruiken en de andere helft had 
hier geen duidelijke voorkeur in. Alleen de leeftijd van de patiënt hing samen met de 
bereidheid om opioïden te gebruiken, waarbij oudere patiënten vaker niet bereid 
waren om opioïden te gebruiken. Angst voor bijwerkingen was de belangrijkste 
reden om niet bereid te zijn om opioïden te gebruiken. De belangrijkste reden om 
wel bereid te zijn was om zo veel als mogelijk te willen doen om zichzelf beter te 
voelen. Patiënten die geen duidelijke voorkeur hadden, gingen vooral af op het 
advies van hun arts. Daarom is passende informatievoorziening aan patiënten 
noodzakelijk. Wanneer een behandeling met lage dosis opioïden overwogen wordt, 
is het belangrijk dat de patiënt en de arts gezamenlijk de voordelen en nadelen van 
de behandeling bespreken.
Tot slot worden in hoofdstuk 9 de belangrijkste bevindingen van dit proefschrift 
uitgebreid besproken in relatie tot eerder gepubliceerde studies. Hierin concluderen 
we dat lage dosis orale morfine met langdurige afgifte een prominente rol speelt 
in de palliatieve behandeling van chronische kortademigheid bij patiënten met 
gevorderde COPD. Morfine verbetert de gezondheid-gerelateerde kwaliteit van 
leven, is veilig en is kosteneffectief. Daarnaast verlicht morfine kortademigheid 
bij een deel van de patiënten. Daarom zou lage dosis morfine altijd overwogen 
moeten worden bij patiënten met gevorderde COPD en ernstige tot zeer ernstige 
kortademigheid. De patiënt en de arts dienen altijd de voordelen en mogelijke 
nadelen van de behandeling gezamenlijk te bespreken voordat de behandeling 
wordt gestart, zodat een weloverwogen gezamenlijke keuze gemaakt kan worden. 
Echter, niet alle aspecten van morfinebehandeling zijn tot op heden duidelijk. 
Daarom zijn toekomstige studies belangrijk om het effect en de kosteneffectiviteit 
op lange termijn vast te stellen en om verder in kaart te brengen welke patiënten 
een klinisch relevante verbetering van de kortademigheid ervaren na behandeling 
met morfine.
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Scientific and social impact
This thesis has provided several findings, which contribute to science and medical 
practice. This paragraph reflects on the scientific and social impact of this thesis, 
which will be discussed from four different perspectives:
• Research: What is the main aim of the included studies and what are the main 
results and conclusions?
• Relevance: What is the (potential) contribution of the scientific results to science 
and to social sectors and challenges?
• Target groups: To whom are the scientific results favorable and/or relevant and 
why?
• Activities: In which way can the identified target groups be involved in and 
informed about the results, so that the knowledge can be used in the future?
Research and relevance
Breathlessness is one of the most common symptoms reported by patients with 
advanced chronic obstructive pulmonary disease (COPD), a chronic condition in 
which the lungs are inflamed and damaged. This stressful symptom has major 
consequences for the patients, such as care dependency, social limitations and 
anxiety. With worsening of the breathlessness, patients experience more difficulties 
in performing daily life activities, more anxiety restricting them to their house 
and growing dependence on loved ones. As COPD can have an irregular course, 
breathlessness and the accompanying problems shift over time with ups and 
downs. Also, worsening of breathlessness over time leads to increasing contacts 
with physicians or admissions to the hospital. This increase in medical care induces 
an increase in healthcare related costs. Therefore, effective treatment of chronic 
breathlessness is important. Opioids are suggested as effective palliative treatment 
for chronic breathlessness. Palliative care aims to provide relief from stressful 
symptoms and to improve quality of life, without curing the underlying disease. 
Within the group of opioids, low-dose, oral morphine with prolonged release has 
shown the best effect in relieving breathlessness.
The main aim of this thesis was to provide an extensive summary of the benefits 
and harms of low-dose, oral morphine. The results have shown that low-dose, oral 
morphine for four weeks improves quality of life in patients with advanced COPD 
without causing serious side effects. Also, patients taking low-dose, oral morphine 
for four weeks were shown to have fewer contacts with healthcare providers and 
lower healthcare related costs compared to patients taking placebo. Therefore, 
low-dose, oral morphine has an important role in the palliative treatment of 
chronic breathlessness in patients with advanced COPD. Finally, the results of this 
thesis showed that some patients are willing to use opioids for breathlessness, 
but some patients are not. The main reason to be willing to use opioids is to do as 
much as possible to feel better. The main reason to be unwilling to use opioids is 
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fear of serious side effects. When patients are indecisive, they mainly rely on the 
information from their physician. Physicians should know about the positive effects 
of morphine and the possible harms, so they can inform patients and their informal 
caregivers about the treatment.
Target groups
Multiple groups benefit from the results of this thesis. Patients directly benefit 
from morphine treatment. As relief of breathlessness can also decrease the care 
dependency of patients, morphine treatment will also benefit the informal and 
formal caregivers of patients. This thesis provides information for physicians about 
the positive effects and possible harms of low-dose oral morphine use, which can 
aid them to inform patients and informal caregivers. Also, the results are relevant 
for future researchers, since some aspects of low-dose morphine treatment remain 
unclear.
Healthcare providers
Healthcare providers experience barriers to prescribe morphine treatment for 
breathlessness. These barriers include insufficient knowledge of the positive 
effects, fear of side effects and resistance of patients. Effects of opioid treatment 
on breathlessness and on quality of life were unclear. Also, it was known that 
morphine relieves breathlessness in some patients, but not in all patients, and it 
was unclear which patient characteristics are related to a positive response. These 
issues are discussed in this thesis. The results show that low-dose, oral morphine 
improves quality of life without causing serious side effects. Also, the results show 
that patients with worse breathlessness are more likely to respond to morphine 
treatment. This can aid physicians to identify to which patients they should prescribe 
low-dose, oral morphine. When morphine treatment is started, the effect of the 
treatment should be monitored. Physicians should ask patients about different 
breathlessness aspects, like average severity and unpleasantness of breathlessness 
over the last 24 hours and worst breathlessness severity in the last 24 hours. Since 
patients indicate that they rely on the information given by their physician, it is 
important that healthcare providers know about the effects and side effects of 
low-dose oral morphine treatment and gain experience with the treatment. These 
healthcare providers include chest physicians, family doctors, physicians in old age 
medicine, physician assistants and nurse specialists.
Patients
Patients directly benefit from morphine treatment, as it improves quality of life. 
Patients indicate to be willing to use opioids for their breathlessness, but also 
indicate to have some concerns. The results of this thesis contributed to a better 
understanding of patients’ concerns related to morphine use. The main concern of 
patients is the occurrence of side effects. This thesis has determined the occurrence 
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of side effects and has shown that no serious side effects occur after treatment 
with low-dose morphine. Patients report that their physician is the most important 
source of information when considering opioid treatment. Therefore, patients 
should be aware of the benefits and possible harms of morphine treatment so 
they can start a conversation about their specific concerns with their physician.
Researchers
This thesis has indicated several aspects important to future research. As a 
start, results indicate that worse breathlessness is related to a positive response 
to morphine treatment. Therefore, only patients with severe to very severe 
breathlessness (modified Medical Research Council [mMRC] breathlessness grade 
3 or 4) should be included in future studies. However, given that we have shown 
that it is difficult to include patients with mMRC grade 3 or 4 in the MORDYC study, 
we recommend a multi-center set up in future studies.
This thesis has also raised several questions. Morphine improves health-related 
quality of life, but no improvement in breathlessness was shown. The working 
mechanism of morphine should be further explored, focusing on the interplay 
between breathlessness, quality of life and daily life activities. Also, the influence 
of age, body mass index, the way breathlessness is described and the presence of 
anxiety or depression on a positive response to morphine treatment should be 
further explored.
Activities and products
Several activities have been undertaken to spread the results of this thesis to 
healthcare providers, patients and researchers. As a start, the results have been 
published in international, peer-reviewed journals and have been presented 
at different national and international congresses and meetings. This will be 
undertaken with results in the future as well. Also, local, national and international 
media have paid attention to the main results of the MORDYC study. The results 
were presented in the Medicine News (Medicijnjournaal) of the Dutch Institute for 
Rational Use of Medicine. The results were also reported on the website of the 
Dutch Lung Foundation.
In order to support the information provision to patients, we developed an 
infographic. This infographic will be available for general practitioners, chest 
physicians and other healthcare providers to share with their patients and informal 
caregivers. The infographic informs patients and their informal caregivers about 
the effects of morphine for chronic breathlessness and helps patients to start a 
conversation with their physician.
Finally, the findings of the MORDYC study are included in the revision of the 
Dutch guideline Palliative care for COPD, which will be published in 2021. The 
revision of this guideline was initiated by the Netherlands Comprehensive Cancer 
Organization and Lung Alliance Netherlands. The revised guideline is developed by 
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a multidisciplinary working group consisting of several healthcare providers and 
patient representatives. The guideline contains recommendations for healthcare 
providers based on the current scientific knowledge and medical practice. Several 
future activities will be performed to implement this guideline and therefore also 
the results of this thesis. These activities include: articles in newsletters of relevant 
professional associations and education to several healthcare providers in order 
to raise awareness of the guideline, the development of a decision tree to aid 
healthcare providers in provision of palliative care to patients with advanced COPD 
and the development of a patient version of the guideline, which will be spread on 
several patient platforms.





De data zijn verzameld, de teksten zijn geschreven, het werk zit er (bijna) op. Ik had 
dit proefschrift niet kunnen schrijven zonder de hulp van jullie allemaal, in welke 
vorm dan ook. En daar wil ik jullie in dit hoofdstuk graag voor bedanken!
Allereerst dank ik alle patiënten die hebben deelgenomen aan mijn onderzoeken. 
Meestal zonder twijfel zeiden jullie ‘ja’ tegen mijn vraag of je wilde deelnemen 
aan mijn onderzoek. Voor sommigen van jullie betekende dit het invullen van een 
vragenlijst, maar voor anderen betekende dit 4 weken lang een medicijn slikken 
wat je alleen van naam kende en waarvan je hoopte dat het verlichting zou bieden. 
Ik werd bij jullie allemaal even gastvrij thuis ontvangen en zonder moeite kwamen 
jullie 2 keer naar Ciro toe. Enorm veel dank voor jullie bijdrage!
Natuurlijk had ik dit proefschrift niet kunnen schrijven zonder de begeleiding van 
mijn promotoren prof. dr. Emiel Wouters en prof. dr. Marieke van den Beuken en 
mijn copromotor dr. Daisy Janssen. Dank jullie wel dat jullie het ruim 6 jaar geleden 
aandurfden met mij, ondanks dat mijn achtergrond niet helemaal aansloot bij het 
project. Ik ben heel blij dat ik aan dit project begonnen ben en kijk terug op een fijne 
samenwerking. Gaandeweg gaven jullie me de vrijheid om er een eigen invulling 
aan te geven. Dank voor dat vertrouwen. Wanneer ik om jullie feedback vroeg, 
hoefde ik vaak geen week te wachten. En jullie waren het doorgaans steeds met 
elkaar eens of vulden elkaar mooi aan, wat het voor mij makkelijk maakte om weer 
verder te kunnen.
Daisy, ik vond het een voorrecht om door jou begeleid te worden en heb onze 
samenwerking als erg prettig ervaren – en nu nog. Jouw kritische blik hielp mij 
om goed na te denken wat ik nu precies wilde schrijven. Je deur stond altijd open, 
ondanks alle werkzaamheden en projecten waar je bij betrokken bent. Ik heb er 
enorm veel bewondering voor hoe jij de zorg voor Qui combineert met je werk 
en vond het fijn om in de auto van Horn naar Maastricht of andersom over onze 
kinderen te kunnen praten. Ook heb ik veel geleerd van de manier waarop je 
spreekt over palliatieve zorg, een onderwerp wat voor patiënten vaak toch niet 
makkelijk is om aan te snijden. Ik ben blij dat we ook in mijn huidige werk nog mogen 
samenwerken.
Marieke, dank je wel voor de fijne samenwerking en enthousiaste begeleiding. 
Jouw instelling van ‘grote stappen, snel thuis’ (zoals je het zelf omschreef) heeft mij 
geholpen om soms niet te kritisch te zijn en niet te lang te blijven hangen op een 
bepaald stuk, maar door te gaan of om hulp te vragen. Het was jammer dat we de 
EAPC in Bern niet samen hebben kunnen meemaken, maar ik hoop dat we in de 
toekomst elkaar nog op diverse congressen tegen gaan komen.
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Prof. Wouters, uw kennis op het gebied van longaandoeningen werkt enorm 
motiverend. Dank dat u mij hier de afgelopen jaren in heeft meegenomen. Steeds 
daagde u mij uit om verder te denken en mijn resultaten in een bredere context te 
zien. Dit heeft de kwaliteit van mijn artikelen en dit proefschrift tot een hoger niveau 
getild. Ook dank ik u en Ingrid Augustin voor de mogelijkheid om mijn onderzoek 
in Ciro uit te voeren.
Daarnaast bedank ik graag iedereen die op een andere manier nauw betrokken was 
bij mijn onderzoek en proefschrift. 
Jos en Carmen, ondanks dat jullie niet tot mijn promotieteam behoren, hebben 
jullie een enorme bijdrage geleverd aan mijn onderzoek. Jos, ik had niemand beter 
kunnen treffen om vanuit HSR mijn projectteam aan te vullen. Als je kamer 0.080 
binnen kwam wandelen, vaak voor Anne, vroeg je altijd even hoe het met mijn 
project ging. Jij stond wat verder van het onderwerp van mijn onderzoek af, wat 
juist maakte dat je vragen stelde waar ik niet bij stil stond. Dat hielp me om wat 
breder te denken. Dank je wel daarvoor. Carmen, bij jou kon ik altijd terecht voor 
mijn vragen over de kostenanalyses. En dit was nogal eens nodig. Dank je wel dat 
je altijd klaar stond om mee te denken en voor je geduld om het me steeds weer 
opnieuw uit te leggen als dat nodig was, zelfs toen je je handen vol had aan je nieuwe 
functie bij het CTCM. 
Beste medeauteurs, dank jullie wel voor het meelezen van en de kritische blik op 
mijn artikelen. Miriam, dank je wel voor je geduld om steeds weer mijn vragen over 
de CIROCO-studie te beantwoorden. Je maakte altijd tijd om me uit te leggen hoe 
deze studie in elkaar stak en me de juiste data aan te leveren. Niels, dank je wel 
voor het meedenken in de multilevel analyses en voor het me wegwijs maken in het 
schrijven van SPSS-syntaxen. Sander, jij hielp me uit de brand toen de meta-analyses 
en imputaties me te ingewikkeld werden. Dank daarvoor! 
Miriam and Sushma, you gave me the opportunity to visit the University of Hull 
and to work together on two reviews. Miriam, thank you for inviting me to Hull, for 
showing me the palliative care facilities you work with and especially thank you for 
the pleasant cooperation. Sushma, thank you for showing me some nice parts of 
Hull and for the helpful suggestions on the data collection of my review!
Voor het rekruteren van de patiënten wil ik graag alle artsen en physician assistants 
in Ciro bedanken: Bita, Bram, Eefje, Frits, Lowie, Maud, Rein, Sandra en Tim. Het 
rekruteren van patiënten voor de MORDYC-studie was niet makkelijk en dit kwam er 
voor jullie bij, bovenop alles wat jullie al met de patiënten moeten bespreken. Dank 
voor jullie enthousiasme en volhoudendheid. Jullie maakte er zelf een wedstrijdje 
van met een terechte winnaar! 




Daarnaast wil ik de longartsen en longverpleegkundigen van de betrokken 
ziekenhuizen bedanken: Monique van Vliet van Zuyderland Medisch Centrum 
en Harry Pouwels, Mieke Lagarde en Janine van den Boom van VieCuri Medisch 
Centrum. Dank dat jullie tijd vrij hebben gemaakt om patiënten te screenen en 
informeren. 
Voor het uitvoeren van de longfunctietesten en bloedafnamen voor de MORDYC-
studie bedank ik de collega’s van biometrie en longfunctie van Ciro, in het bijzonder 
Kitty en Marianne. 
Tijdens het uitvoeren van mijn onderzoeken had ik het geluk om hulp te krijgen 
met het verzamelen van alle data. Danja, per toeval kwam je stagelopen op de 
MORDYC-studie. Het uitvoeren van de metingen kon ik al snel aan jou overlaten. 
Ik was daarom heel blij dat ik ook na je stage een beroep op je kon doen. Lisanne, 
ook jij hielp me bij het uitvoeren van mijn metingen. Je kwam er zonder problemen 
voor naar Horn vanuit Maastricht. Christine, jij hebt me geholpen bij het invoeren 
van alle data. Jouw kritische blik heeft er aan bijgedragen dat alle data zo compleet 
mogelijk ingevoerd zijn. Miranda, wij konden de krachten bundelen bij het uitvoeren 
van onze onderzoeken. Zo hielpen we elkaar. Maar jij vooral mij tijdens mijn 
zwangerschapsverlof bij het verzamelen van mijn laatste data. Dank jullie wel voor 
jullie bijdrage en de fijne samenwerking!
Thanks to the members of the assessment committee, consisting of prof. dr. 
Smeenk, prof. dr. Muris, dr. Magdelijns, prof. dr. van Zuylen and dr. Ekström, for 
the thorough assessment of my thesis. 
Tevens gaat mijn dank uit naar ZonMW voor het financieel mogelijk maken van de 
MORDYC-studie. Daarnaast wil ik dhr. en mevr. van Haren danken voor de financiële 
bijdrage aan mijn project. Uw bijdrage stelde ons in staat de resultaten van ons 
onderzoek nog breder te kunnen implementeren, onder andere door het maken 
van een infographic over de effecten van lage dosis morfine. Hiermee heeft u 
geholpen de behandeling van kortademigheid bij patiënten met COPD nog verder 
te verbeteren. 
Tijdens mijn promotie reisde ik elke dag van het Brabantse land naar Limburg. 
Ik bedank alle collega’s die het de moeite waard maakten om dit steeds weer te 
doen. Om te beginnen mijn kantoorbuddies in kamer 0.080 in Maastricht: Anne 
en Linda. Wij begonnen ongeveer tegelijk aan ons promotietraject en hebben 
daarmee samen de ups en downs van een startende promovendus beleefd. Hier 
heb ik ontzettend veel aan gehad. Alle drie hadden we een complex project, wat 
er voor zorgde dat we geregeld op pad waren. Maar altijd als we dan weer samen 
op kantoor waren, praatten we uitgebreid bij. Natuurlijk konden op maandag (of 
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dinsdag als het zo uit kwam) de voetbaluitslagen niet ontbreken: wat hadden Roda 
JC, FC Twente en PSV dat weekend gedaan? Anne, vanaf het begin was jij een stabiele 
factor in mijn promotietraject. Want elke ochtend als ik op kantoor kwam, was jij 
er al. De rust en gedrevenheid waarmee jij je onderzoek uitvoerde waren enorm 
inspirerend. Het was dan ook geen verrassing dat jij al zo snel je proefschrift af kon 
ronden. Gelukkig bleef je ook daarna nog onze kamergenoot! Linda, wij hebben 
samen aardig wat kilometers gereisd. Meestal per trein, soms samen met de auto. 
Onderweg hadden we alle tijd om van alles te bespreken. Maar het was ook goed als 
we even wilden werken. Deze uren hebben mij echt geholpen om mijn gedachten 
even ergens anders te hebben. Dank jullie wel allebei hiervoor, ik hoop dat we ook 
hierna nog contact kunnen blijven houden! Merel en Johanna, later kwamen jullie 
ons vergezellen in kamer 0.080. De gezellige gesprekken hebben me geholpen om 
ook de laatste loodjes van mijn promotie met plezier naar Maastricht te reizen. Ik 
wens jullie veel succes bij het afronden van jullie promoties!
Lieve Sofie, ook wij hebben aardig wat kilometers samen afgelegd tussen Best en 
Maastricht. Ik was altijd blij als ik jou ’s ochtends op het station zag staan. Dan 
konden we samen in Eindhoven een koffietje halen en onderweg gezellig kletsen. 
Hoe leuk was het dat we kort na elkaar uitgeteld waren van ons eerste kindje. Toen 
Els en Tijn er eenmaal waren, deelden we samen de kolfkamer. Want tja, die tijd kun 
je net zo goed gezellig samen doorbrengen. Het zwemmen op vrijdagochtend was 
ook altijd erg gezellig. Leuk om te zien hoe Els en Tijn samen groot werden. Dankzij 
de opa’s en oma’s kon het zwemmen ook doorgaan toen Mart en Niek er waren. 
Jammer dat dit vanwege corona even niet meer kan en we elkaar niet meer zo veel 
zien. Hopelijk kunnen we dit snel weer oppakken! 
Lieve onderzoekscollega’s van Ciro: Anouk, Anouk, Carmen, Coby, Dionne, Dionne, 
Esther, Fiona, Jeannet, Kiki, Lieke, Maarten, Miranda, Nienke, Panaiotis, Rafael, Roy, 
Sarah, Wai-Yan en Yvonne. Ik kwam als vreemde eend in de bijt bij Ciro en was er 
vaker niet dan wel. Jullie maakte me wegwijs in Ciro en al snel voelde ik me thuis in 
het onderzoekshok. Dat kwam misschien ook wel door alle momenten die gevierd 
werden met iets lekkers of een etentje. Een feest om altijd weer te proeven wat er 
was gebakken. De introductie van mijn kokosbloesemsuiker viel niet bij iedereen in 
goede aarde . Het was fijn om te weten dat er altijd iemand was als ik terugkwam 
van metingen en dat jullie altijd meeleefden met de ups en downs van mijn project. 
Ik hoop dat we onze reünies nog vaker organiseren!
Ook een dank voor alle andere collega’s van HSR en Ciro voor alle fijne jaren, voor 
de gezellige lunches, lunchwandelingen en bijeenkomsten. Maartje, Mariska, Anne 
en Irma, dank voor de gezellige avonden bij PSV-Roda JC en Roda JC-PSV. Brigitte 
en Joanna, dank voor het steeds weer beantwoorden van mijn vragen. Door de 




verschillende samenwerkingen was mijn project soms complex. Jullie hielpen me 
altijd weer op weg bij wie ik waarvoor aan kon kloppen. 
Na mijn tijd bij HSR en Ciro kwam ik bij IKNL terecht in een fijn team van nieuwe 
collega’s: Brigitt, Corinne, Fleur, Francis, Inge en Jacqueline. Ik startte vorig jaar in 
coronatijd vanuit thuis, maar jullie hebben ervoor gezorgd dat ik me direct op mijn 
plek voelde. Gelukkig hebben we elkaar al verschillende keren gezien op kantoor 
en kunnen we dit komende tijd weer meer gaan doen. Dank jullie wel dat jullie me 
de ruimte hebben gegeven om mijn proefschrift af te ronden, ondanks de enorme 
klus die we samen hebben om het meerjarenplan uit te voeren. Birgit en Marlene, 
dank jullie wel dat jullie mij de ruimte geven om mijn expertise in te brengen in dit 
team, dat waardeer ik enorm. Birgit, zoals jij zo mooi zei kun je inderdaad ook via 
Teams een klik voelen. Dit kan ik beamen!
Lieve vrienden, dank jullie wel voor interesse voor mijn werk, ook al was het soms 
lastig uitleggen wat ik nu precies doe. En natuurlijk dank voor de afleiding, in welke 
vorm dan ook.
Lieve Judith, we kennen elkaar sinds de middelbare school. Na de middelbare school 
zagen we elkaar even wat minder, maar ik ben blij dat we dat weer opgepakt hebben. 
Onze gedeelde interesse voor thee, wijn, de medische wetenschap en PSV maakt dat 
we altijd wel wat hebben om ‘even’ bij te kletsen. Dank je wel dat je mijn paranimf 
wilt zijn en straks achter mij staat.
Lieve Els, Hanne, Hester, Jiska, Lieke, Loes, Loes, Marleen, Martine, Monique, 
Samantha en Sanne, we zien elkaar de laatste tijd te weinig en vaker in kleinere 
clubjes dan allemaal samen. Samen delen we aardig wat herinneringen aan 
scoutingmomenten en –kampen. Mooie herinneringen om aan terug te denken. 
Met ieder van jullie vind ik het fijn om bij te kletsen, een theetje of wijntje te drinken 
of met de kids te spelen en hopelijk kunnen we binnenkort weer eens met z’n allen 
op pad!
David en Femke, Geert en Tessa, Harm en Krissy, Jan en Leonie, Jorrit en Reske, Koen 
en Linda, Koos en Jacqueline, Matthijs en Ellen en Vincent en Sophie, jullie kreeg ik als 
vriendengroep 13 jaar geleden cadeau. Ik voelde me direct thuis door de gedeelde 
interesse in voetbal (voor sommigen van jullie dan) en reizen. Dank voor de gezellige 
PSV-avonden, wintersporten en de mooie reis samen naar Australië. 
Lieve Marjan, Ben, Peter en Ingrid. Ruim 13 jaar geleden werden jullie mijn 
schoonfamilie en ik voelde me direct thuis. Jullie zijn altijd oprecht geïnteresseerd 
in waar ik mee bezig ben. Gelukkig wonen jullie dichtbij, waardoor we altijd langs 
kunnen komen voor een kopje koffie of om een hapje mee te eten. Daarnaast zijn 
jullie geweldige opa’s en oma’s voor Tijn en Niek en staan jullie altijd voor ons klaar 
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als we een keertje oppas nodig hebben. Dank jullie wel voor deze onvoorwaardelijke 
steun.
Bram, Ruud, Manon, Marloes, Anouk en Kevin, ook jullie zijn sinds 13 jaar (of iets 
korter) mijn schoonfamilie. Het is mooi om te zien hoe jullie in die tijd groot zijn 
geworden en nu hele fijne ooms en tantes zijn voor Tijn en Niek. 
Lieve Jenny, mijn kleine zusje. Zoals iedereen altijd zegt: wij zijn zo verschillend, 
maar toch ook weer zo hetzelfde. Hoe leuk was het dat jij nog op kamers woonde in 
Maastricht toen ik mijn promotie startte, zodat ik zo af en toe bij jou een hapje kon 
komen eten. Op werkgebied hebben we ieder een eigen weg gekozen. En dat komt 
in dit boekje mooi samen: je wist de boodschap die ik over wilde brengen mooi te 
visualiseren in de cover. Sorry als ik weer eens belde, omdat ik het graag af wilde 
hebben. Het heeft geleid tot een prachtig resultaat. Dank je wel daarvoor, ik ben 
blij dat ook jij achter mij wil staan als paranimf. 
Lieve Glenn, ruim 14 jaar geleden kwam jij in de familie. Ook een scouting-fanaat, 
hoe kon het ook anders. Jullie zijn een mooi koppel en ik vond het een eer om getuige 
te zijn op jullie bruiloft. Jullie zijn een fantastische oom en tante voor Tijn en Niek 
en ik weet zeker dat jullie straks ook fantastische ouders zijn voor jullie kleintje wat 
op komst is. 
Lieve papa en mama, jullie hebben we altijd vrijgelaten in mijn keuzes. Iedereen is 
gelijk en even belangrijk, dat heb ik altijd van jullie geleerd. Dit heeft mij gemaakt 
tot wie ik nu ben. Jullie zijn altijd heel betrokken geweest bij mijn hobby’s, studie 
en werk. Vakanties werden om scoutingkampen heen gepland of jullie kwamen op 
en neer om ons op te halen. En ik kon jullie altijd vragen als er een proefpersoon 
nodig was en jullie waren geschikt. Sander en ik kunnen altijd op jullie rekenen. 
Het was heel fijn dat we een half jaar bij jullie mochten wonen toen ons huis nog 
werd gebouwd. En Tijn en Niek boffen met zo’n leuke opa en oma. Ze vinden het 
fantastisch om elke donderdag bij jullie te spelen of ergens naar toe te gaan in de 
vakanties. Als dit eens vaker nodig is, wat de afgelopen 6 jaar zeker wel eens het 
geval is geweest, dan kunnen we altijd bellen. Al is het maar voor een uurtje. Dank 
jullie wel voor deze onvoorwaardelijke liefde, steun en vertrouwen.
Allerliefste Sander, jij vult mij altijd goed aan. Als ik weer eens twijfel over iets of geen 
keuze kan maken, dan help jij mij om realistisch te denken. Dat heeft mij al meerdere 
keren, maar zeker afgelopen 6 jaar enorm geholpen. Wij zijn allebei geen stilzitters 
en vaak met van alles bezig. Hierin laten we elkaar vrij en steunen we elkaar. Dank 
je wel voor deze steun! Gelukkig delen we een heel aantal gedeelde hobby's, zoals 
scouting, fitness en naar PSV gaan. Het is fijn om dit samen met jou te kunnen doen 
en ik hoop dat we dit nog lang kunnen en mogen doen. Tijn en Niek boffen met jou 
als papa. Ik geniet er enorm van om te zien hoe jij met ze kunt spelen en stoeien. 
Dank je wel voor jou liefde, steun en wijze raad in alles. Lieve schat, ik hou van je!




Allerliefste Tijn en Niek, mijn promotie werd extra leuk toen jullie kwamen. Jullie 
zwaaien mij uit als ik ’s ochtends ga werken (of ik jullie nu ik thuis werk) en jullie doen 
de deur open als ik ’s avonds weer thuis kom. Veel beter kan ik mijn werkdag niet 
beginnen en eindigen. Lieve Tijn, je bent nu al een enorm nieuwsgierig mannetje. 
Ook al vinden we jouw ‘waarom’ en ‘hoezo’ nu soms vervelend, hou dit vooral vol. 
Deze nieuwsgierigheid kan je heel ver brengen! Je bent ook een lieve grote broer, 
het is mooi om te zien hoe je Niek mee wil nemen in dingen die jij al wel kan, maar 
hij nog niet. Lieve Niek, jij bent nog een klein, eigenwijs boefje. Maar je bent ook 
een grote ontdekker en nergens bang voor. Ik geniet ervan om te zien hoe jij groot 
wordt en je grote broer probeert na te doen. Ik hou van jullie!
It’s something unpredictable, but in the end it’s right,
I hope you had the time of your life
Liefs,
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Uitnodiging
Graag nodig ik u uit voor de openbare 
verdediging van mijn proefschrift:
CHRONIC BREATHLESSNESS IN COPD 
Eff ects of low-dose oral morphine 
op vrijdag 29 oktober 2021 
om 12:00 uur 




Aansluitend bent u van harte 
welkom op de receptie ter plaatse.
Voor meer informatie en geldende 
corona-maatregelen zie bijgevoegde 
brief.
Cindy van den Berg-Verberkt
Wetstok 10, 5684 KM Best
c.vandenberg@maastrichtuniversity.nl
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